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Structural and mechanistic studies of mammalian DNA 
repair proteins 
Summary 
Project 1: Small molecule inhibitors of TDP2 
DNA Topoisomerase II (TOP2) has important roles in many cellular processes such as 
DNA replication and transcription, as well as in chromosome segregation. The main 
enzymatic function of TOP2 is to alter DNA topology and release torsional stress, by 
transiently introducing a double strand break (DSB) into a DNA duplex, passing a second 
intact duplex through the break, and then re-sealing the break. This enzymatic process 
involves the formation of TOP2-DNA covalent complexes, where the catalytic tyrosine 
(Y821) is linked to the 5’ phosphate group of a substrate DNA. TOP2 ‘poisons’ such as 
etoposide, doxorubicin and mitozantrone, which have found utility as anti-cancer agents, 
lead to an accumulation of these covalent complexes, leading eventually to cell death in 
rapidly replicating and dividing cells. 
As many tumours treated with TOP2 poisons go on to develop chemo-resistance, it is 
postulated that dual-combination therapy with inhibitors of a second enzyme, 5'-tyrosyl 
DNA phosphodiesterase-2 (TDP2) may prevent this from occurring; TDP2 acts to remove 
TOP2-DNA adducts, liberating DNA ends for repair. Inhibitors of TDP2 may also prove 
useful as a mono-therapy in defined tumour types. 
As part of an ongoing collaboration with the Sussex Drug Discovery Centre (SDDC), 
the aim of the project was to determine high-resolution X-ray crystal structures of TDP2 
in complex with a series of deazaflavin inhibitors. The information acquired will guide 
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ongoing structure-based drug design, with the aim of developing and nominating a hit-to-
lead compound in the near future. 
 
Project 2: The XRCC1 phosphate-binding pocket binds poly(ADP-ribose) 
In living organisms, genomic DNA is constantly exposed to both endogenous and 
exogenous sources of DNA damaging agents, which if not repaired, can result in the 
accumulation of mutations and chromosomal aberrations. Cells have evolved a series of 
DNA-damage repair enzymes and pathways, to cope with this perpetual threat. Poly(ADP-
ribose) polymerase 1 (PARP1) is the founding member of the large ADP ribosyl 
transferase superfamily. Among its broad range of functions, PARP1 can detect the 
presence of both single- and double-strand breaks (SSBs and DSBs) in DNA, upon which 
it becomes catalytically activated. As a result, PARP1 then synthesises poly(ADP-ribose) 
polymer using NAD+ as a co-factor, thereby modifying both itself (auto-ribosylation ) and 
other proteins (trans-ribosylation) in the vicinity of the DNA break. 
During the initial phases of the single-strand break repair (SSBR), the scaffold protein 
XRCC1 is recruited by PARP1, via an interaction between poly(AD-ribose) (PAR) and the 
central BRCT1 domain in XRCC1. However, further investigation is required to elucidate 
the mechanism by which the BRCT1 domain interacts with PAR. This project aims to 
address this question. 
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PARP Poly(ADP-ribose) polymerase 
PBM PAR binding motif 
PBS Phosphate buffered saline 
PBZ PAR binding zinc-finger 
PCNA Proliferating cell nuclear antigen 
PG Phosphoglycolate 
pI Isoelectric point 
PNK Polynucleotide kinase phosphatase 
Polβ DNA polymerase beta 
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Polδ/ε DNA polymerase delta/epsilon 
RAD50 Radiation sensitive 50 
RPA Replication protein A 
ROS Reactive oxygen species 
RNAP RNA polymerase 
RNF8 Ring finger protein 8 
RNF168 Ring finger protein 168 
rpm Revolutions per minute 
SAR Structure activity relationship 
SAXS Small-angle X-ray scattering 
SCAN1 Spinocerebellar axonal neuropathy 1 
SDS Sodium dodecyl sulphate 
SEC Size exclusion chromatography 
SIRT Sirtuin 
S-phase Synthesis phase 
SS Single-strand  
SSB Single-strand break 
SSBR Single-strand break repair 
TAE Tris base, Acetic acid, EDTA 
TARG1 Terminal ADP–ribose protein glycohydrolase 1 
TBE Tris base, Boric acid, EDTA 
TBST Tris-buffered saline and Tween 20 
TDP1  Tyrosyl DNA phosphodiesterase 1 
TDP2 Tyrosyl DNA phosphodiesterase 2 
TEMED Tetramethylethylenediamine 
TMAO Trimethylamine N-oxide  
TOP1 DNA Topoisomerase 1 
TOP2 DNA Topoisomerase 2 
UBA Ubiquitin-associated  
UV Ultraviolet 
V(D)J Variable (Diverse) Joining recombination 
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VPg Viral protein genome-linked 
v/v Volume per volume 
WRN Werner 
WT Wild type 
w/v Weight per volume 
XLF XRCC4-like factor 
XRCC1 X-ray cross complementing 1 
XRCC4 X-ray cross complementing 4 
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1.1 Project 1 – Small molecule inhibitors of TDP2 
1.1.1 The DNA damage response (DDR) 
DNA double-strand breaks (DSBs) can either emerge under pathological circumstances, 
from exposure to environmental agents such as ionizing radiation, or from endogenous 
sources of DNA damage such as oxygen free radicals or abortive activity of 
topoisomerases. These breaks, if left unrepaired, can lead to chromosomal rearrangements, 
carcinogenesis, or cell death (Richardson and Jasin 2000), (Bennett et al. 1993). 
Living organisms evolved a delicate repair system to maintain their genetic integrity. When 
DSBs occur, cells activate a signal transduction network, termed the DNA damage 
response (DDR) (Jackson and Bartek 2009). DDR has multiple functions: controlling the 
cell cycle, remodelling the chromatin to allow the repair system to access the break site 
and recruiting DNA repair proteins to mend the lesions. To undertake these tasks, DDR 
employs a multitude of repair proteins with different roles. First, DNA lesions are 
recognised by sensor proteins, such as the MRN complex (composed of Mre11, Rad50 and 
Nbs1 proteins) or the Ku complex. These sensor molecules then recruit downstream 
transducer molecules, e.g. ataxia telangiectasia mutated (ATM) protein to amplify the 
signal by phosphorylating various target molecules (Uziel et al. 2003) At DSB sites, 
dimeric ATM autophosphorylates itself and dissociates into active monomers (Bakkenist 
and Kastan 2003). The activated ATM then rapidly phosphorylates H2Ax, a histone H2 
variant, at serine 139 (γ-H2Ax) (Rogakou et al. 1998). This modification extends 
approximately one megabase in both directions on DNA and serves as a platform to recruit 
further factors. ATM also phosphorylates checkpoint kinase 1 and 2 (Chk1 and Chk2) 
resulting in delay in cell cycle (Matsuoka et al. 1998). The modification of SMC1 by ATM 
leads to chromatin remodelling to provide an open platform for DNA repair protein (Yazdi 
et al. 2002). Depending on the severity of the damage, cells either attempt to repair the 
DNA lesion by arresting or delaying the cell cycle or commence apoptosis if the DNA 
damage is too extensive by phosphorylating P53 by ATM which can transactivate its 
targets NOXA, BAX and PUMA (Banin et al. 1998) (Yu and Zhang 2008). 
1.1.1.1 Recognition and repair of chemically diverse DNA ends 
DNA strand breaks rarely possess ‘clean’ 3’-hydroxyl and 5’-phosphate moieties that are 
ready for ligation. Instead, the DNA repair machinery deals with chemically divergent 
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DNA termini by employing a wide variety of end processing enzymes. Damaged DNA 
termini can result from ionizing radiation, reactive oxygen species (ROS), abortive ligation 
events, and topoisomerase-induced protein-DNA crosslinks. Radiation- and ROS-induced 
base damage and DNA strand breaks are estimated to arise at a frequency of 10,000 per 
cell per day and generate DNA ends harbouring a fragmented sugar, 3’-phosphate, or 5’-
hydroxyl termini (Lindahl and Nyberg 1972) (Ames et al. 1993). Functional impairment 
of the end processing factors can result in severe neuronal diseases (Rulten and Caldecott 
2013). Polynucleotide kinase 3’-phosphatase (PNKP) is able to restore 3’-phosphate and 
5’-hydroxyl termini to their canonical chemistry, which is 3’-hydroxyl and 5’-phosphate, 
and loss of PNKP activity in humans results in microcephaly with early onset seizures 
(MCSZ) and ataxia with oculomotor apraxia type 4 (AOA4) (Bras et al. 2015). Abortive 
ligation events can result in DNA adenylation and the formation of breaks with 5’-AMP 
ends, which are resolved by Aprataxin (APTX); mutation of which result in ataxia with 
oculomotor apraxia 1 (AOA1)(Moreira et al. 2001). Abortive activity of topoisomerases 
can generate DNA SSBs and DSBs with 5’- or 3’-termini that are covalently linked to the 
topoisomerase, and these adducts are processed by the tyrosyl DNA phosphodiesterases, 
TDP1 and TDP2 (Yang et al. 1996, Cortes Ledesma et al. 2009). Mutations in TDP1 result 
in spinocerebellar ataxia with axonal neuropathy-1 (SCAN1), whereas mutations in TDP2 
are associated with seizures and ataxia (El-Khamisy et al. 2005, Gomez-Herreros, Schuurs-
Hoeijmakers et al. 2014). 
Damaged DNA termini can also be processed by endo- and exonucleases. For example, 
the exonucleases FEN1 and the MRN/CtIP complex resolve 5’-end blocking lesions 
(Murray et al. 1994, Chen et al. 2008). Artemis nuclease has several different nucleolytic 
activities; its 5’-endonucleoltytic activity nicks 5’ overhangs to create blunt ended DNA, 
and its 5’ to 3’ exonuclease activity can act on single stranded DNA (Ma et al. 2002). 
Werner (WRN) protein, which is mutated in Werner syndrome, possess both helicase and 
3’ to 5’ exonuclease activity (Huang et al. 1998). 
1.1.1.2 Double strand break repair 
In mammalian somatic cells the two most common repair systems are nonhomologous end 
joining (NHEJ) and homologous recombination-mediated repair (HR) (Figure 1.1.1) 
(Hartlerode and Scully 2009). NHEJ is the most frequently used repair process in non-
dividing haploid organisms and in diploid organisms that are not in S phase (Lieber 2010). 
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Figure 1.1.1. Schematic representation of nonhomologous end joining (NHEJ) and 
homologous recombination (HR). NEHJ is mainly taking place in non-proliferative cell 
or proliferative cells in G1 phase. DNA double strand break (DSB) are recognised and 
tethered by the Ku70/80 complex, which in turn recruits the catalytic domain of the 
DNA-dependent protein kinase (DNA-PKcs) and 53BP1 and other main NHEJ factors. 
DNA-PKcs phosphorylates mainly itself and several other repair proteins. When 
required, end processing factors restoring the damaged DNA end to their canonical 
chemistry, such as Artemis (depicted). Ligatable ends are joined by Lig4 in complex 
with XRCC4. XLF stimulates Lig4 activity. HR is preferred in replicating cells as 
DBSB can be repaired error free due to the presence of a sister chromatid following 
replication. The MRN complex recruits CtIP allowing end resection. Exposed single 
stranded DNA is coated by replicating protein A (RPA) which subsequently replaced 
by Rad51 filaments. Rad51 mediates the strand invasion and homology search on the 
sister chromatid which is the extended by DNA polymerases and finally ligated. Figure 
is adapted from (Chowdhury et al. 2013). 
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1.1.1.2.1 Nonhomologous End Joining (NHEJ) 
Apart from its repair function NHEJ is also involved in V(D)J recombination and Class 
Switch Recombination CSR during the maturation of T and B cells and thus patients with 
defects in NHEJ are frequently immunodeficient (Lieber 2010).  
 
During NHEJ the broken DNA ends are re-joined without the need of a repair template. 
Consequently, the process is potentially error prone since genetic information may be lost 
at the site of the break. The repair process is initiated by the binding of the Ku heterodimer 
(Ku70 and Ku80) to the DNA ends. The Ku-DNA complex acts as a platform for further 
actions performed by various proteins. Ku70/80 recruit DNA-PKcs (DNA-dependent 
protein kinase catalytic subunit) and its binding promotes the juxtaposition of the two DNA 
ends (Gottlieb and Jackson 1993). If the DSB does not require end processing, NHEJ can 
proceed to the ligation step where the DNA break is sealed by a ligation complex 
comprised of XRCC4, DNA ligase IV, and XLF (XRCC4-like factor; aka Cernunnos) 
(Grawunder et al. 1997) (Ahnesorg et al. 2006). 
 
If the DNA termini require end processing or the removal of damaged nucleotides, NHEJ 
is able to employ nucleases for end processing as described above. In addition, DNA 
Polymerases Pol µ and Pol λ are both able to bind to Ku:DNA complexes via their BRCT 
domains to conduct DNA gap filling (Mahajan et al. 2002). Once both ends are restored, 
DNA ligation can occur (Lieber 2010).  
1.1.1.2.2 Homologous Recombination (HR) 
During S and G2 phases homology directed repair is favoured as sister chromatids stay in 
close proximity providing a repair template. When a DSB occurs on one of the sister 
chromatids the broken DNA is resected at the 5' terminus to create a 3’-single-stranded tail 
(Rupnik et al. 2010). The single stranded tail enables formation of a nucleoprotein filament 
containing the recombinase RAD51, which enables strand invasion into the homologous 
region of the intact sister chromatid, with the original displaced DNA strand forming a D 
-loop (Chen et al. 2008). The lost genetic information at the damaged site is replaced by a 
DNA polymerase using the intact sister chromatid as the template. There are two 
alternative ways to complete the repair process. In the course of DSBR (double Holliday 
junction model) the second 3' overhang end from the broken DNA also engages with the 
sister chromatid forming a second Holliday junction. Resolution of this junction by 
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resolvases can result in crossover or non-crossover recombinant products (Heyer 2004). 
The alternative route is the synthesis-dependent strand annealing (SDSA) where the 
synthetized strand is exchanged between the sister chromatid template and other 3' end of 
the repaired break (Wyman and Kanaar 2006). 
1.1.2 Topoisomerase II (TOP2) 
1.1.2.1 Topoisomerase function and families 
Topoisomerases have indispensable roles in the organization and maintenance of the 
integrity of the chromosomal DNA. By introducing transient breaks topoisomerases can 
release torsional stress, decatenate chromosomes and change the level of supercoiling of 
DNA (Interthal et al. 2001). As transcription and replication machineries slide along the 
DNA duplex they generate positive supercoiling, which tightens the DNA duplex and 
prevents further strand opening (Wu et al. 1988). Negative supercoiling emerges behind 
the acting polymerases, which can lead to non-canonical DNA structures such as R-loops, 
hairpins or guanosine quartets (Aguilera and García-Muse 2012).Topoisomerases are 
found in all kingdoms of life and are of two main classes: type I and type II. Type I enzymes 
cleave one strand of the DNA, and type II topoisomerases cut both strands. A common 
feature of all type of topoisomerases is that they break the DNA by transesterification; an 
active site tyrosine performs a nucleophile attack on the DNA phosphodiester backbone 
and becomes covalently attached to the DNA during the process (Krogh and Shuman 
2000).  
Topoisomerases type IA and type IB, which are subclasses of the type I enzyme family, 
are able to release supercoiling by cutting one strand on the DNA. Type IA facilitates the 
passage of an intact single DNA strand through the opened strand to release torsional stress. 
In contrast, the type IB enzyme allows the rotation of the DNA duplex around the intact 
phosphodiester bond. The reaction is driven by the energy of the DNA supercoiling 
(Corbett and Berger 2004). The human Topoisomerase 1 (TOP1) is a type IB 
topoisomerase and becomes covalently attached to the 3' end of the cleaved DNA. Type 
IIA and IIB topoisomerases (subclasses of the type II family) facilitate the passing of an 
intact duplex through a transient DNA double strand break. Eukaryotic type IIA 
topoisomerases are homodimeric enzymes and in order to catalyse DNA cleavage and 
strand passage they require divalent metallic ions such as Mg2+ and the binding and 
hydrolysis of ATP (Sissi and Palumbo 2009). 
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1.1.2.2 TOP2 enzymes 
Mammalian cells express two type IIA isoforms: Topoisomerase IIα and IIβ (TOP2α and 
TOP2β) (Chung et al. 1989). The two isoforms show similar structural features and 
catalytic activity. TOP2α is essential for all dividing cells and indispensable in the 
separation of sister chromatids and its expression is increased from S phase to M during 
the cell cycle (Kimura et al. 1994). TOP2β is required for neuronal development and 
transcriptional regulation but is dispensable in some cell types (Yang et al. 2000, Lyu et 
al. 2006). 
1.1.2.2.1 Enzymatic mechanism of TOP2 
The enzyme mechanism of topoisomerase type II from yeast (S. cerevisiae) was studied 
extensively by biochemical and structural methods. As previously mentioned, TOP2 is 
homodimeric and each subunit breaks and transiently binds one DNA strand via a 
phosphotyrosyl bond (Dong and Berger 2007). The domain organization of each subunit 
can be seen in Figure 1.1.2. The N-terminal domain is an ATP binding domain followed 
by the TOPRIM domain, which is a well-conserved structure found not only in 
topoisomerases but also primases and other DNA binding enzymes (Aravind et al. 1998, 
Classen et al. 2003). The TOPRIM domain is involved in cation binding required for the 
catalytic step. The central part contains the winged helix domain (WHD) harbouring the 
catalytic tyrosine residue (Y782) and the Tower (or shoulder) domain involved in DNA 
interaction (Berger et al. 1996). The C-gate is linked to the tower domain via a coil-coiled 
structure and it is the exit point for the intact DNA duplex. The C-terminal part is not 
conserved between different topoisomerase type II enzymes from different species and it 
has a role in nuclear localization and protein-protein interaction (Nitiss 2009) (Schmidt et 
al. 2012). 
During decatenation or the relaxation of supercoiled DNA, TOP2 interacts with two DNA 
duplexes (Figure 1.1.3). TOP2 introduces a transient double strand break in one duplex 
termed the G-segment and helps the translocation of the second intact DNA duplex termed 
the T-segment (Rybenkov et al. 1997, Fass et al. 1999). The energy released by cleavage 
of the phosphodiester bond is retained in the newly formed phosphotyrosine bond, and so 
the cleavage/ligation reaction does not require ATP. However, ATP hydrolysis enables 
conformational changes in the enzyme that assist in T-segment passage and release of the 
G-segment (Schmidt et al. 2012). 
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Figure 1.1.2. Structure of TOP2α binding to DNA. A. Schematic representation of TOP2 
domain organization. B. Structural model of the DNA bound TOP2α ternary complex. 
The N-gate (in yellow) binds ATP and it is shown by AMPPNP a non-hydrolysable 
analogue of ATP. The TOPRIM domain (in red) responsible for cation binding. The 
winged helix domain (WHD, in light blue) with the catalytic Y782 residue and the Tower 
domain (in aubergine) are involved in DNA interaction. The Coiled-coil structure forms 
the C-gate (in pink). The C-terminal part is responsible for protein-protein interactions. 
DNA is depicted as 2Fo-Fc density (1.5σ contour) in green. (Figure from Schmidt et al. 
2012) 
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Figure 1.1.3. Type II topoisomerase reaction cycle. First, TOP2 binds the first DNA 
segment (termed G-segment), then by associating with the second DNA segment (T-
segment) introduces a transient double strand break on the G-segment. The DNA ends 
are protected by a 5’ phosphotyrosyl covalent bond formed between the catalytic 
tyrosine residue (Y782 in yeast) and the 5’phosphate end of the DNA. Following the 
opening of the G-segment, the topoisomerase then facilitates the passage of the T-
segment. The open strands of the g-segment are religated and released. TOP2 poisons 
are able to prevent relegation creating TOP2-DNA adduct. Figure is adapted from Vos 
et al. 2011. 
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During strand passage each 5'-phosphate terminus of the DSB is covalently linked to the 
catalytic tyrosine (Y782) residue via a phosphotyrosyl bond and so is protected from 
processing by other enzymes. The presence of these transient breaks (denoted cleavage 
complexes) makes TOP2 a potentially dangerous protein, however. Whilst cleavage 
complexes are obligate intermediates in topoisomerase activity, on occasion they can 
become abortive: the TOP2-DNA complex is stabilised and prevented from religating the 
DNA. These abortive covalent complexes can emerge naturally, due to oxidative stress, 
acidic pH and DNA modification (e.g. abasic site), and can be converted into permanent 
DSBs by collision with replication forks or transcription complexes. Another source of 
trapped topoisomerase-DNA complexes is via exposure to TOP2 poisons (see sections 
below) (Robinson and Osheroff 1990, Wilstermann and Osheroff 2003). 
1.1.2.2.2 DSBs induced by abortive TOP2-DNA complexes are repaired by DSBR. 
The removal of the abortive TOP2-DNA adducts is vital for cell viability (Nitiss 2009). 
The covalently trapped TOP2 enzyme is first targeted to proteolytic degradation by the 
26S proteasome and can be repaired in several ways (Figure 1.1.4). The nucleolytic 
pathway employs the exonuclease complex MRN/CtIP to remove the covalent adduct 
(Hartsuiker et al. 2009). In resting cells DSBs are restored by the NHEJ pathway. As 
exonucleases remove nucleotides during DNA end resection, the process results in 
information loss and error prone repair. An error free, non-nucleolytic pathway involves 
the breakage of the phosphotyrosyl bond between the DNA and the topoisomerase. It has 
been known that tyrosyl DNA phosphodiesterase 1 (TDP1) catalyses the removal of the 
trapped topoisomerase I (TOP1) by hydrolysis of the 3'-phosphotyrosyl bond (Yang, 
Burgin et al. 1996). It was recently discovered that there is an enzyme that processes 5'-
phosphotyrosyl bonds, denoted tyrosyl DNA phosphodiesterase 2 (TDP2). TDP2 is 
involved in many cellular processes such as transcription regulation and signalling 
pathways, and it was demonstrated that it catalyses hydrolysis of the 5'-phosphotyrosyl 
bond that links TOP2 to the 5’-terminus of DNA (Cortes Ledesma et al. 2009). TDP2 will 
be discussed in more detail in the next section. The proteolytic pathway involves the 
degradation of TOP2 by triggering the ubiquitin/26S proteasome pathway (Mao et al. 2001, 
Zhang et al. 2006, Gao et al. 2014). The remaining small peptide bound to the DNA is 
removed by TDP2. Both the proteolytic and the nucleolytic pathways result in DSBs that 
can be processed by either nonhomologous end joining (NHEJ) or homologous 
recombination (HR). 
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Figure 1.1.4. TDP2 is part of the NHEJ pathway. TOP2-DNA abortive complexes can 
either emerge naturally or from poisoning by chemotherapeutic agents. First, the 
complex is targeted for proteolytic degradation. Depending on the stage in the cell cycle, 
double strand breaks can be repaired by either NHEJ or HR. In NHEJ the nucleolytic 
processing of these breaks results in sequence lost and error prone DNA repair. TDP2 
hydrolyses the 5’ phosphotyrosyl bond without sequence lost. The repair is error free. 
Figure is adapted from (Caldecott, 2012). 
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1.1.2.2.3 TOP2 as chemotherapeutic drug target 
Topoisomerase poisoning can emerge not only naturally but also from the effect of drugs 
(Pommier et al. 1985). Because TOP2 is required in proliferating cells, it is a useful target 
for inhibition in cancer chemotherapy (Nitiss 2009). TOP2 inhibitors can be categorized 
into two major groups according to their action on TOP2. Drugs such as novobiocin and 
merbarone can act as catalytic inhibitors and do not increase the level of TOP2-DNA 
complexes. In contrast, TOP2 poisons such as etoposide and doxorubicin can trap the 
enzyme intermediate covalently bound to DNA (Chen et al. 1984) . The increased level of 
TOP2 covalent complexes can block transcription and replication and can lead to 
apoptosis. These poisons were first thought to be effective in highly proliferative tumours 
with high expression level of TOP2α. 
Etoposide was clinically developed and is widely used in a broad range of solid tumours 
and was approved by the FDA in 1983. The etoposide induced stabilization of TOP2-DNA 
complexes was studied extensively (van Maanen et al. 1988). As opposed to other TOP2-
DNA complex poisoning drugs, etoposide is not an intercalating agent and can trap the 
TOP2 homodimers asymmetrically, resulting in mainly single stranded break formation 
(Chen et al. 1984) (Long et al. 1985). Etoposide also very effectively binds both TOP2α 
and TOP2β, whereas other drugs, such as doxorubicin are more selective towards TOP2α. 
Trapping TOP2β by etoposide is mainly the responsible for translocations and the 
induction of secondary leukaemia following chemotherapy (Cowell and Austin 2012). 
 
TOP2α has been proven to be an effective clinical target in chemotherapy; however, recent 
findings suggest that TOP2β might also become a good drug target on its own right 
(Jarvinen and Liu 2006) (Nitiss 2009). TOP2β is recruited with androgen and oestrogen 
receptors to regulatory sites of hormone activated genes. TOP2β initiates transcription by 
introducing a transient double strand break, supposedly to resolve topological constraints 
during the induction of transcription (Ju et al. 2006). The break is recognised by the DNA 
repair machinery and repair factors such as ATM, DNA-PK and PARP1 are recruited to 
the damage site. Many slow proliferative cancer types (prostate and breast) can respond to 
hormone therapy by reinitiating their transcriptional program, therefore, it was 
hypothesised that TOP2β inhibition alongside with cycling hormone therapy could be an 
effective treatment (Haffner et al. 2011). 
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1.1.3 Tyrosyl DNA phosphodiesterase 2 (TDP2) 
1.1.3.1 Introduction 
TDP2 has diverse roles in cellular pathways and the investigation of these functions by 
independent studies resulted in alternative names for this enzyme such as EAPII, TTRAP 
and TDP2. The protein was first identified as a novel intracellular binding partner for CD40 
and was termed TTRAP (TRAF and TNF receptor associated protein) (Pype et al. 2000). 
Yeast two-hybrid screen has shown that this protein also interacts with the transcription 
factor ETS1 hence the alternative designation EAPII (ETS1-associated protein II) (Pei et 
al. 2003). And finally, it was only recently discovered that this protein catalyses the 
removal of protein adducts (TOP2) from DNA by cutting the 5'-phosphotyrosyl bond 
(Tyrosyl DNA phosphodiesterase 2, TDP2) (Cortes Ledesma et al. 2009). 
TDP2 is conserved from worms to mammals. In human this 362-amino acid protein is 
ubiquitously expressed in most tissues such as lung, ovary, prostate and kidney (Li et al. 
2011). The protein has numerous interacting partners involved in many biochemical 
processes. By interacting with members of the TNF receptor superfamily and TRAFs (TNF 
receptor-associated factor) TDP2 negatively regulates TNFα signalling and therefore 
suppresses inflammatory response (Pype et al. 2000). TDP2 can interact with several 
transcription factors such as members of the Ets (E-twenty six) transcription factor family. 
Ets transcription factors control cellular proliferation, differentiation and lymphocyte 
development (Pei et al. 2003). By repressing the transcriptional activity of ETS1, TDP2 
can negatively control the transcription of the MMP1 (matrix metalloproteinase-1) 
promoter. TDP2 also modulates JNK/p38 apoptosis pathway in neuronal cells by 
interacting with DJ-1. Mutated DJ-1 is one of the several genetic factors that are 
responsible for the autosomal recessive Parkinson disease (Li et al. 2011). It was also 
demonstrated that TDP2 is associated with virus response (Lee et al. 2003). 
1.1.3.2 TDP2 hydrolyses 5’-tyrosyl DNA phosphodiester bonds 
TDP2, previously known as TTRAP, was identified in a screen for new tyrosyl DNA 
phosphodiesterase activities (Cortes Ledesma et al. 2009). Tdp1/Rad1 deleted S. cerevisiae 
yeast cells were transformed with a human complementary DNA library and were screened 
for resistance to the TOP1 poison camptothecin (CPT). Compared to TDP1, which 
liberates abortive TOP1-DNA complexes by cleaving the 3’-tyrosyl DNA phosphodiester 
bond, recombinant TDP2 showed ~50-fold lower 3’-tyrosyl DNA phosphodiesterase 
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activity in vitro. However, the enzyme exhibited robust 5’-tyrosyl DNA phosphodiesterase 
activity.  
TDP2 is the primary source of 5'-tyrosyl DNA phosphodiesterase activity in vertebrate 
cells (Zeng et al. 2011). In TDP1 deleted vertebrate cells, TDP2 can also contribute to 3’ 
tyrosyl DNA phosphodiesterase activity, albeit weakly, since DT40 cells in which both 
TDP1 and TDP2 are deleted are more sensitive to the TOP1 poison camptothecin than cells 
in which only TDP1 is deleted (Zeng et al. 2012) 
1.1.3.2 TDP2 -dependent NHEJ protects against genome instability 
TDP2 is the major, if not only, 5’-tyrosyl DNA phosphodiesterase in mammals (Gomez-
Herreros et al. 2013). TDP2 knockout mice do not exhibit any obvious abnormal 
pathology, suggesting that TDP2-independent pathways are able to repair most 
endogenous TOP2 damage in the absence of TDP2. However, these mice have shown 
extreme sensitivity to TOP2 poisons. Etoposide administration results in increased 
mortality due to intestinal damage and toxicity in lymphoid tissues. It was also shown that 
TDP2 is a component of the NHEJ pathway as it was demonstrated that Ku70 and TDP2 
exhibit an epistatic relationship. TDP2 loss results in an elevated DSB repair defect in the 
cell cycle stages G0/G1 and G2 (Gomez-Herreros et al. 2013).  
1.1.3.3 TDP2 protects transcription from abortive topoisomerase activity and is 
required for normal neural function 
The removal of topoisomerase-DNA adducts is crucial to protect the genetic integrity not 
only in cells, but also at the level of the whole organism. Impeded DNA phosphodiesterase 
function can result in neurodegenerative disorders. SCAN1 (spinocerebellar ataxia with 
axonal neuropathy-1) is a hereditary human disease, affecting terminally differentiated 
neurons (Takashima et al. 2002). In this disease, a recessive mutation in the active site 
histidine H493 to arginine in TDP1 greatly reduces the enzyme activity (Interthal et al. 
2005). 
Recent findings have shown that TDP2 is required for proper expression of TOP2β -
dependent genes, many of which are implicated in normal neuronal development (Gomez-
Herreros et al. 2014). Human individuals with impaired TDP2 activity show intellectual 
disability, seizures and ataxia. It was also demonstrated that TDP2 activity is required for 
normal levels of transcription of a set of androgen-receptor responsive genes in prostate 
cancer cells, even in the absence of exogenous TOP2 poisons (Gomez-Herreros et al. 
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2014). This finding also supports the idea of targeting TDP2 in cancer chemotherapy as 
hormone induced transcription of a set of genes heavily relies on TDP2 activity. 
1.1.3.4 TDP2 as VPg unlinkase 
It was recently demonstrated that TDP2 enzymatic function is hijacked by certain viral 
pathogens upon infection (Virgen-Slane et al. 2012). During their life cycle, the positive-
strand RNA viruses of the picornavirus family (e.g. poliovirus and human rhinovirus) use 
a small viral protein (VPg) as a primer for RNA synthesis. This VPg needs to be removed 
upon polysome association. The enzyme which facilitates the 5’-tyrosyl RNA scission 
have been called VPg unlinkase but the true identity of this enzyme had been remained 
elusive for decades. By employing multi step purification, alongside with VPg unlinkase 
activity assays from uninfected HeLa cells, TDP2 was identified as VPg unlinkase. The 
finding that TDP2 is able to process protein-RNA complexes was further substantiated by 
biochemical assays and structural studies (Gao et al. 2014). The discovery of the 
involvement of TDP2 in host-pathogen interactions have shown another aspect of TDP2 
function, and also identified TDP2 as potential drug target in viral infections (Caldecott 
2012). 
1.1.3.5 Structure-function examination of TDP2 
Recent reports (Schellenberg et al. 2012) (Shi et al. 2012) have solved the structure and 
catalytic mechanism, of TDP2. A schematic overview of the domain organization of the 
molecule can be observed in Figure 1.1.5.  
 
Shi et al. reported the structure of the full-length TDP2 from C. elegans (Shi et al. 2012). 
The structure is modular and composed of three parts: a forty amino acid long N-terminal 
stretch with no secondary elements followed by a small α-helical bundle composed of four 
helices (UBA-like domain), and the C-terminal catalytic domain. In the crystal structure 
the N-terminal part of TDP2 interacts in trans with the catalytic domain, resulting in two 
molecules in the asymmetric unit. The N-terminal stretch rich in glutamate and aspartate 
residues inserts into the DNA binding groove and the active site of the catalytic domain of 
an other molecule. This single stranded DNA mimicry suggests a specific type of 
regulation. The α-helical bundle makes contact with the catalytic domain via a hydrophobic 
interface. The multimerization of the full-length protein was also confirmed by small-angle 
X-ray scattering (SAXS) in physiological conditions. The proposed autoregulation of 
enzymatic activity by the N-terminal part of TDP2 remains to be investigated. 
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Figure 1.1.5. Domain structure of TDP2. A. Schematic representation of the domain 
organisation of TDP2. The N-terminal UBA domain is involved in the ubiquitination 
pathway and the C-terminal catalytic domain facilitates the scission of the 
phosphotyrosyl bond. B. Tertiary structure of the catalytic domain in complex with the 
cleavage product. The 5’ end of the DNA is accomodated and oriented into the active 
site by the motifs ‘Cap’ and ‘Grasp’. The magnesium cation (red sphere) is involved in 
phosphodesterase reaction. (Schellenberg et al. 2012) 
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An earlier report (Li et al. 2011) predicted that the N-terminal part of TDP2 encodes a 
ubiquitin-associated (UBA)-like domain. The classical fold of the (UBA)-like domain is 
composed of three helices and it is a common structural motif in enzymes involved in the 
ubiquitination pathway. It is also worth noting that the catalytic domain of TDP2 harbours 
a SUMO-interaction motif. Sumoylated and ubiquitinated TOP2 is targeted for proteolysis 
and it is hypothesised that these modifications also facilitate the recruitment of TDP2 to 
degraded abortive TOP2 cleavage complexes to liberate DNA ends ready for ligation (Gao 
et al. 2014). 
 
The catalytic domain is responsible for the phosphodiesterase activity (Figure 1.1.5). 
Databank searching and sequence alignment identified six well-conserved motifs, which 
consigns TDP2 to the Mg2+/Mn2+ dependent phosphodiesterase superfamily (MDP) 
(Rodrigues-Lima et al. 2001). Within the MDP superfamily, TDP2 is most closely related 
to the apurinic/apyrimidinic endonuclease APE1, which is involved in BER (Sukhanova et 
al. 2005). 
 
According to structural studies by Schellenberg et al., the catalytic domain of the murine 
TDP2 has a globular α-β fold composed of a 12-stranded β-sandwich surrounded by eight 
α-helices (Schellenberg et al. 2012). The DNA is directed to the active site by the ‘cap’ 
and ‘grasp’ architectural motifs forming a cleft. The ‘grasp’ is composed of amino acids 
located on the M7-loop and mainly facilitates DNA binding by hydrophobic interaction. 
The ‘cap’ is located at the opposite site of the cleft; conserved amino acid residues making 
contact with the phosphate-sugar backbone of the DNA directing the 5’ terminus into the 
active site. Based on structural and mutagenesis data, the mechanism by which TDP2 
cleaves 5’-phophotyrosyl bonds is via single-metal-ion catalysis; Asp272 activates a water 
molecule for a nucleophilic attack on the 5’-phosphate. Mg2+ and three conserved residues 
(His236, His359 and Ser239) interact with the substrate phosphate to stabilize the 
pentacovalent transition state. The formation of a transient covalent complex was predicted 
in earlier reports as vanadate inhibits the catalytic activity of TDP2 reference (Zeng et al. 
2011). It was also demonstrated that optimal Mg2+ concentration is essential for the 
catalytic activity of TDP2 (Adhikari et al. 2012). Elevated Mg2+ concentration has an 
inhibitory effect on TDP2 enzyme activity. 
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Interestingly TDP2 does not show structural similarities to the 3'-tyrosyl DNA 
phosphodiesterase (TDP1). TDP1 is a member of the diverse phospholipase D superfamily 
(PLD) (Interthal et al. 2001). TDP1 is a monomeric protein with two domains and contains 
two HKD (His, Lys and Asp) motifs which are responsible for the catalytic activity. The 
HKD motif is a common feature within the DLP superfamily and the catalytic reaction 
involves covalent complex formation between TDP1 and the 3'-end of DNA via a His 
residue of one of the HKD motifs. Structural studies of TDP1 complexed with vanadate (a 
common inhibitor of TDP1) have shown that vanadate is covalently linked the catalytic 
His residue (Davies et al. 2003). 
1.1.3.6 TDP2 as potential drug target 
The identification of TDP2 as a potential drug target is immediately suggested from its 
ability to resolve TOP2-DNA abortive complexes (Cortes Ledesma et al. 2009). TDP2 
inhibitors might have utility in combination therapy with the TOP2 ‘poison’ etoposide, 
which kills tumour cells by inducing TOP2 cleavage complexes. In addition, TDP2 
inhibitors could be employed as a monotherapy in hormone-driven cancer types as their 
transcription program heavily relies on TDP2 activity (Gomez-Herreros et al. 2014). 
Unexpectedly, TDP2 was also identified as VPg unlinkase, an important factor in 
picornavirus infection (Virgen-Slane et al. 2012). TDP2 inhibitors might thus prove 
beneficial in the treatment of diseases such as meningitis, encephalitis, hepatitis or the 
common cold. 
To identify small molecule inhibitors of TDP2, a high-throughput screening (HTS) strategy 
was developed (Thomson et al. 2013). Thomson and co-workers, in a collaboration 
between my laboratory and the Paterson Institute of Cancer Research, developed a 
chromogenic assay format, using 4-nitrophenyl phenylphosphonate (NPPP) as a 
chromogenic TDP2 substrate (Thomson et al. 2013). Approximately 100 000 compounds 
were screened in this HTS format, and toxoflavins and a singleton deazaflavin were 
identified confirmed hits (Raoof et al. 2013). Although toxoflavins showed clear structure 
activity relationship (SAR) for TDP2 inhibition, their redox liability hindered further 
exploration of this series. The single hit from a deazaflavin was developed into a promising 
series of compound showing clear SAR through a focused screen. These compounds had 
no observable redox liability, had good inhibition values and showed dosed dependent 
inhibition of TDP2 (Raoof et al. 2013).  
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1.1.4 The aim of Project I 
My aim was to obtain structural information about TDP2 in complex with small molecule 
inhibitors to aid future drug development. In chapter 3 I will describe the early expression, 
purification and crystallisation trials of TDP2. In Chapter 4, the results of TDP2 binding 
and activity assays in the presence of small molecule inhibitors will be discussed and how 
these assays led to crystallisation trials which concluded in obtaining the first low-
resolution dataset of a complex between TDP2 and an inhibitor. Chapter 5 describes the 
development of a surrogate protein in order to obtain high-resolution structure of these 
complexes, and Chapter 6 describes the results of initial cell-based assays to test the 
efficacy of these inhibitors.  
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1.2 Project 2 – Molecular analysis of the role of the 
XRCC1 BRCT1 domain 
 
1.2.1 Single Strand Break Repair (SSBR) 
DNA Single-strand breaks (SSBs) are the most common types of DNA damage and can 
arise at a frequency of tens of thousands per cell per day. These SSBs can arise directly by 
endogenous reactive oxygen species (ROS) and indirectly as intermediates of the base 
excision repair (BER) pathway (Pogozelski and Tullius 1998, Demple and DeMott 2002). 
SSBs can also arise from abortive Topoisomerase 1 (Top1) activity (El-Khamisy and 
Caldecott 2006). TOP1 releases torsional stress from DNA, which accumulates during 
transcription and DNA replication. If Top1 cleavage complexes are trapped by the 
presence of nearby lesions and/or collide with DNA or RNA polymerases, it can result in 
Top1-linked SSBs and DSBs, which if unrepaired it can lead to genetic instability or cell 
death. The most common pathway for repair of SSBs is single strand break repair (SSBR), 
which utilises four main steps: SSB detection, DNA end processing, DNA gap filling and 
finally DNA ligation (Figure 1.2.1) (Caldecott 2008).  
In brief, poly(ADP-ribose) polymerase 1 (PARP1) detects SSBs and triggers the 
subsequent steps in the SSBR, by modifying itself and other proteins with long branched 
chains of poly(ADP-ribose) (PAR) (Kim et al. 2005). Autoribosylated PARP1 can promote 
the re-localisation of other repair proteins to damage sites (Pleschke et al. 2000). An 
important binding partner of PARP1 is the scaffold protein X-ray repair cross-
complementing protein 1 (XRCC1) (El-Khamisy et al. 2003). XRCC1 orchestrates the 
subsequent repair steps by interacting and stimulating the different enzymatic components 
of SSBR and will be discussed in more detail in section 1.2.6. PARP1 is also implicated in 
DNA base excision repair pathway (BER), which is initiated by a DNA glycosylase that 
removes damaged or inappropriate bases by hydrolysis of the N-glycosidic bond (Durkacz 
et al. 1980, Krokan et al. 1997). The resulting apurinic-apyrimidic sites (AP sites) are 
cleaved either by AP endonuclease 1 (APE1), hydrolytically, or via the E-lyase function of 
a bifunctional DNA glycosylase (Wilson et al. 1997, Rykhlevskaya and Kuznetsova 2000). 
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Figure 1.2.1. Schematic representation of single strand break repair. Single strand break 
can emerge directly or indirectly from apurinic/apyrimidinic (AP) sites removed by AP 
endonuclease I (APE1) or the lyase activity of bifunctional DNA glycosylases. TOP1-
DNA adducts are mainly removed by Tyrosyl-DNA phosphodiesterase 1 (TDP1). The 
gap is detected by poly(ADP-ribose) polymerase 1 (PARP1). Activated PARP1 auto-
ribosylates itself and other protein molecules, mainly histones. The ribosylation recruits 
downstream repair factors such as the scaffold protein XRCC1. When required, end 
processing enzymes (e.g. PNKP and APTX) restore the damaged ends to their canonical 
chemistry. During gap filling Polβ can insert a single nucleotide (short patch), or can 
synthesise a 10-12 nucleotide long flap which is then resected by Flap endonuclease 1 
(FEN1) (long patch repair). The DNA ends are then ligated by either Lig3 (short patch 
repair) or Lig1 (long patch repair). KEY: RNAP, RNA polymerase, α, β, 3’-α, β 
unsaturated aldehyde; Ade, aldehyde; AMP, 5'-AMP; dRP, 5'-deoxyribose phosphate; 
OH, 5'-hydroxyl; P, 3'-phosphate; PG, 3'-phosphoglycolate. Figure is adapted from 
Caldecott, 2008 (Caldecott, 2008). 
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During DNA end processing the damaged 3'-and 5'-termini are restored to 3’-hydroxyl (3'-
OH) and 5'-phosphate (5’-P) termini. The chemistry of these damage termini can be quite 
diverse, (e.g. 3’-phosphate, 5’-hydroxyl, 5’-aldehyde or phosphoglycolate) and so this step 
requires the availability of a broad range of enzymes (Figure 1.2.1). These enzymes were 
discussed in section 1.1.1.1. Once DNA termini are restored to their canonical chemistry, 
DNA gap filling can occur. This can involve either short patch or long patch gap filling 
(Frosina et al. 1996). Short patch gap filling involves the incorporation of a single 
nucleotide by DNA polymerase β (Polβ), whereas long patch gap filling involves the 
incorporation of two or more nucleotides, using Polβ, an/or Polδ/Polε (Polδ/ε). Flap 
endonuclease 1 (FEN1) is also required during long patch gap filling, to remove the 
displaced nucleotides as a 5’-single-strand flap (Liu et al. 2005). This reaction is stimulated 
by PARP1 and the proliferating cell nuclear antigen (PCNA) (Gary et al. 1999). 
 
The final step of SSBR is DNA ligation by DNA ligases (Cotner-Gohara et al. 2008). DNA 
ligase III (Lig3) restores an intact phosphodiester backbone, thereby ligating the break, 
during short-patch repair step, whereas during long-patch repair SSBs are thought to be 
ligated by DNA ligase I (LIG1). However, recent reports suggest that there is much 
enzymatic redundancy in this step, with Lig1 and Lig3 fulfilling overlapping functions 
(Simsek et al. 2011).  
 
1.2.2 ADP ribosylation is a post-translational modification 
ADP-ribosylation is a common protein post-translational modification, and is triggered 
during DNA repair, transcription, and cell cycle progression (Schreiber et al. 2006, Leung 
2014). Poly(ADP-ribose) polymerases (PARPs) synthesise PAR polymer at the expense of 
NAD+ (Chambon et al. 1963). The cellular concentration of NAD+ is 400-500μM in 
undamaged mammalian cells (Elliott and Rechsteiner 1975). However, during extensive 
DNA damage, the intracellular concentration of NAD+ can decrease to 10-20% of the 
normal level (Goodwin et al. 1978). 
1.2.2.1 Mono(ADP-ribosylation) 
ADP ribosylation is phylogenetically well-conserved modification of target molecules 
(Ame et al. 2004). A subtype of this reaction is mono (ADP-ribosylation) and it is common 
in both eukaryotes and prokaryotes (Okazaki and Moss 1999). In prokaryotes, the best-
studied mono-ribosylating enzymes are bacterial toxins, such as cholera toxin, heat-labile 
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enterotoxin and diphtheria toxin (Corda and Di Girolamo 2003). Cholera toxin targets the 
α-subunits of GTP-binding proteins resulting in constant activation and high level of 
cyclic-AMP, which stimulates the release of fluids and ions from intestinal epithelial cells. 
The main amino acids modified by enterotoxins are glutamate, aspartate, cysteine and 
asparagine. ADP ribosylation of the diphthamine residue (modified histidine residue) on 
the eukaryotic elongation factor 2 (eEF-2) by the diphtheria toxin results in translational 
inhibition (Mateyak and Kinzy 2013).  
The sirtuin (SIRT) family is an intracellular mono (ADP-ribosylating) enzyme family and 
well conserved in eukaryotes, prokaryotes and archaea (Corda and Di Girolamo 2003). 
SIRT proteins regulate development, metabolism, heterochromatin formation, DNA 
transcription and DNA repair (Yamamoto et al. 2007). Most mammalian SIRTS are 
involved in histone deacetylation; however, SIRT2 is a known tubulin deacetylase. The 
family of the eukaryotic mono-ADP-ribosyltransferases (e-MARTs) possess extracellular 
mono(ADP-ribosylase) activity. e-MARTs are either cell membrane proteins or secretory 
proteins, targeting arginine or cysteine residues on extracellular proteins (Okazaki and 
Moss 1996).  
There are members of the PARP [poly(ADP-ribose) polymerase] family (discussed in 
detail in section 1.2.3), which also possess mono(ADP-ribosylase) activity. PARP3 is a 
nuclear protein and involved in DNA repair and is stimulated by both DSBs and SSBs, but 
exhibits a preference for breaks with 5’-phosphorylated termini (Rulten et al. 2011, 
Langelier et al. 2014); PARP enzymes PARP6-8, PARP10-12 and PARP14-16 are also 
mono(ADP-ribosylase) enzymes (Gibson and Kraus 2012). Nuclear substrates for mono-
ribosylation are mainly histones. H1 histones are modified on glutamate residues E2, E15 
and E114/E115/E117 and on Arg33; H2B mono-ribosylated on Glu2 (Burzio et al. 1979, 
Ogata et al. 1980). Other studies indicated arginine residue modification on H2A, H2B, 
H3 and H4 histones (Golderer and Grobner 1991). 
1.2.2.3 Poly (ADP-ribosylation) 
ADP ribosylation of target molecules can result in long, branched chains of poly(ADP-
ribose) (PAR). PAR polymer is a homopolymer of ADPr units linked via glycosidic ribose-
ribose 1’-2’ bonds (Miwa et al. 1979) (Figure 1.2.2). The forming polymer is negatively 
charged and can alter the activity of the modified protein through steric or electrostatic 
changes. The chain length can reach 200-400 units and branching can occur very  
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Figure 1.2.2. The cycle of ribosylation by PARP. PARP enzymes catalyse the transfer 
of an ADP-ribose onto a target molecule on the expense of substrate NAD+. The PAR 
polymer can be recognised by several PAR binding motifs and domains. Macrodomains 
recognise terminal ADP-ribose, and the WWE domain recognises iso-ADP-ribose. PBZ 
domain facilitates PAR binding by stacking interaction with the adenine moiety and the 
glycosidic bond at the ADP-ribose-ADP-ribose junction. PAR chains are hydrolysed by 
PARG and ADP-ribosylhydrolyse 3 (ARH3), however, the most proximal ADP-ribose 
remains attached to the protein. Mono(ADP-ribose) is removed by MACROD1/2 and 
TARG1. Figure is adapted from (Barkauskaite et al. 2013). 
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irregularly (in every 20 or 50 elongation steps) (Kiehlbauch et al. 1993). During branching, 
the O-glycosidic bond forms between two nicotinamide-proximal ribose rings (N-ribose), 
whereas in the elongation step the incoming N-ribose binds to the adenine-proximal ribose 
of the growing polymer (Ruf et al. 1998, Otto et al. 2005). The structure of the polymer 
can be very complex and it was hypothesised that certain polymers can adopt helicoidal 
secondary structures (Minaga and Kun 1983). A proteome wide analysis of PARylated on 
aspartic and glutamic residues identified 340 target proteins (Zhang et al. 2013).  
1.2.3 Poly(ADP-ribose) polymerase 1 (PARP1)  
PARP1 is the founding member of the diverse poly(ADP-ribose) polymerase superfamily 
(PARPs), so far comprised of 17 proteins (Sousa et al. 2012). All PARPs share the 
conserved ADP-ribosyl transferase fold (D'Amours et al. 1999). Several PARPs have 
polymerase activity (PARP1, 2, 4 and 5a and 5b), the majority possesses mono-ribosylase 
function (see section 1.2.2.1) and two enzymes are enzymatically inactive (PARP9 and 13) 
(Gibson and Kraus 2012). PARP1 displays similar functional features as PARP2 and 
PARP3 (Ame et al. 1999, Boehler et al. 2011). The main roles of PARP1-3 in DNA damage 
responses are DNA damage sensing and signalling, DNA repair, and cell death induction. 
Some of these functions can overlap as Parp1-/- or Parp2-/- animals are viable, whereas 
Parp1-/-/Parp2-/- mice exhibit embryonic lethality (Menissier de Murcia et al. 2003). 
PARP3 has a role in DSBR by recruiting APLF, which in turn increases the recruitment or 
the retention of XRCC4-LigIV at sites of DNA damage (Rulten et al. 2011). Apart from 
its well-established roles in DNA damage response, PARP1 also involved in transcription 
activation of genes by modulating the chromatin environment (Krishnakumar et al. 2008) 
and in the stress response (Luo and Kraus 2012).  
 
PARP1 is 116kDa, and contains three major functional units: the N-terminal DNA binding 
region (NTR), the central BRCT domain (or auto modification domain, AMD) and the 
carboxy-terminal catalytic region (Figure 1.2.3) (Kreimeyer et al. 1984, Suzuki et al. 1987, 
Uchida et al. 1987, Ushiro et al. 1987). The DNA binding domain contains two tandem 
DNA binding zinc fingers, a third zinc binding domain that binds DNA and transmits 
allosterically binding to the catalytic domain (Langelier et al. 2008). PARP1 recognises 
and binds to single- and double-strand breaks and other aberrant DNA forms, such as 
cruciform DNA (Kim et al. 2004). Structural studies have shown that the first zinc finger 
and the second zinc finger from separate PARP1 molecules form a heterodimer aiding  
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Figure 1.2.3. Schematic view of PARP1 domain organization. The N-terminal DNA 
binding domain (DBD) is composed of two zinc fingers (Zn1 and Zn2) and a zinc-
binding domain. The central auto-modification domain (AMD) is a BRCT domain the 
main target for auto-ribosylation, and the well-conserved C-terminal catalytic domain 
(CD) is consisted of the WGR motif, the helical subdomain (HD) and the ART 
subdomain. 
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PARP1 dimerization and consequently trans-ribosylation (Ali et al. 2012). The central 
BRCT domain is the main PAR acceptor during auto- and trans-ribosylation, however, a 
recent study identified several ribosylation sites in the DNA binding region and in the 
catalytic domain as well. The main acceptors are aspartic and glutamic residues, although 
few lysine resides were also identified (Chapman et al. 2013) as PARylation sites. 
 
The WGR (Trp, Gly and Arg rich) motif binds DNA and has an important role in mediating 
domain-domain contact essential in DNA dependent activity (Langelier et al. 2012). The 
conserved CD domain contains the helical subdomain (HD), and the NAD+ binding ART 
subdomain [ART: (ADP-ribosyl) transferase]. ART contains the conserved glutamate 
residue (Glu 988) required for poly (ADP-ribose) polymerase activity (Marsischky et al. 
1995). The E988Q mutation renders the protein to a mono-ribosylating enzyme.  
 
Upon DNA binding the catalytic domain is activated and PARylates itself and a variety of 
other nuclear proteins such as DNA dependent protein kinase (DNA-PK), Topoisomerase 
I and histone molecules. The main target for PARylation is PARP1 itself. The rate and type 
of PARP1 auto-modification depends on the severity of the DNA damage. Mild or 
moderate stress leads to DNA response (Kim et al. 2005) and PARP1 functions to re-
establish genome integrity. Severe PARP1 activation can lead to senescence or distinct cell 
death programs, such as necrosis, apoptosis or parthanatos (Ha and Snyder 1999, Gobeil 
et al. 2001). Hyper activated PARP1 can deplete cellular NAD+ and ATP, which leads to 
necrosis. Activated PARP1 can also stabilise the tumour suppressor p53, which 
subsequently commence apoptosis (Soldani and Scovassi 2002) (Boulares et al. 1999). 
Activated caspases cleave PARP1 into inactive 24 and 81 kDa fragments, preventing the 
depletion of NAD+ and ATP pools. 
Parthanatos differs from apoptosis, necrosis and autophagy (Wang et al. 2009). When the 
accumulating DNA damage far exceeds the cell’s repair capacity, PARP1 is over activated, 
which results in large scale PAR synthesis. If PAR production reaches a critical level it can 
lead to NAD+ depletion. The overproduced PAR translocates from the nucleus to the 
cytosol and interacts with mitochondria. Apoptosis Inducing Factor (AIF) is released upon 
the interaction and translocates to the nucleus where it binds to DNA and triggers large-
scale DNA fragmentation (Daugas et al. 2000). 
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Due to its role in DNA damage sensing PARP1 is an excellent chemotherapeutic drug 
target. Inhibiting PARP in homologous repair deficient cells (BRCA1 or BRCA2 deficient 
cells) leads to synthetic lethality by blocking base excision repair pathways (Helleday 
2011). Olaparib and veliparib are potent PARP inhibitors and they are in advanced clinical 
trials. Studies indicate the besides their inhibitory function they trap PARP-DNA 
complexes which results in cytotoxicity (Murai et al. 2012).  
1.2.4 PAR metabolism 
The nature of the PAR polymers is transient due to their rapid degradation; the typical half-
life of a polymer extends from 40 sec to 6 min (Boulikas 1992). The decomposition of 
PAR is dependent on length and branching; long, single-branched polymers degrade faster 
than short, multi-branched PARs (Li and Chen 2014). The main enzyme which degrades 
the PAR polymer by cleaving the glycosidic ribose-ribose 1’-2’ bond is the poly (ADP-
ribose) glycohydrolase enzyme (PARG) (Miwa and Sugimura 1971, Lin et al. 1997). 
PARG possesses both endo and exoglycolytic activity, and these activities can result in 
free, unbound polymer and ADPr, respectively (Braun et al. 1994). PARG is essential in 
the rapid turnover of PAR; PARG deficient mouse is embryonic lethal due to the 
uncontrolled accumulation of PAR. ADP-ribosylhydrolyse 3 (ARH3) is also a PAR 
processing enzyme, although less active than PARG (Mueller-Dieckmann et al. 2006, 
Niere et al. 2012). Both enzymes leave the most proximal ADPr attached to the target 
protein. The half-life of mono-ADP-ribosylation is significantly longer than PARylation. 
The single, most proximal ADPr moiety attached to the target molecule via an ester bond 
removed by the enzymatic activity of macrodomain containing enzymes (Jankevicius et al. 
2013). Up to date there are 3 macrodomain enzymes described: Macrodomain-containing 
protein 1 and 2 (MACROD1 and MACROD2) and Terminal ADP–ribose protein 
glycohydrolase 1 (TARG1 or previously known as C6orf130). It was shown that 
homozygous deficiency in TARG1 can result in neurodegenerative disease (Sharifi et al. 
2013). 
1.2.5 PAR recognition motifs 
Several different protein modules can facilitate PAR binding. 
Poly(ADP-ribose) binding motifs (PBMs) are the most abundant PAR binding motif and 
are present in a broad range of proteins. The motif is approximately 20 amino acids long 
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and mainly composed of Lys and Arg clusters interspaced with hydrophobic residues. 
However, the mechanism/s of PAR recognition by these motifs are unclear. This motif has 
been identified in several DNA repair proteins, including s XRCC1, XPA, Ku70, and also 
on histones, p53, and apoptosis inducing factor (AIF) (Pleschke et al. 2000). 
PAR binding zinc-finger (PBZ) domains are small (3.5kDa) modules, and first were found 
on the DNA damage response protein Checkpoint with Forkhead-associated and RING 
Domains (CHFR) (Oberoi et al. 2010). The fold is unordered and stabilized by a rigid zinc-
coordinated backbone which facilitates PAR binding by stacking interaction with the 
adenine moiety and the glycosidic bond at the ADP-ribose-ADP-ribose junction. Tandem 
PBZ domains of APLF have affinities for ADP-ribose in the subnanomolar range 
(Eustermann et al. 2010) (Figure 1.2.4 A). 
WWE domain was named after its most conserved residues. Iduna (RNF146) is a ubiquitin 
3 ligase and its WWE domain facilitates PAR binding by recognising the iso-ADP-ribose 
moiety (Wang et al. 2012) (Figure 1.2.4 B). PARylated proteins can be targeted to 
proteosomal degradation by PAR dependent ubiquitylation (DaRosa et al. 2015). The 
specificity for iso-ADP-ribose over ADP-ribose shows preference for binding to PAR over 
mono-ADP-ribose. Other proteins harbouring the WWE domain are PARP enzymes 
(PARP11 and PARP14) and E3 ubiquitin ligases further supporting the idea that WWE 
domains link PARylation to ubiquitin pathways (He et al. 2012). 
Macrodomain folds are found in all kingdom of life. The domain was named after 
macroH2A, a histone variant in which this domain fold was first identified. MacroH2A1.1 
employs PAR binding to regulate chromatin remodelling (Timinszky et al. 2009). The 
domain fold is composed of a six-stranded β-sheet and five α-helices. The recognition of 
ADP-ribose is mainly facilitated by stacking interaction with the adenine ring, and 
additional interactions with the pyrophosphate and the distal ribose further increases the 
specificity (Figure 1.2.4 C). Macrodomains have been identified in several other proteins, 
and in particular in histone variants, PARP enzymes and chromatin remodelling enzymes. 
Some macrodomain containing proteins can also show catalytic activity and can remove 
the most proximal glutamate-linked ADPr unit, therefore fully reversing the PARylation 
of target proteins. MACROD1, MACROD2 and TARG1 (C6orf130) (Jankevicius et al. 
2013) are all terminal glycohydrolases as it was discussed previously. PARG -the main 
PAR metabolizing enzyme- also harbours the macrodomain fold (Wang et al. 2014). 
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Figure 1.2.4 Molecular cartoon representation of known PAR binding modules. A. 
The first PBZ (Poly(ADP-ribose)-binding Zinc finger) domain of human APLF in 
complex with ribofuranosyladenosine; a PAR mimetic (PDB accession code: 2KQD) 
(Eustermann et al. 2010) B. WWE domain of RNF146 in complex with iso-ADPr 
(PDB accession code: 3V3L) (Wang et al. 2012) C. Macrodomain of macroH2A1.1 
in complex with ADPr (PDB accession code: 3IIF) (Timinszky et al. 2009). ADPr 
and its mimetics are shown in stick representation (carbon atoms coloured green). 
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Forkhead-associated (FHA) domains were first identified in forkhead transcription factors 
(Hofmann and Bucher 1995). This highly conserved domain is a known phospho-protein 
binding module (Durocher et al. 1999) and has a strict preference towards phospho-
threonine (pThr). However, it is able to recognise diverse patterns surrounding pThr 
(Mahajan et al. 2008). Proteins harbouring the FHA domain have been identified in 
eukaryotes and certain prokaryotes and these proteins are involved in many cellular 
processes, such as signal transduction, transcription, protein transport, DNA repair and 
protein degradation. The domain itself is composed of 80-100 amino acids and folds into 
an 11 stranded β sandwich, which can contain small helical insertions embedded between 
the loops connecting β strands (Durocher et al. 2000). The homology region of the FHA 
domain spans 8 β strands on one face of the β sandwich and harbours the phospho-peptide 
recognition motif. Phospho-peptide binding is mediated by the connecting loops of β3/β4 
β4/β5 and β5/β6 (Durocher et al. 2000). FHA domain harbouring proteins also has 
important roles in DNA repair. The FHA domain of NBS1 and Ring Finger Domain 8 
(RNF8) recognises the pThr motifs of MDC1, and these interactions facilitate the 
amplification of DNA damage signalling (Huen et al. 2007). Recently, the FHA domain of 
PNKP and APTX has been identified as PAR binding domain (Li et al. 2013). Li et al 
(2013) also demonstrated that similar to the phosphate-binding pocket identified on other 
FHA domains, two conserved lysine residues form the PAR-binding pocket in both PNKP 
and APTX. ITC assays have demonstrated that the FHA domain binds iso-ADPr and not 
ADPr. The FHA-BRCT fusion domain of NBS1 was also shown to interact with PAR, and 
mutational analysis has shown that the BRCT domain is responsible for the interaction (Li, 
Lu et al. 2013). 
BRCT domains are denoted such from their identification at the C-terminus of the breast 
cancer type 1 susceptibility protein (BRCA1) (BRCT stands for BRCA1 Carboxy Terminal 
domain) (Koonin et al. 1996). Further screening in protein databases identified a great 
number of nonorthologous proteins containing this well conserved domain (Bork, 
Hofmann et al. 1997). BRCT domains are remarkably versatile and involved in many 
different interactions (Leung and Glover 2011). They can mediate protein-protein 
interactions by recognising phospho serine (pSer) motifs by their phosphate-binding 
pocket (Yu et al. 2003) formed of conserved lysine and serine residues. E.g. the MDC1 
BRCT domain interacts with pS139 on H2Ax (Stucki et al. 2005). BRCT domains can 
appear in tandem in several proteins [i.e. the p53 binding protein (53BP1), Rad9 and 
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BRCA1] or in multiple copies separated by a loop (i.e. XRCC1) or as a single copy (DNA 
ligase 3 (LIG3) and PARP1) (Derbyshire 2002) (Nnakwe et al. 2009) (Taylor et al. 1998) 
(Loeffler et al. 2011). Tandem BRCT domains can achieve high selectivity towards 
phosphorylated proteins.  E.g. in BRCA1 the N-terminal BRCT1 domain harbours the 
phosphate-binding pocket selective towards pSer, and a secondary recognition site is 
formed at the BRCT1/BRCT2 interface (Clapperton et al. 2004). 
It was recently demonstrated that BRCT domains are also involved in poly(ADP-ribose) 
binding; e.g. BARD1 BRCT1 recognises PAR (Li and Yu 2013). A further study also 
identified the BRCT domain of Ligase4 as poly(ADP-ribose) binding module (Li et al. 
2013). ITC assays have shown that the domain binds ADPr, and the interaction is mediated 
by conserved lysine and serine residues. 
1.2.6 XRCC1 
XRCC1 is a scaffold protein and its function is to facilitate SSBR by interacting with 
enzymatic components of the repair process. Cells lacking functional XRCC1 are 
hypersensitive to genotoxins (Thompson et al. 1982) (Shen et al. 1998). EM9 is a well-
studied XRCC1-mutant Chinese hamster ovary cell line (CHO) in which there is increased 
sensitivity (10-fold) to alkylating agents such as ethyl methanesulfonate (EMS) or methyl 
methanesulfonate (MMS) (Cantoni et al. 1987). Reduced level of sensitivity caused by 
near-visible light, blue light and UV (Churchill et al. 1991). The rate of SSBR is reduced 
five-fold and the elevated level of unrepaired SSBs and if these unrepaired lesions collide 
with replication forks it can result in higher number of DSBs (Kuzminov 2001). XRCC1 
is indispensable during embryonic development (Tebbs et al. 1999); and it is also required 
in neurogenesis of cerebellar interneurons (Lee et al. 2009). 
 
XRCC1 is comprised of three domains connected by two linker regions (London 2015). 
The first interdomain region between the N-terminal domain and the BRCT1 domain 
harbours the nuclear localization signal (NLS) (Masson et al. 1998). This linker region has 
also been reported to be site of the interaction with Proliferating Cell Nuclear Antigen 
(PCNA) (Fan et al. 2004); PCNA is a homotrimeric loading clamp, implicated in DNA 
replication and also in DNA repair (Jaskulski et al. 1988, Shivji et al. 1992). The second 
linker region resides between the BRCT1 and BRCT2 domains and contains several casein 
kinase 2 (CK2) phosphorylation sites (Loizou et al. 2004) (Parsons et al. 2010). The 
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phosphorylation of XRCC1 by CK2 stimulates the binding and activity of PNKP, APTX 
and APLF via their FHA domain (Date et al. 2004, Iles et al. 2007, Ali et al. 2009). 
Each domain interacts with different repair protein binding partners (Figure 1.2.5) 
(Caldecott 2003). The N-terminal domain (NTD) interacts with Polβ (Caldecott et al. 1996, 
Kubota et al. 1996, Gryk et al. 2002). The central BRCT1 domain is the most conserved 
region of XRCC1 and can be found in plants and insects. The structure of BRCT1 was 
solved by Nagashima et al, using NMR spectroscopy (PDB accession code: 2D8M). 
However, there is currently no published report available. The domain fold is a typical 
BRCT fold, a central β-sheet formed by 4 parallel β-strands flanked by 3 α helices. Due to 
the high number of basic amino acids, the domain has a pI of 10.2, which is consistent with 
its role in PAR mediated interactions. Pleschke et al identified a PAR-binding motif (PBM) 
at the C-terminal part of BRCT1, composed of mainly hydrophobic and basic residues 
(Figure 1.2.6 A) (Pleschke et al. 2000). However, a more recent report identified the 
phosphate-binding pocket as the site of PAR binding (Figure 1.2.6 B) (Li et al. 2013). The 
phosphate-binding pocket is a well-conserved motif in BRCT domains mediating phospho-
serine binding, and mutating the conserved Lys369 in BRCT1 abolished PAR interaction. 
The main role of the BRCT1 domain is to mediate PAR dependent recruitment of XRCC1 
to sites of DNA damage (Masson et al. 1998, El-Khamisy et al. 2003). 
The structure of the C-terminal BRCT2 domain of XRCC1 was solved in 1998 (Zhang et 
al. 1998). BRCT1 and BRCT2 domains show great homology and 20% identity in amino 
acid composition. The BRCT2 domain forms a complex with Lig3α (Caldecott et al. 1995). 
As Lig3α completely lacks nuclear localization signal, its transport to the nucleus relies on 
the interaction with BRCT2 (Ellenberger and Tomkinson 2008). The BRCT2 domain of 
XRCC1 was shown to interact directly with DNA (Yamane et al. 2000), however, the 
physiological implication of this needs to be addressed. Other reports also suggested that 
XRCC1 preferentially binds DNA with single-strand breaks with a gap size of less than 
five nucleotides (Mani et al. 2004). 
 
1.2.7 The aim of Project II 
My goal was to investigate the interaction between the BRCT1 domain of XRCC1 and 
poly(ADP-ribose) applying cell biology and molecular biology techniques. 
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Figure 1.2.5. Schematic view of XRCC1 domain organisation. The N-terminal domain 
(NTD) interacts with Polβ. BRCT1 domain is the site for the PAR interaction and 
BRCT2 is the site of interaction with LIG3. The grey box represents the nuclear 
localization signal (NLS). The two interdomain linker regions between the three domains 
are also involved in protein-protein interactions. ** denotes phosphorylation sites by the 
protein kinase CK2. 
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Figure 1.2.6: Ribbon diagram representing the structure of the BRCT1 domain of 
XRCC1. A. On the right: the hypothetical poly(ADP-ribose) binding motif composed of 
mainly basic and hydrophobic residues is depicted (in green). B. On the left: the 
phosphate-binding pocket is composed of well-conserved amino acid residues. 
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1.3 Introduction to X-ray Crystallography 
1.3.1 Protein crystallisation 
Through a controlled dehydration process, proteins can be forced to adopt a crystalline 
form. Crystallisation is thought to occur when the concentration of the protein reaches a 
metastable or ‘supersaturated’ state, which promotes the formation of micronuclei, from 
which a crystal is ‘seeded’ and can grow. This equilibrium process is described by the 
‘phase-diagram’ depicted in Figure 1.3.1 (Chayen and Saridakis 2008). 
More than 150 years after the crystallisation of haemoglobin was reported, the approach to 
crystallising proteins is still largely one of trial and error – as the successful formation of 
protein crystals is dependent on many different experimental factors, including: 
temperature, pH, salt concentration, the presence of other chemical agents, as well as the 
purity of the protein sample itself. 
In 1958, John Kendrew and his team reported the structure of sperm whale myoglobin, the 
first protein structure to be determined, albeit at low resolution (6Å) (Kendrew et al. 1958). 
Two years later, Kendrew et al., reported a high resolution structure (2Å) of the same 
protein (Kendrew et al. 1960). No Protein Data Bank (PDB) entry represents the original 
myoglobin structure, since the databank was not established until 1971. However, in 1973, 
Watson and Kendrew deposited a refined model, at a resolution of 2.0 Å, available under 
accession code 1MBN. 
1.3.2 Crystallisation methods 
Several different methods have been developed, in order to overcome the inherent 
difficulties of crystallising proteins. Each method has its own distinct advantages, which 
may be useful for crystallisation certain types of proteins. A brief summary of the most 
common techniques is presented below. 
1.3.2.1 Vapour Diffusion 
Vapour diffusion is the most widely employed method of protein crystallisation. In this 
method a small droplet, created by mixing together protein and buffer/precipitant 
(crystallisation solution) is allowed to equilibrate against a reservoir containing a larger 
volume of the same mother liquor. 
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Figure 1.3.1. Phase diagram for protein crystallisation. Adjustable parameters (x-axis) 
include concentration of precipitation agent, pH or temperature. Solubility is defined as 
the concentration of protein in solution that is in equilibrium with crystals. The four 
major crystallisation methodologies are represented on the phase diagram: (i) 
Microbatch, (ii) Vapour diffusion, (iii) Micro-dialysis and (iv) Free-Interface Diffusion 
(FID). The starting condition for each method, and expected path through the phase 
diagram, are represented by the grey circle, and grey arrow respectively. Two alternative 
starting points are depicted for the dialysis and the FID methods, which depend on 
whether the protein was set up with precipitant or not. (Figure adapted from Chayen and 
Saridakis, 2008.) 
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Over time, water vapour is transferred from the droplet (less concentrated solution) to the 
reservoir (more concentrated solution), resulting in dehydration of the droplet, and an 
increase in both protein and precipitant concentrations. If the appropriate parameters are 
found for a given protein, crystal growth will occur in the droplet. The two most common 
vapour diffusion techniques are Hanging Drop and Sitting Drop (Figure 1.3.2). 
1.3.2.2 Micro-batch 
In the micro-batch method, the protein / crystallisation solution mixture is dispensed under 
low-density paraffin oil. The droplet is protected from evaporation, and from exposure to 
air (oxidation). In contrast to Hanging Drop, the concentrations of the protein or 
crystallisation solution will not markedly change over the time-scale of the experiment, 
due to the limited level of diffusion and evaporation through the oil layer. 
1.3.2.3 Micro-dialysis 
In the micro-dialysis method, the protein solution is separated from the crystallisation 
solution by a semi-permeable membrane, which allows the slow mixing and equilibration 
of chemical components, but prevents the diffusion of any protein molecules (Figure 
1.3.2). 
1.3.2.4 Free interface diffusion  
In the Free interface diffusion method (FID), the protein solution and the crystallisation 
solution are in contact with each other, but are not pre-mixed.  This is usually achieved in 
a sealed glass capillary. By equilibration and diffusion of molecules, across the 
protein/buffer interface, a concentration gradient is formed, which at the optimal level of 
supersaturation promotes nucleation and crystal growth. 
1.3.3 Crystallisation screening methods 
As the precise conditions to crystallise a given protein are still almost impossible to predict, 
several different screening methodologies have been developed. The most commonly 
employed methods are briefly described below. 
1.3.3.1 Sparse Matrix Screening 
The sparse matrix method uses ‘screens’ that are made up from collections of many 
different crystallisation solutions, proven to be successful in other crystallisation trials. 
Many sparse matrix crystallisation screens are commercially available from a wide range 
of suppliers.  
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Figure 1.3.2. Diagram of different crystallisation set-ups. A. Hanging-drop B. Sitting-
drop C. Microdialysis. Over time, water vapour is transferred from the droplet to the 
reservoir (large arrows) resulting in dehydration of the droplet, and an increase in both 
protein concentration and precipitant. If the appropriate parameters are found for a given 
protein, crystal growth will occur in the droplet. In C. the protein solution is separated 
from the mother liquor by a semipermeable membrane that allows slow equilibration of 
buffer components. 
(Source: https://en.wikipedia.org/wiki/Protein_crystallization) 
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1.3.3.2 Grid screen 
When a ‘hit’, i.e. crystals are formed, is found in sparse matrix screening, the crystallisation 
condition can be optimised (if required) by careful step-wise changes in the chemical 
parameters, e.g. one can screen the effect of pH and the concentration of a given buffer 
system, or salt concentration on crystallisation. 
1.3.3.3 Additive Screens 
Additive screens are typically libraries of small molecules and/or salts, which can affect 
protein solubility and crystallisation by manipulating protein-protein and protein-solvent 
interactions. Additive screens are also commercially available from many different 
suppliers. 
1.3.4 Harvesting and Cryo-protection of Protein Crystals 
Crystals are normally harvested from droplets with a ‘cryo-loop’, and then transferred into 
a suitable cryo-buffer, before either being frozen directly in a liquid nitrogen cryo-stream, 
or by plunging into in liquid N2.  
Cryo-protection of protein crystals greatly reduces the accumulation of radiation damage 
during data collection. During the cryo-protection process (as protein crystals contains 
substantial amounts of water) any ice crystal formation can physically damage the protein 
crystal.  
A ‘cryo-buffer’ is usually a mixture of the crystallisation mother liquor and a cryo-
protective agent, e.g. glycerol, glycol or sucrose, which prevents ice formation, and instead 
promotes a glass-like vitrification of the solution. 
1.3.5 Crystals, space-groups and symmetry 
Crystals are formed from individual molecules, which coalesce to form an ordered array, 
or repeating lattice. The repeated unit can contain multiple copies of the protein molecule 
and is termed the ‘unit cell’. The unit cell can be described as a parallelepiped with lengths 
a, b and c, and angles α, β and γ. The internal symmetry of the unit cell can be described 
by its space-group.  
There are 230 possible space-groups created using combinations of mathematical or 
‘symmetry’ operations (rotation, translation, inversion and reflection). As proteins are 
intrinsically chiral molecules, the allowed symmetry operations are reduced to just rotation 
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and translation, leaving only 65 possible space-groups. Furthermore, there are only four 
possible rotational symmetries allowed in 3 dimensions: 2-fold (180º), 3 fold (120º), 4-fold 
(90º) and 6-fold (60º), as it is not possible to ‘fill space’ with the other symmetry types. 
This also results in 11 types of allowed ‘screw-axes’, where rotational symmetry 
operations are combined with translation. 
The space-group is also defined by its crystal system and lattice type.  A Bravais lattice 
(Auguste Bravais, 1850) is an infinite array of discrete points, generated by translation 
operations, and is described by the following equation: 
 R = n1a1 + n2a2 + n3a3  (equation 1.3.1) 
Where ni is any value of integer and an is known as primitive vector. 
In 3 dimensions, there are 14 Bravais lattice types: constructed by combination of the 7 
crystal systems (triclinic, monoclinic, orthorhombic, tetragonal, rhombohedral, hexagonal 
and cubic) and the five lattice centering operations (primitive, centered, face centered, 
internal and rhombohedral), which determine symmetry operators in the unit cell. The 
space-group is described by a letter denoting the lattice type, followed by the symmetry 
elements, represented by numbers with each axis with a symmetry element greater than 1 
listed in order. For example: P 21 21 21, describes a primitive cell having a two-fold 21 
screw axis on each unit cell axis. 
The asymmetric unit (ASU) is the smallest unit of the crystal, which contains all the 
information required – when coupled with the symmetry operations defined by the space 
group – to mathematically reproduce the entire crystal lattice. Additional symmetry 
elements within the asymmetric unit can give rise to so-called ‘non-crystallographic 
symmetry’ but these symmetry elements are not defined by the space group of the unit cell.  
1.3.6 X-ray diffraction 
In this thesis, two different types of X-ray sources were used: (A) a MicroMax-007HF 
rotating anode source (Rigaku, Sevenoaks, UK), with a copper rotating anode providing 
monochromatic (single-wavelength) X-rays with a wavelength of 1.5418 Å. (B) Diamond 
Light Source synchrotron (DLS, Didcot, UK).   
X-radiation (formed of X-rays) is defined as an electromagnetic radiation with 
wavelengths between 0.01-10 nm. This range of wavelengths matches the interatomic 
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distance of, and therefore can interact with, the electron cloud of atoms. Because of this, it 
is ideally suited for examination of molecules, where inter-atomic distances are on average 
around 0.15 nm (1.5Å) in length. 
When an incident X-ray interacts with the electron cloud of an atom, its direction of 
propagation can be altered, though the process of elastic scattering. Elastic scattering 
conserves the kinetic energy of an incoming particle/wave, but modifies its direction of 
propagation. The scattered X-rays can also interact with each other, through either 
constructive or destructive interference.  
During data collection the X-ray beam is directed through a collimator that renders the X-
rays into parallel paths, producing a narrow beam. The diameter of beam can be further 
reduced by using focusing mirrors. The cryoloop holder containing the crystal is mounted 
onto a goniometer head, which help orient and move the crystal with great precision in 
order to stay in the path of the incoming X-ray beam during data collection. The crystal is 
kept at low temperature by nitrogen or helium stream to reduce radiation damage. The 
reflection intensities can be measured by detectors. There is a beam stop mounted beyond 
the crystal to prevent excessive radiation reaching the centre of detector. Detectors are 
scintillation counters counting incoming X-ray photons using phosphorescent material; the 
latest designs employ charge-couple devices (CCD camera). 
In the crystal, each unit cell can be intersected by imaginary parallel planes defined by 
‘Miller’ or lattice indices, termed h, k and l. The integers, represented by h, k and l denote 
where these planes intersect the unit cell axes a, b and c. Under certain conditions, a set of 
parallel planes in the crystal will interact to produce a ‘Bragg peak’ or ‘reflection’. William 
Lawrence Bragg and William Henry Bragg demonstrated that such reflections are 
generated by constructive interference, but only occurs if the path difference between two 
parallel incident X-rays is equal to an integer multiple (n) of the wavelength (λ) of the 
incident radiation (Figure 1.3.3), where d is the inter-planar distance and θ is the scattering 
angle. Bragg’s law or Bragg’s diffraction is described by equation 1.3.2: 
 2d sinθ = nλ  (equation 1.3.2) 
Every atom of a given hkl crystal plane contributes to the reflection, and a reflection with 
an intensity of Ihkl is the result of the constructive interference of diffracted X-rays. The 
intensity of the reflection can also be described as a Fourier series. It is therefore possible  
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Figure 1.3.3. Diagrammatic representation of Bragg’s law. Constructive interference 
only occurs when the pathway difference (dsinθ) of parallel incident X-rays (R1 and R2) 
is equal to an integer (n) multiple of wavelength (λ), and depends on the incident angle 
(θ) of the X-ray and the inter-planar distance (d). If the additional distance (2dsinθ) is 
not equal to the integral multiple of λ, destructive interference occurs.  
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to calculate the electron density at a given position (xyz) in the unit cell, by applying the 
following Fourier transform to hkl planes. 
                
(equation 1.3.3)                                               
Where: ρ(xyz) is the electron density at position (xyz), V is the unit cell volume, |Fhkl |is the 
structure factor amplitude of the scattered X-ray and αhkl is the associated phase. 
The measured diffraction intensity is directly proportional to the square of the amplitude, 
i.e. Ihkl = |Fhkl|2. As the intensities of each reflection can be measured during data 
collection, the amplitudes can be deduced, however, the phase information αhkl is not 
measured, and is lost. This is called the ‘phase’ problem. 
There are several methods to recover the lost phase information. In this project, both single-
wavelength anomalous dispersion and molecular replacement techniques were used in 
order to obtain phase information. 
1.3.7 Obtaining Phases 
1.3.7.1 Molecular replacement 
Molecular replacement makes use of the ‘Patterson function’, in order to match a ‘search’ 
model, with known structure, to the ‘target’ molecules within the crystal lattice. Using the 
Patterson function does not require any a priori knowledge of phases (αhkl). It is, however, 
calculated using the same Fourier summation (used to determine the electron density map) 
but only uses intensity information (Ihkl) rather than phases (equation 1.3.4).  
 
      (equation 1.3.4) 
Where P(u, v, w) is the Patterson function, (u, v, w) coordinates locate a point in the Patterson 
map and |Fhkl| is the structure factor amplitude. 
The resulting ‘Patterson map’ is a set of position vectors describing the distances between 
each pair of atoms in the structure (relative positions). Vectors either correspond to pairs 
of atoms within the same molecule (self-Patterson vectors) are short, with their end points 
close to the origin of the Patterson map, or to pairs of atoms in symmetry-related molecules 
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(cross-Patterson vectors), which are longer, and with end-points far from the origin. Self-
Patterson vectors calculated for both the search model and the target molecule are used to 
find the rotational relationship between the two sets of molecules, though a mathematical 
rotation function. The correctly oriented molecules are then matched by a mathematical 
translation function, using the cross-Patterson vector calculated between symmetry-related 
molecules. The correctly positioned model is then used to calculate initial phases, then 
further refinement using these phases and the experimental structure factor amplitudes 
|Fhkl | can be used. 
1.3.7.2 Anomalous scattering 
When the energy (or frequency) of an incident X-ray photon is close to the ‘absorption 
edge’ of a particular atom, it is sufficient to promote an electron from the orbitals close to 
the atom nucleus (K or L-shell) directly to a higher shell, which has a higher average 
energy. These orbital alterations, result in the phenomenon of ‘anomalous scattering’ that 
causes small, but measurable differences in the intensity of reflections measured at planes 
h, k, l and -h, -k, -l (Friedel pairs) that are not normally present. Therefore, in crystals 
containing anomalous scatterers (atoms heavier than Sulphur) Friedel’s law breaks down. 
Friedel’s law states that in a centrosymmetric crystal the intensities of h, k, l and -h, -k, -l 
reflections are equal: 
 Friedel’s Law: |Fhkl | = |F-h-k-l | and αhkl = α-h-k-l   (equation 1.3.4) 
Where: |Fhkl| and |F-h-k-l| are the structure factor amplitudes, and αhkl and α-h-k-l are the 
phases of Friedel pairs. 
The differences in Friedel Pair intensities, for anomalously scattering atoms, can be 
explained by an Argand diagram (Figure 1.3.4). 
H, C, N and O atoms have negligible anomalous scattering in the range of X-ray 
wavelengths (0.35 – 3.5Å) typically used for diffraction experiments. However, good 
signals can be obtained at the K-edge of Selenium for example (Figure 1.3.5 A). 
The difference in Friedel Pair intensities, can be used to locate the position of the 
anomalous scatterers in the unit cell, allowing phase information to be determined by either 
direct methods or by Patterson maps. 
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Figure 1.3.4. Argand diagram for Anomalous Diffraction. In the presence of an 
anomalous scatterer, Friedel’s law breaks down: |Fhkl | ≠ |F-h-k-l | and αhkl ≠ α-h-k-l. 
Structure factors are represented by vectors, where the measured amplitude is 
represented by the vector length, and phase by the angle from the normal axis. The 
vectors coloured in dark green represent the structure factors emerging from non-
anomalously scattering atoms; where the amplitudes are equal, but opposite in phase. 
The vectors coloured in dark blue represent the structure factors from anomalously 
diffracting atoms. The amplitudes are no longer equal, but still opposite in phase. The 
total structure factor, resulting from both sets of atoms is represented by summation of 
the displayed vectors: F0 is the normal scattering term, F’ is the dispersive term and F’’ 
is the imaginary absorption term, shifted 90° in phase. This shift causes the differences 
in the amplitudes. 
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Figure 1.3.5. X-ray Absorption Spectra. A. Absorption spectra for the K-edge of 
selenium, showing scattering terms f ’ and f’’ at different energies (wavelength). B. Real 
(f ’) and imaginary (f’’) anomalous scattering factors vary greatly with X-ray wavelength. 
In Multiwavelength Anomalous Diffraction phasing, data sets are taken at the heavy 
atom absorption maximum (λ1), at the inflexion point (λ2), and at a remote wavelength 
(either at λ3 or λ4).  
(Source: http://skuld.bmsc.washington.edu/scatter/AS_wavechoice.html) 
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1.3.7.3 Single-wavelength Anomalous Dispersion (SAD) 
There are two main methods to measure anomalous diffraction. In Multi-wavelength 
Anomalous Diffraction (MAD) experiments, diffraction data are typically collected at 
three separate energies (wavelengths): a ‘peak’ dataset, calculated to give the largest 
anomalous signal (f’’); an ‘inflection’ or ‘edge’ dataset, which is half-way down the f’’ 
absorption edge, i.e. at the inflection point of the curve, typically just a few eV less than 
the peak; and a ‘remote' wavelength, either ‘high’ or ‘low’ depending on it is measured 
above or below the absorption edge (typically a difference of ~ +/-200 Ev) (Figure 1.3.5 
B). Each measurement provides a distinct set of structure factors that can then be used to 
determine phase information. 
In contrast, Single-wavelength Anomalous Dispersion (SAD) experiments employ just a 
single X-ray wavelength when collecting diffraction data. The incident wavelength is 
carefully chosen to produce the largest difference in Friedel Pair intensities (f’’). The 
anomalously scattering atom substructure can be determined using a difference Patterson 
function using the amplitudes of the Friedel par. The total scattering of the protein can be 
calculated using equation (1.3.5): 
   
                                       (equation 1.3.5) 
Where FPA is the total scattering of the protein and anomalously scattering atoms, FP is the 
normal and dispersive elements from the scattering atoms, iF’’A is the imaginary phase 
component.  
It is worth noting that two sets of phases, with opposite ‘hands’, are calculated from this 
type of experiment. This phase ambiguity is typically ‘solved’ by examination of the 
‘quality’ of resulting electron density maps after density modification. 
Using SAD, and modern experimental set-ups, it is now possible to measure the relatively 
weak anomalous scattering emerging from sulphur atoms (i.e. from cysteine and 
methionine side chains of a protein), and use this to phase x-ray diffraction data; the so-
called ‘native-SAD’, or ‘sulphur-SAD’ method. 
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1.3.8 Data collecting and processing 
Preliminary to data collection, the properties of a crystal are first analysed by collecting 
two to three small wedges of diffraction, typically separated by 30-90q, in order to allow 
‘indexing’ – the process of determining the Bravais lattice (point group) of the crystal, its 
unit cell dimensions, as well as an estimate of the resolution of diffraction and mosaicity.  
Estimates of X-ray exposure time and optimal detector distance can also be obtained at this 
stage. With this information, an experimental strategy can then be determined, which 
allows a complete diffraction dataset to be collected with at least 2-fold multiplicity (2 
measurements of each reflection). Proprietary software is generally available at 
synchrotron light sources, i.e. GDA (Diamond Light Source, Didcot, UK) or MXCube 
(European Synchrotron Radiation Facility, Grenoble, France) to facilitate this process.  
Other computer software suites, such as those provided by the Crystallographic Computing 
Project 4 (CCP4, (Winn et al. 2011)) can also be used for data processing and manipulation, 
e.g. when diffraction data has been collected at a home source, or re-processing – for 
example, to alter point group assignments or resolution limits – is necessary/required. 
In this thesis, either iMosflm (Leslie 2006), XDS (Kabsch 2010) or the xia2 automated 
pipeline (Winter 2010) were used for indexing and integration of all diffraction data.   
Once indices have been assigned, the intensity of each reflection on each diffraction image 
can be measured. The collated data is then merged, scaled and truncated in order to produce 
a single experimental data file (MTZ file or equivalent), typically using the Pointless / 
Aimless / Ctruncate pipeline of the CCP4 suite (Winn et al. 2011). 
Briefly, the merging processing involves the averaging of reflection intensities that are 
directly equivalent by crystal symmetry, as well as the summation of reflection intensities 
that have been recorded over several frames (so-called partials). Scaling then attempts to 
put all these observations onto a common scale, whilst also correcting for errors and 
inconsistencies caused either by the instrument or the crystal itself. The truncation process 
then converts the measured intensities into structure factor amplitudes (|F|). 
The final output includes the averaged intensities (I) as well as structure factors (F), a 
significance score (estimate of uncertainness in the measured intensity), the completeness 
of the collected dataset, the mean signal to noise ratio mean (I/σI) and the statistical 
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parameters, Rmerge and/or Rpim which aim to show how unique reflection measurements 
agree/deviate from one another. 
1.3.9 Model building, refinement and validation 
After obtaining initial estimates of phases by either molecular replacement or by 
SAD/MAD experiments — the agreement between the measured and calculated 
amplitudes (from the initial model) can be improved by adjusting/moving the atomic 
coordinates of the model in small iterative steps. Restraints/constraints of these movements 
are based on theoretical and observed parameters, pertaining to known bond lengths, 
angles, stereo-chemical and conformational properties, which allow the model to be altered 
to better fit the electron density map, but to maintain expected/ideal geometries. The new 
model, and thus improved phases, can be then be used to generate a new electron density 
map – which can then itself facilitate further improvements to the model to be made – i.e. 
an iterative process, tending towards eventual convergence. 
During model building and refinement, the agreement between the calculated model and 
the measured crystallographic data is validated by calculating an R-factor (Rwork) (equation 
1.3.6): 
  𝑅𝑤𝑜𝑟𝑘 =
Σℎ𝑘𝑙||𝐹𝑜𝑏𝑠|−|𝐹𝑐𝑎𝑙𝑐||
Σℎ𝑘𝑙|𝐹𝑜𝑏𝑠|                     (equation 1.3.6) 
Where |𝐹𝑜𝑏𝑠| is the observed structure factor and |𝐹𝑐𝑎𝑙𝑐| is the calculated dataset.  
A low R-factor means that there is a good agreement between the model and the recorded 
dataset. A desirable R-factor for a protein model at 2.5Å resolution is ≤ 20%; which is in 
contrast to crystal structures of small organic molecules, at sub-1Å resolution, which can 
typically can be refined to Rwork < 0.5%.  The poor modelling of bulk solvent (water) in 
macromolecular crystallography is thought to be largely responsible for this discrepancy 
in R-factor values. 
To avoid over-modelling, cross-validation is carried out throughout the refinement process, 
by calculation of Rfree factor, where a small random subset of data is excluded from the 
refinement process (typically 5% of the total number of unique reflections). The value of 
Rwork and Rfree factors should be different by a factor of around 5%; any larger discrepancy 
indicates over interpretation of the electron density / model.  During the refinement process 
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root-mean-square (rms) deviations of both the model’s bond lengths and angles are also 
typically monitored. 
In this thesis, either REFMAC5 (CCP4 software suite (Murshudov et al. 2011)) and/or 
phenix.refine (Adams et al. 2010) were used to refine the crystallographic model. The 
program COOT (Emsley et al. 2010) was used for model inspection and manual building 
into electron density maps. 
REFMAC5 refinement typically consists of 10 cycles of maximum likelihood refinement 
to produce a refined model as well as two types of electron density map, the weighted map 
of 2m|𝐹𝑜𝑏𝑠| - D|𝐹𝑐𝑎𝑙𝑐| and |𝐹𝑜𝑏𝑠| - |𝐹𝑐𝑎𝑙𝑐|. The two map types guide model building 
in COOT; extra electron density in the difference map of |𝐹𝑜𝑏𝑠| - |𝐹𝑐𝑎𝑙𝑐| can demonstrate 
the necessity for additional components in the model. The model then once again is refined 
in REFMAC. These steps were repeated until the model could not be improved further, 
and no improvement in Rwork/Rfree was observed; i.e. the refinement had reached 
convergence. 
Models were also analysed with MolProbity, throughout the refinement process (Chen et 
al. 2010) to assess the quality of the model based on covalent-geometry and torsion-angle 
criteria. The MolProbity score represents the central protein quality statistics combining 
percentage Ramachandran not favored and bad side-chain rotamers. MolProbity also 
compares the model’s geometry to other models with similar resolution in the PDB. 
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CHAPTER TWO 
 
Materials and Methods 
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2.1 DNA cloning 
2.1.1 Bacterial transformation 
50µl chemically competent E. coli cells were thawed on ice, then incubated for 30 min in 
the presence of 1µg plasmid DNA. Cells were heat-shocked for 30 sec at 42°C, then 
transferred back to ice for an additional 2 min. 300µl antibiotic-free LB (Luria-Bertani) 
media was added to the cells, which were then incubated at 37°C, 220 rpm in a C25 
incubator shaker (New Brunswick Scientific, Edison, NJ, USA) for an hour. Cells were 
then plated on LB-Agar plates (10g Tryptone, 5g Yeast extract, 10g NaCl and 15g Agar in 
1L distilled water) supplemented with the required antibiotics for selection (e.g. 50µg/ml 
ampicillin) and then incubated overnight at 37°C in a static incubator (Heraeus Incubator, 
Thermo Fisher Scientific, East Grinstead UK).  
2.1.2 Plasmid DNA preparation 
To prepare plasmid DNA, a single transformed bacterial colony was used to inoculate 5ml 
LB media supplemented with the required antibiotics. The culture was incubated overnight 
at 37°C, 220 rpm in a C25 incubator shaker (New Brunswick Scientific). The next day, 
cells were harvested by centrifugation, at 4500 rpm for 10 min at room temperature, using 
an Allegra X-22R Centrifuge (Beckman Coulter, High Wycombe, UK), equipped with a 
SX4250 rotor. Pelleted cells were either stored at -20°C until required, or used directly for 
plasmid extraction. A QIAprep Spin Miniprep Kit (Qiagen, Manchester, UK) was used to 
isolate plasmid DNA, following the manufacturer’s ‘centrifuge’ protocol. The purity and 
concentration of the plasmid DNA was measured using a NanoDrop 2000c 
spectrophotometer (Thermo Fisher Scientific). Purified plasmid DNA was stored at -20°C. 
2.1.3 Polymerase Chain Reaction (PCR) 
All PCR reactions were performed in a MWG Biotech Primus 25 thermal cycler. DNA 
fragments were amplified with KOD Hot Start DNA Polymerase (Merck Millipore, 
Feltham, UK) using dNTPs and buffers provided. All PCR primers were purchased from 
Eurogentec (Southampton, UK). Reaction mixes were typically composed of 10ng 
template DNA, 0.1µM forward and reverse primers, 200µM dNTP mix, 5µl 10x reaction 
buffer, 0.5µM MgSO4 and 1µl KOD enzyme. Ultrapure water (supplied) was added to the 
reaction to a final volume of 50µl. PCR programs are provided in the relevant sections. 
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2.1.4 Agarose gel electrophoresis 
Agarose (Genetic Analysis Range, Thermo Fisher Scientific) was dissolved in 1xTAE 
buffer in a microwave, and then supplemented with ethidium bromide (Sigma-Aldrich, 
Gillingham, UK) at a final concentration of 0.2µg/ml. The dissolved agarose was poured 
into a Horizon 58 gel casting deck to set (Thermo Fisher Scientific). 
1x DNA loading buffer, from a 6x stock (0.15% w/v Bromophenol blue, 0.15% w/v Xylene 
cyanol and 30% v/v glycerol in water) was added to each DNA sample, before being loaded 
onto the agarose gel. The final concentration (w/v) of the agarose was determined by the 
expected size of the DNA sample. DNA samples were separated by electrophoresis at 
120V for 30 min using a Horizon 58 Horizontal Gel Electrophoresis System (Thermo 
Fisher Scientific). A molecular mass standard (GeneRuler 1kb Plus DNA ladder, Thermo 
Fisher Scientific) was run alongside the samples in order to determine the size of the DNA 
analysed. 
2.1.5 Agarose gel extraction 
Following electrophoresis, DNA migrating at the desired molecular size was excised from 
the gel and either stored at -20°C or processed immediately. To obtain purified DNA, an 
Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare, UK) was used, 
following the manufacturer’s recommended protocol. 
2.1.6 TOPO cloning 
2µl (~200ng) insert DNA was mixed with 1µl pCR4 Blunt TOPO vector (Thermo Fisher 
Scientific), 1µl supplied TOPO salt solution (1.2M NaCl, 60mM MgCl2) and 2µl water, to 
give a total volume of 6µl. The reaction was incubated for 30 min at room temperature, 
before being used to transform a suitable strain of E. coli. 
2.1.7 Restriction digest 
Restriction enzymes were purchased from either Roche Life Science (Mannheim, 
Germany) or New England Biolabs (NEB, Hitchin, UK). For double digests, a restriction 
buffer compatible with both enzymes was chosen according to the manufacturer’s 
recommendations. Typically, ~300ng of plasmid DNA was mixed with 0.5µl of each 
restriction enzyme, 2.5µl 10x restriction enzyme buffer, and water added to give a total 
volume of 25µl. The reaction was incubated for 60 min at 37°C. 
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2.1.8 DNA ligation 
To prevent self-ligation, the 5’ ends of the digested DNA vector were treated with Calf 
Intestinal Phosphatase (CIP, from NEB) prior to the ligation reaction. The phosphatase 
reaction was typically carried out during the restriction digest by adding 0.5µl CIP to the 
reaction mixture. 
Gel-extracted insert and CIP-treated vector, at a molar ratio of 3:1, were mixed with 2µl 
10x T4 DNA ligase buffer (NEB), 1µl T4 DNA ligase enzyme (NEB) and ultrapure water 
to a total volume of 20µl. The mixture was incubated at room temperature for 30 min. 5µl 
volume of the reaction was used to transform a suitable strain of E. coli competent cells. 
2.2 Protein expression and purification 
2.2.1 General Procedure 
Transformation of E.coli strains, suitable for protein expression, follows the same protocol 
as previously described (Section 2.1.1). Once transformed, cells were streaked onto LB-
agar plates supplemented with appropriate antibiotic(s) and then incubated overnight at 
37°C, in a static incubator. All liquid cultures were grown in either Minitron or Multitron 
shaking incubators (Infors HT, Bottmingen, Switzerland). 
Cells from 5ml and 50ml small-scale cultures were harvested by centrifugation in an 
Allegra X-22R Centrifuge (Beckman Coulter) using a SX4250 rotor, at 4500 rpm for 10 
min at 4°C. 
Cells from large-scale cultures (>1L) were harvested by centrifugation in an Avanti J-26XP 
centrifuge (Beckman Coulter) using a JLA8.1 rotor, at 5500 rpm for 10 min at 4°C. 
Harvested cells were either used immediately or stored at -20°C until required. 
In general, cell pellets were thawed on ice, and re-suspended in ‘Lysis buffer’. They were 
then disrupted by sonication, using a Sonics Vibra-Cell VCX 500 ultrasonic processor 
equipped with a large parallel probe (VWR, Lutterworth, UK). Cell debris and insoluble 
material were removed by high-speed centrifugation in an Avanti J-26XP centrifuge 
(Beckman Coulter) with a JA-25.50 rotor, at 20,000 rpm for 1 hour at 4°C. Where required, 
the resulting cell lysate was filtered through a 0.5µm Millex Syringe Filter unit (Merck 
Millipore). 
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For SDS-PAGE analysis, samples were applied to Novex 4-12% Tris-Glycine Protein Gels 
(Thermo Fisher Scientific) or TruPAGE precast gels (Sigma-Aldrich), and separated by 
electrophoresis for 35 min at 180V. Either Precision Plus Protein Standard (Dual Color, 
from Bio-Rad, Hemel Hempstead, UK) or SeeBlue Plus2 Protein Standard (Thermo Fisher 
Scientific) were used as molecular mass markers. An ÄKTApurifier 10 Protein Purification 
System operated by UNICORN 5.11 software (GE Healthcare) was used for all protein 
purification steps. Purified proteins were concentrated using Vivaspin 20 (5,000 and 
10,000 MWCO) centrifugal concentrators (Sartorius Stedim), by centrifugation in an 
Allegra X-22R Centrifuge (Beckman Coulter), using a SX4250 rotor, at 4000 rpm and 4°C, 
until the desired volume was attained. The concentrated sample was then aliquoted, flash-
frozen in liquid N2 and then stored at -80°C until required. 
2.2.2 Bacterial protein expression constructs 
pTWO-E is an in-house modified form of pET-17b, encoding an N-terminal human 
rhinovirus-3C cleavable (HRV-3C) His6 affinity tag. pTHREE-E is an in-house modified 
form of pGEX-6P-1, encoding an N-terminal HRV-3C cleavable, glutathione-S-
transferase (GST) affinity tag. Both vectors were kindly provided by Dr Antony W. Oliver, 
University of Sussex. 
2.2.3 Bacterial protein expression  
Chemically competent E.coli were transformed according to section 2.1.1. For expression, 
strains BL21(DE3), BL21(DE3)pLysS (Promega, Chilworth, UK) and Rosetta2(DE3) 
pLysS (Merck Millipore) were used. For Selenomethionine labelling the auxotroph 
B834(DE3) (Novagen) E. coli strain was used.  
2.2.4 Protein expression in insect cells 
For protein expression in insect cells the Bac-to-Bac Baculovirus Expression System 
(Thermo Fisher Scientific) was used. Cultures of serum-free adapted Sf9 cells were grown 
in Sf-900II SFM media, supplemented with 5µg/ml Penicillin and Streptomycin, in 1L 
polycarbonate Erlenmeyer Flasks (Corning, USA) in a Multitron shaking incubator (Infors 
HT) set at 27 and 150 rpm. Infected cells were harvested by centrifugation, in an Avanti J-
26XP centrifuge (Beckman Coulter) with a JLA8.1 rotor, at 1000 rpm for 10 min at 4°C. 
Cell counts and cell viability were determined by a Countess Automated Cell Counter 
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(Thermo Fisher Scientific) using a Trypan Blue staining method (Thermo Fisher 
Scientific).  
DNA inserts were subcloned into the multiple cloning site (MCS) of pTWO-B at the NdeI 
and EcoRI restriction sites, using standard cloning procedures (see above). pTWO-B is a 
modified form of the pFastBac1 vector (Thermo Fisher Scientific) encoding an N-terminal 
HRV-3C cleavable, His6 affinity tag. The vector was kindly provided by Dr Antony W. 
Oliver, University of Sussex.  
The initial transformation of the DH10Bac strain of E.coli, and the generation of 
recombinant bacmid, followed the manufacturer’s recommended protocol. Confirmed 
recombinant bacmids were resuspended in 40µl ultra-pure water and stored at -20°C until 
required. 
Recombinant bacmid DNA was analysed by PCR using KOD Hot Start DNA polymerase 
(Merck Millipore). pUC/M13 forward (5c-CCCAGTCACGACGTTGTAAAACG-3c) and 
reserve (5c-A GCGGATAACAAT TTCACACAGG-3c) primers were used in combination 
with TDP2 reverse (5’-GAATTCTCATCACAGGATAAT-3’) and TDP2(S101) forward 
or TDP2(G111) forward (5’-CATATGAGTCCGAGCGAAGATACC-3’, 5’-
CATATGGGCAGTATGTTTAGCCTGA-3’, respectively) to generate the diagnostic 
PCR amplicon.  
The subsequent amplification of recombinant baculovirus and the determination of viral 
titres followed the manufacturer’s recommended protocol. 
2.2.5 Expression and purification of full-length human PARP1 
2x 0.5L Sf9 cell culture (2x106 cell/ml, at a viability greater than 95%) was infected with 
a P3 (passage 3) viral stock that expressed full length, human PARP1 (Dr Raquel Arribas 
/ Dr Antony W. Oliver, University of Sussex), at a MOI (multiplicity of infection) of 2. 
Infected cultures were then incubated at 27°C and 150 rpm in a Multitron shaking 
incubator. After growth for 3 days, cells were harvested by centrifugation in an Avanti J-
26XP centrifuge (Beckman Coulter) with JLA8.1 rotor at 1,000 rpm for 10 min at 4°C. 
The resulting cell pellet was stored at -80°C until required. 
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Purification of full-length human PARP1 essentially followed the protocol described by 
Giner at all (1992). The purified protein was concentrated to 4.7mg/ml (4.1µM) and then 
stored in aliquots at -80°C until required. 
2.2.6 Expression and purification of TDP2 
2.2.6.1 Cloning and expression trials of full length human TDP2 
2.2.6.1.1 Cloning of full length human TDP2 
A pUC57 plasmid containing the cDNA encoding full length human TDP2 (pUC57-
hTDP2) was synthesised by GenScript, UK. The synthetic gene was flanked by NdeI and 
EcoRI restriction sites. 1µg of the pUC57-hTDP2 plasmid was cut with both NdeI and 
EcoRI (New England Biolabs, NEB) to release the DNA encoding TDP2. DNA migrating 
at the expected size was gel-extracted from a 1%, 1x TAE, and then ligated into the 
corresponding NdeI and EcoRI sites of both pTWO-E and pTHREE-E. 
The appropriate recombinant expression constructs were identified by bacterial 
transformation and restriction digest of plasmid minipreps. The resultant constructs were 
termed pTWO-E/hTDP2 and pTHREE-E/hTDP2. 
2.2.6.1.2 Small-scale expression trials  
Experimental parameters are summarised in the following table (Table2.1): 
Expression 
Construct pTWO-E/hTDP2 and pTHREE-E/hTDP2 
E. coli strain BL21(DE3)  
Growth media LB 
Antibiotic selection 50µg/ml Ampicillin 
Growth parameters 37°C, 220 rpm in shaking incubator until OD600 =1 
Induction of protein 
expression 
Addition of 0.4mM IPTG, then adjustment of growth temperature 
(37°C for 3 hours, or 20°C overnight) 
Lysis buffer 25mM HEPES-NaOH pH 7.5, 500mM NaCl, 0.5mM TCEP, 5% v/v 
glycerol 
Table 2.1. Summary table of expression parameters for the full length human TDP2. 
2.2.6.2 Cloning and expression trials of the catalytic domain of hTDP2 (hTDP2-
CAT101-362 and hTDP2-CAT111-362) 
To create expression vectors containing just the catalytic domain of hTDP2, the original 
synthetic hTDP2-pUC57 plasmid was used as a template for PCR amplification using the 
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follow primer sets: Forward [5’-CATATGAGTCCGAGCGAAGATACC-3’] and Reverse 
[5’-GAATTCTCATCACAGGATAAT-3’] amplified the region coding for amino acids 
Ser101-Leu362, and Forward [5’-CATATGGGCAGTATGTTTAGCCTGA-3’] and 
Reverse [5’-GAATTCTCATCACAGGATAAT-3’] amplified the region coding for amino 
acids Gly111-Leu362. Forward and reverse primers were designed to include flanking 
NdeI and EcoRI restriction sites, respectively. 
PCR protocol:  
2 min denaturation step at 95°C, 20 extension cycles (15 sec at 95°C, 15 sec at 58°C and 
30 sec at 72°C). The final extension step was at 72°C for 210 sec. Amplicons of the 
expected size were gel-purified from 1% (w/v) agarose, 1x TAE gels and then ligated into 
both pTWO-E and pTHREE-E vectors, at the corresponding NdeI and EcoRI sites. The 
generated expression constructs were pTWO/hTDP2101-362, pTWO-E/hTDP2111-362 
pTHREE-E/hTDP2101-362, and pTHREE-E/hTDP2111-362. Small-scale expression trials for 
these constructs were carried as per section (3.2.1.2).  
2.2.6.3 Expression and purification of the mutant (C161S) catalytic domain of TDP2 
(hTDP2-CATC161S) 
Expression and purification parameters are summarised in the following table (Table 2.2). 
Expression 
Construct pET28A/hTDP2-CATC161S 
E. coli strain B834(DE3) 
Growth media Turbo broth 
Antibiotic selection 50 µg/ml Kanamycin 
Growth parameters 37 °C, 220 rpm, until OD600 =2 
Induction of protein 
expression 
Addition of 0.4mM IPTG, then adjustment of growth temperature 
to 30°C, for 3.5 hours 
 
Purification 
Lysis/washing buffer  50mM HEPES, pH7.5, 250mM NaCl, 10mM Imidazole and 
0.5mM TCEP 
Cell disruption  Sonication 
1st Chromatography step  IMAC, gravity flow column 
Resin 5ml TALON 
Elution buffer Batch elution; 50mM HEPES, pH7.5, 250mM NaCl, 0.3M 
Imidazole and 0.5mM TCEP 
2nd Chromatography step 5ml HiTrap Heparin HP column (5ml) elution by linear salt 
gradient from 0% to 50% high salt buffer 
Low salt buffer 50mM HEPES pH7.5, 150mM NaCl, 1mM TCEP 
High salt buffer 50mM HEPES pH7.5, 2M NaCl, 1mM TCEP 
3rd Chromatography step HiLoadTM 16/600 SuperdexTM 75pg (GE Healthcare) 
Table continues on the next page 
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Gel filtration buffer 20mM HEPES pH7.5, 300mM NaCl and 0.5mM TCEP 
Storage of protein Concentrated to 7.3mg/ml and stored at -80°C. 
Table 2.2. Summary table of expression and purification parameters for the catalytic 
domain of hTDP2. The His-tag was not removed during the purification procedure. 
2.2.6.4 Expression and purification of Selenomethionine labelled hTDP2-CATC161S 
Expression parameters are summarised in the following table (Table 2.3). 
Expression 
E. coli strain BL834 (DE3)  
Growth media Selenomethionine containing media (Section 2.2.6.4.1 ) 
Antibiotic selection 50µg/ml Kanamycin 
Growth parameters 37 °C, 220 rpm, until OD600 =1 
Induction of protein 
expression 
Adjustment of growth temperature to 30°C, then addition of 0.4mM 
IPTG, and induction for 3.5 hours. 
Table 2.3. Summary table of expression parameters for the Selenomethionine 
labelled hTDP2-CATC161S. The purification protocol is identical to the procedure 
described for hTDP2-CATC161S (Section 2.2.6.3). 
2.2.6.4.1 Preparation of Selenomethionine containing minimal media 
21.6g of SelenoMet Medium Base (Molecular Dimensions) was dissolved in 1L ultrapure 
water and sterilized by autoclaving. 5.1g SelenoMet Nutrient Mix was dissolved in 50ml 
ultrapure water and sterilized by filtering. The solution was added to the minimal media 
alongside with 4ml Selenomethionine solution (250x), aseptically.  
2.2.6.5 Expression and purification of the catalytic domain of mTDP2-CAT 
Expression and purification parameters are summarised in the following table (Table 2.4). 
Expression 
Construct pET15b/mTDP2-CAT 
E. coli strain Rosetta 2(DE3)pLysS  
Growth media LB 
Antibiotic selection 50µg/ml Ampicillin and 34µg/ml Chloramphenicol 
Growth parameters 37°C, 220 rpm, until OD600 =1 
Induction of protein expression Addition of 0.4mM IPTG, then induced at 37°C for 4 hours 
 
Purification 
Lysis/washing buffer: 50mM HEPES, pH7.5, 250mM NaCl, 10mM Imidazole, 1mM TCEP 
Cell disruption Sonication 
Centrifuge step 50 min at 40000g at 4°C 
1st Chromatography 
step:  
IMAC, gravity flow column 
Resin:  5ml TALON 
Table continues on the next page 
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Elution buffer Batch elution; 50mM HEPES, pH7.5, 250mM NaCl, 0.3M Imidazole 
and 0.5mM TCEP 
Desalting step HiPrepTM 26/10 desalting column  
Desalting buffer 50mM HEPES pH7.5, 150mM NaCl, 1mM TCEP, SENP1 protease 
added for overnight digestion at 4°C 
2nd Chromatography 
step:  
5ml HiTrapTM Heparin HP column 
Elution Linear salt gradient, 0% to 50% high salt buffer 
Low salt buffer: 50mM HEPES pH7.5, 150mM NaCl, 1mM TCEP 
High salt buffer 50mM HEPES pH7.5, 2M NaCl, 1mM TCEP 
3rd Chromatography 
step: 
HiLoadTM 16/600 SuperdexTM 75pg 
Gel filtration buffer: 20mM HEPES pH7.5, 300mM NaCl and 0.5mM TCEP 
Storage of protein Concentrated to 9.6mg/ml and stored at -80°C. 
Table 2.4. Summary table of expression and purification parameters for the catalytic 
domain of the murine TDP2 (mTDP2-CAT). 
2.2.6.6 Expression and purification of the catalytic domain of the humanised 
mTDP2-CAT (m2hTDP2)  
Expression and purification parameters are summarised in the following table (Table 2.5). 
Expression 
Expression 
construct 
pET15b/m2hTDP2-CAT 
Expression strain Rosetta 2(DE3)pLysS  
Growth media Turbo broth 
Antibiotic selection 50µg/ml Ampicillin and 34µg/ml Chloramphenicol 
Growth parameters 37°C, 220 rpm, until OD600 =2 
Induction of protein 
expression 
Addition of 0.4mM IPTG, then adjustment of growth temperature to 
20°C, growth overnight 
 
Purification 
Lysis/washing buffer: 50mM HEPES, pH7.5, 250mM NaCl, 10mM Imidazole, 1mM 
TCEP 
Cell disruption Sonication 
Centrifuge step 50 min at 40000g at 4°C 
1st Chromatography step:  IMAC, gravity flow column 
Resin:  5ml TALON  
Elution buffer Batch elution; 50mM HEPES, pH7.5, 250mM NaCl, 0.3M 
Imidazole and 0.5mM TCEP 
Desalting step HiPrep 26/10 desalting column 
Desalting buffer 50mM HEPES pH7.5, 150mM NaCl, 1mM TCEP, SENP1 
protease added for overnight digestion at 4°C 
2nd Chromatography step:  5ml HiTrapTM Heparin HP column  
Elution Linear salt gradient, 0% to 50% high salt buffer 
Low salt buffer: 50mM MES, pH6.5, 150mM NaCl, 1mM TCEP 
High salt buffer 50mM MES, pH6.5, 2M NaCl, 1mM TCEP 
Table continues on the next page 
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3rd Chromatography step: HiLoadTM 16/600 SuperdexTM 75pg 
Gel filtration buffer: 20mM MES, pH6.0, 300mM NaCl, 1mM TCEP 
Storage of protein Concentrated to 7.4mg/ml and stored at -80°C. 
Table 2.5. Summary table of expression and purification parameters for the catalytic 
domain of the humanised mTDP2-CAT (m2hTDP2-CAT). 
2.2.7 Expression and purification of the catalytic domain of the 
human tankyrase 1 (TNKS-1) 
The expression and purification of the catalytic fragment of the human tankyrase 1 
followed the protocol described in Lehtiö et al (2008).  
2.2.8 Expression and purification of Human Sentrin-specific 
protease 1 catalytic domain (SENP1) 
Expression and purification parameters are summarised in the following table (Table 2.6). 
Expression 
Expression 
construct 
pGEX-6P-1/SENP1 (residues 427 to 644) 
Expression strain Rosetta™ 2(DE3)pLysS 
Growth media LB 
Antibiotic selection 100 Pg/ml Carbenicillin and 34 Pg/ml Chloramphenicol 
Growth parameters 37°C, 220 rpm, until OD600 =2 
Induction of protein 
expression 
Addition of 0.4mM IPTG, then adjustment of growth temperature to 
16°C, for overnight 
 
Purification 
Lysis/washing buffer: 50mM HEPES pH 7.5, 500mM NaCl, 0.5mM TCEP, 10% v/v 
glycerol 
Cell disruption Sonication 
Centrifuge step 50 min at 40000g at 4°C 
1st Chromatography step:  Glutathione Sepharose 4 Fast Flow resin, gravity flow 
Elution buffer 25mM MES pH 6.5, 50mM NaCl, 0.5mM TCEP, 5% v/v glycerol, 
20mM Glutathione 
2nd Chromatography step:  5ml HiTrapTM SP HP column 
Elution Linear salt gradient, 0% to 100% high salt buffer 
Low salt buffer: 25mM HEPES pH7.5, 50mM NaCl, 5% v/v glycerol, 0.5mM 
TCEP 
High salt buffer 25mM HEPES pH7.5, 1M NaCl, 5% v/v glycerol, 0.5mM TCEP 
3rd Chromatography step: HiLoadTM 26/60 SuperdexTM 200pg 
Gel filtration buffer:  25mM HEPES pH 7.0, 150mM NaCl, 0.5mM TCEP and 5% v/v 
glycerol 
Storage of protein Concentrated to 2mg/ml and stored at -80°C in 50% glycerol. 
Table 2.6. Summary table of expression and purification parameters for the catalytic domain 
of SENP1. 
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2.2.9 Expression and purification of MACROD1 
Expression and purification parameters are summarised in the following table (Table 2.7). 
Expression 
Expression construct pET16b/MACROD1 (the vector was a kind gift of Dr Gabrielle Grundy) 
Expression strain BL21(DE3)pLysS 
Growth media LB 
Antibiotic selection 50µg/ml Ampicillin 
Growth parameters 37 °C, 220 rpm, until OD600 =1 
Induction of protein 
expression 
Adjustment of growth temperature to 16°C, addition of 0.4 mM IPTG, 
induction for overnight 
 
Purification 
Lysis/washing buffer: 50mM Tris-HCl pH7.5, 150mM NaCl, 10mM Imidazole and 
0.5mM TCEP 
Cell disruption Sonication 
Centrifuge step 50 min at 40000g at 4°C 
1st Chromatography step:  IMAC, gravity flow column 
Resin:  5ml TALON 
Elution buffer Batch elution; 50mM Tris-HCl pH7.5, 150mM NaCl, 300mM 
Imidazole and 0.5mM TCEP 
2nd Chromatography step: HiLoadTM 16/600 SuperdexTM 75pg 
Gel filtration buffer:  20mM Tris-HCl, pH7.5, 300mM NaCl, 0.5mM TCEP 
Storage of protein Concentrated to 0.4mg/ml and stored at -80°C. 
Table 2.7. Summary table of expression and purification parameters for full length 
MACROD1. 
2.2.10 Cloning and expression of XRCC1161-406 
2.2.10.1 Cloning of XRCC1161-406 wild type and R335A/K369A mutant  
To create the extended XRCC1-BRCT1 expression constructs, the parental plasmids 
pCD2EXHRWT and pCD2EXHR335A/K369A (encoding human XRCC1-His WT and 
R335A/K369A, respectively) were used as templates. The ORF encoding XRCC1 residues 
161-406 were amplified by PCR using oligonucleotides 5’-
CATATGCCGTCCCAGAAGGTGAC-3’ (forward primer) and 5’-
GAATTCTCATCATGGCCCTGCCATGAGG-3’ (reverse primer) (from Eurogentec). 
The PCR protocol was as follows: 2 min denaturation step at 95°C, 20 extension cycles of: 
denaturation for 15 sec at 95°C, annealing for 15 sec at 56°C and elongation for 30 sec at 
72°C, followed by a final extension step at 72°C for 210 sec, before cooling to 4°C. 
PCR products were loaded onto 1% Agarose gel supplemented with ethidium bromide and 
run for 30 min at 140V at constant current of 400mA. The main band was cut out from the 
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gel and purified with an illustra GFX PCR DNA and Gel Band Purification Kit (GE 
Healthcare) and then captured by cloning into pCR4 Blunt-TOPOvector (Thermo Fisher 
Scientific) (the TOPO cloning methodology is fully described in 2.1.6). The plasmids were 
transformed into DH5α E. coli competent cells and were streaked onto LB plates 
supplemented with 50µg/ml kanamycin and incubated overnight at 37°C. The following 
day single colonies were picked and inoculated into 5ml LB media with 50µg/ml 
kanamycin and were incubated overnight at 37°C. Next day plasmids were extracted using 
QIAprep® Spin Miniprep kit (Qiagen). Plasmids were subjected to double digest using the 
restriction enzymes NdeI and EcoRI to verify clones with insert. Positive clones then were 
sent for sequencing for further verification. The insert was excised by NdeI-EcoRI (both 
enzyme from New England Biolabs, NEB) restriction digest, then loaded onto 1% agarose 
gel. Following gel electrophoresis the correct band was gel extracted and ligated into an 
NdeI-EcoRI double digested, Calf Intestinal Phosphatase (CIP, from NEB) treated pTWO-
E vector. 5µl of the ligation reaction was transformed into DH5α E. coli competent cells. 
Cells were streaked onto LB plates, supplemented with 50µl ampicillin and incubated at 
37°C for overnight. Next day single colonies were inoculated into 5ml LB with 50µl 
ampicillin and incubated for overnight at 37°C. The following day plasmids were extracted 
and subjected to diagnostic digest. Positive clones were sent for sequencing. 
2.2.10.2 Expression and purification of XRCC1161-406 WT and XRCC1161-406 RK  
Expression and purification parameters are summarised in the following table (Table 2.8).  
Expression 
Expression 
construct 
pTWO-E/ XRCC1161-406 WT and pTWO-E/ XRCC1161-406 RK 
Expression strain RosettaTM2 (DE3)pLysS 
Growth media LB 
Antibiotic selection 50µg/ml Ampicillin and 34µg/ml Chloramphenicol 
Growth parameters 37 °C, 220 rpm, until OD600 =1 
Induction of protein 
expression 
Adjustment of growth temperature to 30°C, addition of 0.4 mM IPTG, 
induction for 4 hours 
 
Purification 
Lysis/washing buffer: 50mM HEPES, pH7.5, 250mM NaCl, 10mM Imidazole, 1mM 
TCEP 
Cell disruption Sonication 
Lysate clarified by Centrifugation for 50 min at 40000g at 4°C 
1st Chromatography step:  IMAC, gravity flow column 
Resin:  5ml TALON 
Elution buffer Batch elution; 50mM HEPES, pH7.5, 250mM NaCl, 0.3M 
Imidazole and 0.5mM TCEP 
Table continues on the next page 
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2nd Chromatography step:  5ml HiTrapTM Heparin HP column  
Elution Linear salt gradient, 0% to 50% high salt buffer 
Low salt buffer: 50mM HEPES pH7.5, 150mM NaCl, 1mM TCEP 
High salt buffer 50mM HEPES pH7.5, 2M NaCl, 1mM TCEP 
Storage of protein Concentrated to 0.3mg/ml and stored at -80°C. 
Table 2.8. Summary table of expression and purification parameters XRCC1161-406 
truncated proteins constructs. 
2.3 TDP2 activity assays  
2.3.1 Labelling protocol 
Oligonucleotide A: 5’-Y-P-AATTCTTCTCTTTCCAGGGCTATGT-3; where Y = 5’-
phosphotyrosine link (Midland Certified Reagent Company, USA) 
Oligonucleotide B: 5’-AGACATAGCCCTGGAAAGAGAAG-3’ (Sigma-Aldrich). 
For annealing 2µl of 10µM 5´Y oligonucleotide A and 4µl of 10µM oligonucleotide B 
were mixed together, in a final volume of 30µl in ultrapure water. Oligonucleotide B was 
added in excess to maximize the complete annealing of oligonucleotide A. The annealing 
reaction was completed in an MWG Biotech Primus 25 thermal cycler and the following 
program used: 95°C for 10min, 70°C for 10, 45°C for 10min, 20°C for 10min, and finally 
4°C for 10min; ramp: 5°C/min.  
The annealed DNA duplex was then labelled using Klenow Fragment (3’→5’ exo-; New 
England BioLabs) in the presence of 2 µl of 10mM ddTTP (GE Healthcare) and 2µl α-32P 
dCTP (Perkin Elmer) in a reaction volume of 40µl. The reaction was incubated for 1 hour 
at 37°C, in a heating block, and then the DNA duplex purified away from any 
unincorporated radiolabel using an Illustra MicroSpin G25 column (GE Healthcare) at 
3000 rpm for 2 min at room temperature and then stored at -20°C until required. The final 
concentration of DNA duplex was approximately 500nM. 
2.3.2 Enzymatic activity assay  
hTDP2-CATC161S, mTDP2-CAT and m2hTDP2-CAT were mixed with reaction buffer (50 
mM Tris-HCl, pH 7.5, 50 mM KCl, 1 mM MgCl2, 1 mM DTT, 100 μg/ml BSA); at a final 
DMSO concentration of 1% v/v. Reactions were set up with or without the inhibitory 
compound, in a compound: protein molar ratio of 50:1, with a volume of 16.2µl. To start 
the reaction 1.8µl labelled substrate DNA was included, making a final reaction volume of 
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18µl. The final concentrations of hTDP2-CAT, mTDP2-CAT and m2hTDP2-CAT were 
1nM, 3nM and 1nM, respectively; mTDP2-CAT may have been not enzymatically as 
active as the other two enzymes. After incubation at 37°C, and withdrawal of 6µl samples 
taken at 2, 5 and 10 min time points, the reaction was stopped by the addition of 1x loading 
buffer containing formamide. Samples were loaded onto an SDS-Urea gel [20% 
Acrylamide:Bis-Acrylamide 19:1 (Thermo Fisher Scientific), 36% w/v Urea (Thermo 
Fisher Scientific) and 1x TBE buffer] and run in a V15·17 vertical gel electrophoresis 
apparatus (Thermo Fisher Scientific) at a constant power of 20W for 80 min. When the run 
was completed, the gel was placed into a BAS-MS 2025 Imaging Plate (Fuji, UK) for 15 
min. The plate was then scanned by a Fujifilm FLA-5100 imaging system in standard 
reading mode with a 635nm laser setting. 
2.4 Crystallisation trials with purified recombinant proteins  
2.4.1 Crystallization of TDP2 
For initial screening MRC 2 well crystallisation plates (Swissci, Hampton Research, USA) 
were used in a sitting drop vapour diffusion set up. The plate is a two drop chamber format 
with 96 wells. Buffers and protein solutions were dispensed using the Phoenix robot 
system. The initial trials employed crystallisation screens from Hampton research.  
When additional (or secondary) screening was required, hanging drop vapour diffusion 
method was used employing 24-well VDX Plates (with sealant, Hampton Research). All 
crystallisation trials were undertaken at 20°C. 
2.4.1.1 Crystallisation of the unliganded (apo-form) of hTDP2-CATC161S 
Hanging drop 24-well VDX Plates: 1µl 7.3mg/ml hTDP2-CATC161S mixed with 1µl mother 
liquor: 0.45M NaCl, 5mM MgCl2, 100 mM bis-tris propane pH7.0 and 1.5% v/v 
trimethylamine N-oxide – and equilibrated with 1 ml of mother liquor. After ~5 days, 
crystals were harvested and frozen in liquid nitrogen in the presence of 40% w/v sucrose 
as a cryoprotectant. 
2.4.1.2 Crystallisation of the hTDP2-CATC161S in complex with inhibitors 
Compound C14297 (22.5mM in 90% v/v DMSO and 100mM HEPES-NaOH pH7.5) was 
added to the protein (final compound: protein molar ratio was 2.7:1, with a final DMSO 
concentration of 2.7 % v/v, TDP2 concentration was 7.2mg/ml) and then incubated on ice 
for 30mins.  
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Sitting drop MRC 2 well plates: 0.3µl protein-compound solution was mixed with 0.3µl 
crystallization buffer and equilibrated with 50µl mother liquor. Index, PEG/Ion and SaltRx 
HT crystallisation screens were set up (Hampton Research). After ~7 days, crystals from 
condition C9 of the SaltRx HT (1.2M DL Malic acid pH 7.0, 0.1M bis-tris propane pH7.0, 
Hampton Research) were harvested and then plunge-frozen in liquid nitrogen in the 
presence of the crystallisation buffer with 30% v/v glycerol added as a cryoprotectant. 
2.4.1.3 Crystallisation of Selenomethionine-labelled hTDP2-CATC161S 
Hanging drop 24-well VDX Plates: 1µl 7.3mg/ml hTDP2-CATC161S mixed with 1µl mother 
liquor: 0.45M NaCl, 5mM MgCl2, 100 mM bis-tris propane pH7.0 and 1.5% v/v 
Trimethylamine N-oxide – and equilibrated with 1 ml of mother liquor. After ~5 days, 
crystals were harvested and frozen in liquid nitrogen in the presence of 40% w/v sucrose 
as a cryoprotectant. 
2.4.1.4 Crystallisation of m2hTDP2-CAT with C14297 
Compound C14297 (22.5mM in 90% v/v DMSO and 100mM HEPES-NaOH pH7.5) was 
added to the protein (final compound: protein molar ratio was 2.7:1, with a final DMSO 
concentration of 2.7 % v/v, TDP2 concentration was 7.2mg/ml) and then incubated on ice 
for 30mins.  
Sitting drop MRC 2 well plates: 0.2µl protein-compound solution was mixed with 0.2µl 
crystallization buffer and equilibrated with 50µl mother liquor. Index, PEG/Ion and SaltRx 
HT crystallisation screens were set up (Hampton Research). After ~5 days, crystals from 
condition G11 of the PACT premierTM HT (0.2M Sodium Citrate, 0.1M bis-tris propane 
pH7.5, 20% w/v PEG 3,350, Hampton Research) were harvested and then plunge-frozen 
in liquid nitrogen in the presence of the crystallisation buffer with 8% glycerol and 5% 
glucose added as a cryoprotectant. 
2.4.1.5 Crystallisation of m2hTDP-CAT with LEP-0259 
Compound LEP-0259 (22.5mM in 90% v/v DMSO and 100mM HEPES-NaOH pH7.5) 
was added to the protein (final compound: protein molar ratio was 2.7:1, with a final 
DMSO concentration of 2.7 % v/v, TDP2 concentration was 7.2mg/ml) and then incubated 
on ice for 30mins.  
Sitting drop MRC 2 well plates: 0.2µl protein-compound solution was mixed with 0.2µl 
crystallization buffer and equilibrated with 50µl mother liquor. Index, PEG/Ion and SaltRx 
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HT crystallisation screens were set up (Hampton Research). After ~5 days, crystals from 
condition F9 of the PACT premierTM HT (0.2M Potassium sodium tartrate tetrahydrate, 
0.1M bis-tris propane pH6.5, 20% w/v PEG 3350, Hampton Research) were harvested and 
then plunge-frozen in liquid nitrogen in the presence of the crystallisation buffer with 8% 
glycerol and 5% glucose added as a cryoprotectant.  
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2.5 In vitro binding assays 
2.5.1 In vitro binding assay, Slot blot 
2.5.1.1 Slot Blot, XRCC1161-406  
50µl of recombinant XRCC1161-406 WT or XRCC1161-406 RK at 100nM was first diluted in 
binding buffer (20mM Tris-HCl pH7.5, 100mM NaCl) and then transferred onto 
Amersham Protran nitrocellulose membrane (GE Healthcare), using a PR 648 Slot Blot 
Manifold, 48-well device (GE Healthcare) by applying vacuum. Following transfer, the 
membrane was blocking for 30 minutes at room temperature in 5% w/v milk powder 
(Marvel, UK) dissolved in binding buffer. The membranes were subsequently incubated 
with either mock-ribosylated or auto-ribosylated recombinant PARP1 for 30 min at room 
temperature.  
Ribosylation reactions were as follows: 100nM PARP1 enzyme was mixed either with zero 
or 10µM NAD+ (Sigma-Aldrich), 20nM single-stranded oligodeoxyribonucleotide (5’-
CATATGCCGGAGATCCGCCTCC-3’, Eurogentec) and ultrapure water to a final 
volume of 500µl. The reaction was allowed to proceed at room temperature for 30 min. 
After incubation with PARP1, the membrane was washed twice with 2% w/v milk-binding 
buffer, and then incubated with either 1:300 dilution mouse anti-PARP1 (#A6.4.12, Bio-
Rad) or 1:1000 mouse anti-Poly(ADP-ribose) (#10H, Enzo Life Sciences, Exeter, UK) 
monoclonal antibodies in 2% w/v milk-binding buffer overnight at 4°C. The next morning 
the membranes were washed 3 times with 2% w/v milk-binding buffer and then incubated 
with 1:5000 dilution HRP-conjugated rabbit anti-mouse IgG (Dako, Ely, UK) for 1h at 
room temperature. The membrane was washed again with milk-binding buffer, and then 
placed into Amersham ECL Western Blotting Detection Reagent (GE Healthcare). 
Amersham Hyperfilm Blue (GE Healthcare) was used to detect the resultant 
chemiluminescent signal.  
2.5.1.2 Slot Blot, PAR blotted 
A dilution series of PAR polymer (Trevigen, Abingdon, UK) was prepared in phosphate-
buffered saline buffer (PBS: 137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, and 1.47mM 
KH2PO4), and then slot-blotted (as before) onto an Amersham Hybond-XL nylon 
membrane (GE Healthcare). The membrane was allowed to dry at room temperature for 
10 min after vacuum transfer, and then cross-linked by exposure to UV light for 25 sec 
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using UV Stratalinker 2400 (Stratagene, USA) ultraviolet cross-linker device. After 
blocking for 30 min in 5% w/v milk-binding buffer at room temperature the membrane 
was incubated with either 100nM XRCC1161-406 WT or XRCC1161-406 RK protein diluted in 
binding buffer and then incubated at room temperature for a period of 30 min. After three 
wash steps using 2% w/v milk-binding buffer, the membrane was incubated with 1:3000 
mouse monoclonal anti-polyhistidine antibody (#HIS-1, Sigma-Aldrich) for overnight at 
4°C. The next morning after three washes with 2% w/v milk-binding buffer the membrane 
was probed as before with 1:5000 HRP-conjugated rabbit anti-mouse IgG (Dako) for 1h at 
room temperature. The membrane was then washed as per the previous protocol (Section 
2.5.1.1), and any retained protein detected as before. As a control, a membrane containing 
only dilution series of PAR was probed for anti-Poly(ADP-ribose)(10H) (1: 1000, Enzo 
Life Sciences) antibody to measure the level of PAR signal emerging from each dilution. 
2.5.2 Plate binding assays 
For plate-binding assays, the wells of a flat-bottomed 96 well PS-microplate (Greiner, 
Germany) were filled with 50 µl of either recombinant histone H1 (protein stock was a 
kind gift of Dr Gabrielle Grundy, University of Sussex), PARP1, BSA (Sigma-Aldrich) or 
Calf Thymus Histone type II (Sigma-Aldrich) at 0.1 mg/ml in PBS was absorbed onto 
plates at 4°C overnight. The next day the wells were rinsed four times with 0.2 ml PBS 
containing 0.1% v/v Triton X100 (Sigma-Aldrich). 
2.5.2.1 Poly(ADP-ribose) binding assays  
Adsorbed histone H1, PARP1 and BSA were mock-ribosylated (in the absence of NAD+) 
or trans-ribosylated in the presence of the indicated concentration of NAD+ (Sigma-
Aldrich), in 50 µl of PARP1 reaction buffer (50 mM Tris-HCl pH 8, 0.8mM MgCl2, 1% 
v/v glycerol and 1.5 mM DTT) containing 40nM single-stranded oligodeoxyribonucleotide 
(see section 2.5.2.1) and 5nM PARP1 (recombinant, human, full length) at room 
temperature for 30min. After four successive rinses with 50 µl of PBS containing 0.1% v/v 
Tween 20, 50 µl of either XRCC1161-406 WT or XRCC1161-406 RK (diluted to 25nM in 20 mM 
Tris pH 7.5, 130mM NaCl) was added to the wells and then incubated on ice for 30min. 
The wells were again rinsed four times as above, and then incubated with 50µl of 20 mM 
Tris pH7.5, 130nM NaCl containing 1:3000 mouse monoclonal anti-polyhistidine antibody 
(Sigma-Aldrich). The wells were rinsed again (4x) followed by incubation with 50µl buffer 
containing 1:500 HRP-conjugated rabbit anti-mouse IgG (Dako) for 30min on ice. After a 
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final wash with 50 µl of PBS containing 1% v/v Tween 20, 50µl of TACS Sapphire reagent 
(Trevigen) was added to the wells and incubated for 15min in the dark. The colorimetric 
reaction was stopped by adding 50µl of 0.2 M HCl, and the absorbance was read at 450nm 
in a POLARstar Omega (BMG Labtech, Germany) microplate reader. 
2.5.2.2 Auto- and trans-ribosylated PARP1 competition assay  
Before XRCC1 proteins were added to the wells, they were pre-incubated with mock-
ribosylated and auto-ribosylated PARP1 (with the indicated concentration of NAD+ for 30 
min at 4°C. The washing and detections steps were the same as described in Section 
2.5.2.1. 
2.5.2.3 Mono(ADP-ribose) and poly(ADP-ribose) competition assays 
Before XRCC1 proteins was added to the wells, they were pre-incubated with mono(ADP-
ribose) (Sigma-Aldrich) or poly (ADP-ribose) (Trevigen) competitor at the concentrations 
indicated for 30 min at 4°C. The washing and detections steps were the same as described 
in Section 2.5.2.1. The same competition assay was also conducted in the presence of 
purified PAR fractions with distinct unit lengths in a sequential dilution series (15µM, 
1.5µM, 0.15µM and 15nM). 
2.5.2.4 Plate binding assays employing biotinylated PAR polymer 
Adsorbed Calf thymus histone was either mock-ribosylated or trans-ribosylated with 
biotinylated NAD+ in the presence of PARP1. For mono-ribosylation reactions 100nM 
recombinant PARP3 in PARP reaction buffer (50mM Tris-HCl pH8, 0.8mM MgCl2, 1% 
glycerol and 1.5mM DTT) was used, and was incubated at room temperature for 30 min. 
PAR polymer was digested with 1ng/ml PARG enzyme (Trevigen) in 50µl reaction buffer 
(20mM KPO4 (pH 7.2), 50mM KCl, 0.1 mg/ml BSA, 0.1% Triton® X-100, 1mM DTT, 
5% Glycerol) at room temperature for 30 min.  
Mono-ribosyl moieties from the acceptor protein were removed by digestion with 15µg/ml 
recombinant MACROD1 in PARP reaction buffer at room temperature for 30 min.  
Biotinylated PAR polymer and mono(ADP-ribose) were detected by HRP-conjugated 
streptavidin antibody (1:10,000 dilution in 20mM Tris-HCl pH7.5, 130mM NaCl; Thermo 
Fisher Scientific). 
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2.5.3 Preparation of homogenous PAR polymer 
2.5.3.1 Preparation of dihydroxyboryl groups coupled to BioRex 70 beads 
The full protocol is described in (Bredehorst et al. 1981). In short, 50g Bio-Rex resin (100-
200 mesh, Bio-Rad) was incubated with 5g aminophenyl-boronic acid (Sigma-Aldrich) 
and 5g N-ethyl-N’-(3-diethylaminopropyl)-carbodiimide (Sigma-Aldrich) overnight at pH 
5.0 at 20°C. The next day the sample was washed with water 3 times, then with 0.1M Na 
acetate, and 1M NaCl buffer (pH 4.5), then with 0.1M NaHCO3, and 1M NaCl buffer (pH 
9.0), and again with water. The resin was finally washed with 6M guanidine HCl, and then 
0.5M MES buffer (pH 6.0) and stored in the same buffer. 
2.5.3.2 Preparation of large scale homogenous PAR polymer 
The purification protocol is based on (Tan et al. 2012) with some minor alterations. The 
PARylation reaction was as follows: 1mg/ml calf thymus histones (Sigma-Aldrich) in 
PARP reaction buffer (50mM Tris-HCl pH 8, 0.8mM MgCl2, 1% v/v glycerol and 0.5mM 
DTT), 20mM NAD+ (Sigma-Aldrich) were mixed with 1mg/ml TNKS1 enzyme. The total 
reaction volume was 1ml and the reaction was incubated at room temperature for 1 hour. 
The reaction was stopped by adding an equal volume of 20% v/v ice-cold trichloroacetic 
acid, then incubation on ice for 15 min. The precipitated ribosylated protein was pelleted 
by centrifugation at top speed at 4°C. After decanting the supernatant, the pellet was 
dissolved in 100µl 1M KOH/50mM EDTA and was incubated for 60 min at 60°C with 
regular vortexing. After the incubation period, 900µl of AAGE9 buffer (250mM 
ammonium acetate, 6M guanidine HCl, 10mM EDTA, pH 9.0) was added and the sample 
was loaded onto 1ml dihydroxyboryl Bio-Rex resin pre-equilibrated with AAGE9 buffer. 
The resin was washed (in a gravity column format) with 10ml AAGE9 buffer, 20ml 1M 
ammonium acetate (pH 9.0) buffer and eluted with 6ml water in 1ml fractions. Successive 
fractions were analysed by UV spectroscopy, using a NanoDrop2000 (Thermo Fisher 
Scientific) at a wavelength of 258nm. Fractions containing bulk PAR were pooled and then 
loaded onto a 1ml MonoQ 5/50 chromatography column (GE Healthcare). The column 
was first washed with Buffer A (25mM Tris-HCl, pH9.0) to remove any unbound material. 
Bound PAR was eluted by the application of the following linear gradient series from 
Buffer A to Buffer B (25mM Tris-HCl, pH 9.0, 1M NaCl): 0% to 15% B over 5 column 
volumes (cv), then 15% to 40% B over 130 cv, followed by 40% to 45% B over 80cv, and 
a final step from 45% to 100% B over 3cv. Fractioned peaks were dried in a Savant 
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DNA120 SpeedVacTM concentrator (Thermo Fisher Scientific) and then stored at -20°C 
until required. Successive runs of the MonoQ column were required in order to generate a 
sufficient quantity of fractionated PAR. Fractions containing PAR, with the same elution 
volume, were pooled together and re-dissolved in water to final volume of 1ml, which was 
then loaded onto a PD MidiTrap G-10 column (GE Healthcare) pre-equilibrated with 
water. After elution from the column (following the manufacturer’s protocol) the resulting 
sample was again dried in the Savant concentrator before being stored at -20°C. 
2.5.3.3 Acrylamide gel electrophoresis of purified PAR fractions 
Purified PAR fractions were adjusted to a final concentration of 0.3µM and then diluted in 
loading buffer (40% w/v urea, 4mM EDTA, 0.02% w/v Bromophenol blue, and 0.02% w/v 
Xylene cyanol) to a final volume of 15µl and then loaded onto a 20% v/v polyacrylamide 
gel (acrylamide: bis-acrylamide ratio 19:1, Thermo Fisher Scientific) containing 1x TBE 
buffer. The gel was run at a constant power of 15W until the dye front migrated 
approximately 50% of the gel; after which the gel was fixed in a 50% v/v ethanol and 5% 
v/v acetic acid solution for 2 hours. After fixing, the gel was washed with 4 consecutive 
15 min washes in ultrapure water. The gel was then stained with a Pierce Colour Silver 
Stain Kit (Thermo Fisher Scientific) following the manufacturer’s protocol. Briefly: 
‘working solution’ was added to the gel then incubated for 30 min, it was then rinsed briefly 
in ultrapure water, before ‘reducer solution’ was added and further incubation for 2 
minutes. Next, the gel was incubated in ‘stabiliser solution’ for 30 min. The stained gels 
were then sealed in plastic bags and scanned using a scanning device (Epson) connected 
to a PC. All staining steps were carried out at room temperature. 
2.6 In vitro biophysical assays  
2.6.1 Thermal denaturation assay 
For thermal denaturation, samples containing protein at a given concentration and 5 x 
SYPRO Orange (diluted from a 5000 x stock supplied in DMSO; catalogue number S5692, 
Sigma-Aldrich) were prepared in sample buffer [50mM HEPES pH 7.5, 300mM NaCl, 
0.5mM TCEP]. Denaturation curves were monitored in 96-well PCR plates in a Roche 
LightCycler 480 II, using 465 and 580 nm filters for excitation and emission wavelengths, 
respectively. The program was as follows: 1 min at 20°C and then the plate was heated at 
a continuous increment of 0.03°C/s to 85°C. Temperature midpoints (Tm) for each folded 
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to unfolded transition were determined by either calculating a first-order derivative of the 
observed melting profile (built-in analysis tool supplied with the LightCycler) or by non-
linear regression fitting of a modified Boltzmann model to normalized data in Prism5 
(GraphPad Software). 
 
Where: an and ad are the slopes, bn and bd the y-intercepts, of the native and denatured 
baselines respectively. Tm is the melting temperature, and m a slope factor. 
2.6.2 Circular dichroism 
For circular dichroism, spectra were measured between the wavelengths 198nm and 
280nm, at 20 ˚C, in a JASCO J-715 spectropolarimeter attached to a JASCO PTC-384W 
temperature control system. Protein samples in 10mM HEPES, pH7.5, 300mM NaCl and 
0.5mM TCEP were concentrated to 1.55mg/ml and put into a Type 20 demountable cell 
(path length 0.1mm, Starna Scientific). CD Spectra represent the average of 10 individual 
scans, where the absorbance from a buffer control has been subtracted. 
2.7 Cell biology techniques 
2.7.1 Maintaining cell cultures 
Cells were maintained as a monolayer culture in either 75cm2 or 175cm2 flasks (T75, T175, 
Corning) grown in a NuAire Microbiological CO2 incubator. Cells were provide with α-
MEM media (Gibco) supplemented with 10% v/v Foetal Calf Serum (FCS), 1% v/v L-
Glutamine (Gibco) and 1% v/v Penicillin-Streptomycin (10,000 U/mL) (Gibco). Cell 
manipulation and aseptic techniques were all performed in a NuAire Safety cabinet. Cell 
counts were determined with a Marenfield counting chamber (haemocytometer).  
Stocks of cells were prepared in media containing 10% v/v DMSO at 0.5x106 cell count 
and stored in TruCool cryogenic vials (Biocision). Vials first were cooled down in a Mr 
Frosty Cryo 1°C Freezing Container (Thermo Fisher Scientific) and then transferred and 
stored in liquid N2. 
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2.7.2 XRCC1 pull down assays 
Stably transfected EM9 cells [a derivative of the Chinese hamster ovary (CHO) cell line, 
which is XRCC1-/-] expressing full length His6-tagged XRCC1, either wild-type (EM9 
XH) or phosphopeptide-binding site mutant (EM9 R335A/K369A), were grown in T75 
flasks in α-MEM media (Gibco) supplemented with 10% v/v Foetal Calf Serum (FCS), 1% 
v/v L-Glutamine (Gibco) and 1% v/v Penicillin-Streptomycin (10,000 U/mL) (Gibco). 
After reaching confluence, cells were washed with PBS and then trypsinized (0.5% w/v 
trypsin-PBS) to detach them from the flask and counted using a haemocytometer. 1x107 
cells were then transferred to a 15ml Falcon tube (Thermo Fisher Scientific) and were 
centrifuged at 1500 rpm for 5min at room temperature in a Hettich Rotina 38R centrifuge 
with a 4 place swing out rotor (A1724) (DJB Labcare, Newport Pagnell, UK). After 
aspirating the media the cell pellet was resuspended in 5ml fresh media and centrifuged as 
before. The media was once again aspirated, and the cell pellet re-suspended in ice cold 
PBS and it was centrifuged at 1500 rpm for 5min at 4°C. The cell pellet was resuspended 
in 1ml PBS and was transferred to a 1.5ml Eppendorf tube.  
Cells were harvested by centrifugation at 1500 rpm at 4°C for 5 minutes in a Hettich Rotina 
38R centrifuge with a 4 place swing out rotor (A1724) (DJB Labcare). Cells were washed 
once in 5 ml of fresh growth media, and once with 5ml ice-cold PBS, with centrifugation 
between each wash to harvest cells. The washed cell pellet was resuspended in 1ml PBS 
and transferred to a 1.5 ml Eppendorf tube. Again, cells were harvested by centrifugation 
(13,000 rpm at 4°C, 1 min, in a benchtop microcentrifuge) and then either snap-frozen in 
liquid N2 and stored at 80°C or processed immediately. 
For pull down experiments, the following buffer was used: 25mM HEPES pH 7.8, 150mM 
NaCl, 10% v/v glycerol, 0.5% v/v Triton-X, 1/100 Protease inhibitor cocktail (Sigma-
Aldrich) and 1/100 Phosphatase inhibitor cocktail 3 (Sigma-Aldrich) were prepared. 
Lysis/Washing buffer was comprised of the same buffer but supplemented with 1mM DTT 
and 25mM imidazole. The Elution buffer is comprised of the same buffer, but 
supplemented with 1mM DTT and 250mM imidazole.  
Lysis buffer was added to the cell pellet in order to adjust the cell count to 400µl/5x106 
cells, and was then placed on ice for 20 min. The cells were disrupted by sonication for 2x 
5 seconds at 20% power using a small parallel probe (Sonics Vibra-Cell, VWR), and cell 
debris and insoluble material removed by centrifugation at 13000 rpm at 4°C for 20 min 
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in a benchtop refrigerated centrifuge. 300 µl of the supernatant was added to 100µl pre-
equilibrated Ni-agarose resin slurry (50µl resin and 50µl wash buffer) and then incubated 
with mixing on a rotating wheel at 4°C for 30 min. The resin was then pelleted by 
centrifugation at 3000 rpm for 1 min in benchtop refrigerated centrifuge. The flow-through 
was retained (unbound) and the beads were washed with five successive applications of 
500 µl of wash buffer, pelleting the resin after each wash by centrifugation as before; the 
final wash was retained (wash). 200µl elution buffer was added to the resin and after 
resuspension incubated on ice for 5min. The resin was again pelleted by centrifugation and 
the supernatant (retained) was retained for further analysis. Finally, 125µl Laemmli buffer 
was added to the resin and was heated to 100°C for 5 min (beads). Laemmli buffer was 
added to the other samples (unbound, wash, retained) and heated to 100°C for 2min. 20µl 
of each sample were analysed by SDS-PAGE. 
Western blot 
After separation by SDS-PAGE, proteins were transferred to Amersham Protran 
nitrocellulose membrane (GE Healthcare) using acrylamide gel electrophoretic apparatus 
at 100V for 90 min, in TOWBIN transfer buffer (25mM Tris-Base pH 8.3, 192mM glycine 
and 10% v/v methanol). 
After transfer, the membrane was blocked in 5% milk-PBS for 1 hour at room temperature. 
After blocking, the membrane was incubated with 1:3000 dilution of mouse monoclonal 
anti-PARP1 (Bio-Rad) antibody, diluted in 1% milk-PBS, overnight at 4°C. The next 
morning the membrane was washed 3 times with 1% milk-PBS and then probed with 
1:5000 dilution of HRP-conjugated rabbit anti-mouse IgG (Dako) antibody for 1h at room 
temperature. The membrane was washed 4 times with PBs, and then soaked in Amersham 
ECL Western Blotting Detection Reagent (GE Healthcare). The resultant 
chemiluminescent signal was detected on Amersham Hyperfilm Blue film (GE 
Healthcare). 
In order to re-probe for XRCC1, the membrane was stripped to remove the antibodies. 
Membranes were incubated with 4 successive applications of stripping buffer [40mM Tris-
HCl pH 6.8, 0.6% v/v β-mercaptoethanol, 2% v/v SDS] for 10 min at 50°C, washed with 
ultrapure water, and 3 successive applications of Tris-buffered Saline (TBS) buffer with 
0.1% v/v Tween 20 (Sigma-Aldrich) added (TBS-T). 
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Membranes were blocked in 5% milk TBS-T, then the presence of full length XRCC1 was 
detected with a 1:5000 dilution of rabbit anti-phospho XRCC1 polyclonal antibody 
(pS485/pT488) (A300-231A, Bethyl Laboratories) in 5% milk-TBST, or XRCC1161-406 
constructs with a 1:500 dilution of mouse anti-Myc monoclonal antibody (9B11, Cell 
Signalling Technology) in 5% milk-TBST. After successive washes to remove any 
unbound antibody (described above), either a 1:5000 dilution of anti-rabbit or anti-mouse 
HRP-conjugated IgG antibody (Dako) was used as secondary antibody. As before, 
detection of chemiluminescence was by film. 
2.7.3 Clonogenic survival in U2OS cells using small molecule 
inhibitors of hTDP2 in the presence of etoposide (VP16) 
The osteosarcoma cell line U2OS was maintained as a monolayer culture in 75cm2 flasks 
(T75, Corning) in modified Eagle’s medium (α-MEM) media (Gibco) supplemented with 
10% v/v Foetal Calf Serum (FCS), 1% v/v L-Glutamine (Gibco) and 1% v/v Penicillin-
Streptomycin (10,000 U/mL) (Gibco). Cell culture was maintained in a NuAire 
Microbiological CO2 incubator at 37°C. After reaching approximately 90% confluence, 
the cells were washed with PBS and then trypsinised (as per EM9 cells, Section 2.7.2) to 
detach them from the flask, and then counted using a haemocytometer.  
For 0, 200 and 400nM etoposide treatments, 500 cells were seeded; for 400, 600 and 
800nM treatments 5000 cells were plated onto Petri culture dishes (Corning) in 10ml 
media. Dishes were incubated at 37°C for 4 hours, to allow the cells to adhere to the bottom 
of the dishes. Half of the dishes were treated with 5µM hTDP2 inhibitor in the presence of 
0.5% v/v DMSO and the other half treated with 0.5% DMSO alone (as a vehicle control), 
and then incubated for 4 hours at 37°C in a NuAire Microbiological CO2 incubator. 
After the incubation period, the plates were treated with 0, 200, 400, 600 and 800nM 
etoposide (VP16) and was incubated for a further 4 days at 37°C, after which the plates 
were washed with PBS and fresh media was added. The dishes were then incubated for an 
further 10-12 days and checked for colony formation. Dishes were then washed with PBS 
and stained/fixed with methylene blue solution [2% w/v methylene blue (Sigma-Aldrich) 
in 70% Ethanol]. Fixed and stained colonies were then counted manually using a Stuart 
colony counter (Sigma-Aldrich). 
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2.7.4 γH2AX foci counting in 1BR cells after hTDP2 inhibitor and 
etoposide treatment 
1BR human fibroblast cells were maintained as a monolayer culture in 75cm2 flasks (T75, 
Corning) in modified Eagle’s medium (α-MEM) media (Gibco) supplemented with 15% 
v/v Foetal Calf Serum (FCS), 1% v/v L-Glutamine (Gibco) and 1% v/v Penicillin-
Streptomycin (10,000 U/mL) (Gibco). Cell culture was maintained in a NuAire 
Microbiological CO2 incubator at 37°C. After reaching 90% confluence, cells were washed 
with PBS then trypsinised (as per EM9 cells, Section 2.7.2) to detach them from the flask 
and then counted using a haemocytometer. 
25-30,000 cells/ml/plate were seeded in 15% v/v FCS containing media onto Nunc 4-well 
dishes (Thermo Fisher Scientific) containing round glass coverslips (neuVitro) to which 
the cells adhere. Cells were incubated at 37°C until they reached confluency (typically 
after 2 days), the media then was aspirated, and the coverslips washed with PBS. 1ml media 
containing 0.1% v/v FCS was added and the cells were incubated for an additional 5 days 
to induce cell cycle arrest.  
Cell-cycle arrested cells were either pre-treated with 5uM hTDP2 inhibitor in 0.5% v/v 
DMSO or with 0.5% v/v DMSO as a vehicle control for 1 hour. After pre-incubation, 
20µM etoposide (Sigma-Aldrich) in 0.5% v/v DMSO (final DMSO content was 1% v/v) 
was added to the cells. As a control, a set of cells was not subjected to VP16 treatment. 
After incubations for a further hour, the media was aspirated, and the coverslips washed 
with PBS; this step was set as the ‘zero time’ point. Control cells and one set of the treated 
cells were immediately fixed in 0.5ml 4% PFA (Paraformaldehyde)-PBS for 5 min at room 
temperature, and then washed with 2 successive applications of 0.5ml PBS. Fixed cells 
were stored at 4°C overnight in PBS. After washing the coverslips, fresh media was added 
back to the wells (pre-treated condition) and then incubated at 37°C. Cells were fixed at 
30, 90 and 180 min time-points after VP16 treatment. 
γH2AX foci counting: immuno-labelling protocol for 1BR cells  
0.5ml PBS containing 0.2% v/v Triton-X100 was added to the wells containing the 
coverslips and then incubated for 5 min at room temperature. 0.5ml 5mg/ml BSA–PBS 
was then added and incubated for 1 hour at room temperature. 200µl 1mg/ml BSA–PBS 
buffer supplemented with 1:1000 dilution of mouse monoclonal anti-γH2AX antibody 
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(#2577, Cell Signalling Technology) and 1:1000 dilution of rabbit polyclonal anti-CENPF 
antibody (#ab5, Abcam) was added to the coverslips, and incubated for 1 hour at room 
temperature, followed by 3 successive applications of 0.5ml PBS containing 0.1% v/v 
Tween-20 and 0.2% v/v SDS (PBS-Tween-SDS) at room temperature. After that a 1:1000 
dilution of Alexa Fluor 488-conjugated goat anti-mouse antibody (#A-11001, Thermo 
Fisher Scientific) and 1:1000 dilution of Alexa Fluor 555-conjugated goat anti-rabbit 
antibody (#A-21428, Thermo Fisher Scientific) in 1mg/ml BSA–PBS was added to the 
coverslips, and incubated for 1 hour at room temperature in the dark. Following this step, 
a 1:10,000 dilution of DAPI (Thermo Fisher Scientific) in PBS was added to the coverslips, 
which was then incubated for 5 min, followed by a final washing step with in PBS-Tween-
SDS. The seeded cover slips were then mounted onto glass slides using VECTASHIELD 
mounting media (Vector Laboratories), and sealed with nail varnish. For foci counting a 
NIKON E400 microscope was used at 100x magnification. 40 cells arrested in G1 phase 
were chosen from each experimental set up to count γH2AX foci manually. 
  
100 
 
 
 
 
 
 
 
 
 
CHAPTER THREE 
 
Expression, purification and 
crystallisation of human TDP2 
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3.1 Introduction 
In order to pursue a structure-based drug design approach, one needs to first obtain 
reproducible high-resolution structural data for the protein in question. This approach 
typically requires a significant amount of protein at high purity that will be used to generate 
crystals, which will hopefully diffract to high resolution.  
It was therefore necessary to first optimise the expression and purification of human TDP2. 
TDP2 is composed of two domains connected by a twenty amino acid interdomain loop 
reference. This loop represents a region of high flexibility that could potentially cause 
problems during crystallogenesis, therefore expression constructs containing either the 
full-length protein or catalytic domain (in isolation) were generated (Figure 3.1).  
Expression trials of synthetic, codon-optimised full-length and catalytic domain hTDP2 
constructs were undertaken in a bacterial expression system. 
3.2 Results 
A synthetic and codon-optimised gene encoding full length human TDP2 for expression in 
Escherichia coli (E.coli) was purchased from GenScript (Piscataway NJ, USA). The 
protein coding sequence was flanked by NdeI and EcoRI restriction sites to facilitate 
downstream sub-cloning into expression vectors. 
3.2.1 hTDP2 expression trials in E. coli 
Protein expression in bacterial expression systems has distinct advantages; it is fast and 
relatively cheap compared to other methods, but also has some associated problems: 
proteins of a mammalian origin will lack certain post-translational modifications, whilst 
multi-domain proteins may not fold properly. Protein expression trials usually begin in 
bacteria, but if sufficient recombinant protein is not produced, another expression host is 
often worth considering. For expression in E.coli, two expression plasmids were used: 
pTWO-E and pTHREE-E. pTWO-E is an in-house vector modified from pET-17b 
encoding an N-terminal human rhinovirus-3C cleavable (HRV-3C) His6 affinity tag. 
pTHREE-E is an in-house vector modified from pGEX-6P-1 encoding an N-terminal 
HRV-3C cleavable glutathione-S-transferase (GST) affinity tag. Both plasmids were a 
kind gift of Dr A.W. Oliver, University of Sussex. DNA encoding both the full-length and 
catalytic domains of human TDP2 were sub-cloned into each expression plasmid. 
102 
 
 
Figure 3.1. The domain structure of human TDP2. TDP2 contains two domains, an N-
terminal ubiquitin-associated (UBA) domain and a C-terminal catalytic domain 
connected together by an approximately 20 amino acid interdomain loop. The amino 
acid boundaries of the two catalytic domain expression constructs are also indicated. 
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3.2.1.1 Expression trials of full length hTDP2  
The TDP2 open reading frame (ORF) was excised from the hTDP2-pUC57 plasmid by a 
NdeI / EcoRI restriction enzyme double digest and ligated into linearised, phosphatase-
treated pTWO-E and pTHREE-E plasmids. Positive clones were verified by restriction 
enzyme double digest, followed by DNA sequencing. This sub-cloning step generated the 
expression vectors pTWO-E/hTDP2-FL and pTHREE-E/hTDP2-FL (Appendix A.1). 
The pTWO-E/hTDP2-FL plasmid was introduced into E.coli strains BL21(DE3) and 
Rosetta(DE3) pLysS by transformation (see Materials and Methods 2.1.1). Rosetta(DE3) 
pLysS cells provide tighter control of protein expression as they also express T7 lysozyme, 
which reduces the basal level of expression from the T7 promoter found within the pTWO-
E plasmid (Zhang and Studier 1997). Small-scale expression trials (5ml) were conducted 
by growing cells at 37°C or 20°C for 3 hours or overnight, respectively, with protein 
expression induced by the addition of 0.4mM IPTG, once the OD600 of the culture had 
reached 1.0. Protein extracts were prepared as described in Materials and Methods 
(2.2.6.1), and were analysed by SDS-PAGE using Novex 4-12% Tris-Glycine Protein Gels 
(Life Technologies, Paisley, UK) and staining of proteins with InstantBlue (Expedeon, 
Cambridge, UK). The expected molecular mass of polyhistidine-tagged full-length hTDP2 
is 42 kDa.  
The observed level of recombinant hTDP2 expression was much higher when cells were 
grown at 37°C than at 20°C, in both BL21(DE3) and Rosetta(DE3) pLysS cells. However, 
the recombinant protein was largely present in the insoluble fraction (Figure 3.2). 
In order to confirm the presence of any hTDP2 in the soluble fraction, a larger 50ml culture 
was grown in L-broth, using BL21(DE3) cells, and induced for 3 hours at 37°C. 
Recombinant histidine-tagged hTDP2 was purified from the clarified supernatant using 
gravity flow column and immobilised metal affinity chromatography (IMAC) using 
TALON resin (Clontech, St-Germain-en-Laye, France). Whilst this approach resulted in 
the purification of some soluble hTDP2, the presence of a protein that migrated just below 
the 62kDa molecular weight marker suggested the presence of the bacterial chaperonin 
protein GroEL, which is highly indicative of misfolded protein (Figure 3.4A). 
In parallel with the experiments discussed above, expression trials with a different affinity 
tag were undertaken, in an attempt to improve solubility. A glutathione S-transferase 
(GST) tag can help increase the solubility of a target protein and is readily captured from  
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Figure 3.2. Small-scale expression trials of His-tagged full-length hTDP2. The indicated 
expression strain of E. coli was transformed with pTWO-E/hTDP2-FL plasmid. 
Expression trials were conducted in L-broth, at temperature of 20 or 37°C as indicated. 
Samples were run on Novex 4-12% Tris-Glycine Protein Gels and then stained with 
InstantBlue Protein Stain. KEY: (Ø): pre-induction sample, (W): whole cell lysate, (S): 
supernatant, and (P): pellet. The molecular weight (MW) of the full-length His6-hTDP2 
is 42kDa. An arrow indicates the expected size of the recombinant protein. 
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cell lysates by affinity chromatography. The pTHREE-E/hTDP2-FL plasmid was 
transformed into BL21(DE3) competent cells. As the pTHREE-E plasmid contains the tac 
promoter (a hybrid of the trp and the lac promoters), expression of the target protein is 
driven by the host’s RNA polymerase, and not by T7 RNA polymerase – which means that 
there is no advantage in using pLysS strains of E.coli for tight control of protein expression. 
Small-scale expression trials (5ml) in L-broth were set up as before. After disruption of 
cells, and analysis of the soluble and insoluble fractions by SDS-PAGE, it became evident 
that most of the expressed protein was insoluble. However, given that there was a small 
amount of protein in the supernatant (Figure 3.3), this expression system was explored 
further. 
The supernatant was loaded onto Glutathione Sepharose (GS) resin, unbound material 
removed by successive washes with lysis buffer, and the bound material recovered by 
boiling in SDS-PAGE loading buffer. SDS-PAGE revealed two bands of ~62kDa, again 
suggesting association of the recombinant TDP2 protein (~66kDa) with GroEL (~60kDa) 
(Figure 3.4B). To examine this further, I repeated the expression experiment as above, but 
using a larger 50ml culture. In addition, GST-hTDP2 was retained on the resin and 
subjected to overnight digestion by HRV-3C to remove the GST tag. The next day, 
fractions corresponding to the overnight digest, wash and bead fractions were analysed by 
SDS-PAGE. From this analysis, it was clearly obvious that hTDP2 and GroEL were still 
associated. The presence of co-purifying GroEL for both the His- and GST-tagged versions 
of full-length hTDP2 was verified by Western blot (Figure 3.4 C). 
3.2.1.2 Expression trials of the catalytic domain constructs hTDP2-CAT101-362 and 
hTDP2-CAT111-362 
In parallel with the experiments described in the previous section, attempts to clone and 
express just the catalytic domain of hTDP2 were undertaken (Materials and Methods 
2.2.6.2) (Appendix A.2). To increase the likelihood of obtaining stable and soluble protein, 
two ORFs were generated by PCR, which differed in the number of N-terminal amino 
acids included, with hTDP2-CAT101-362 encoding 10 extra amino-terminal amino acids 
than hTDP2-CAT111-362. Both ORFs were sub-cloned into the expression plasmids pTWO-
E and pTHREE-E (Table 3.1). pTWO-E/hTDP2-CAT101-362 and pTWO-E/hTDP2-CAT111-
362 were transformed into BL21(DE3) and Rosetta(DE3) pLysS E. coli strains and 
expression tested in small scale experiments at different temperatures, induction times and 
growth media (Figure 3.5A and 3.5B, and Table 3.2). These set of experiments suggested  
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Figure 3.3. Small-scale expression trials of the GST-tagged full-length hTDP2. 
Expression of full-length hTDP2 was induced from pTHREE-E/hTDP2, encoding GST-
tagged hTDP2. Expression trials were conducted in L-broth, at 20°C or 37°C as 
indicated. Samples were run in Novex® 4-12% Tris-Glycine Protein Gels (Life 
Technologies). Abbreviations: (Ø): pre-induction sample, (W): whole cell lysate, (S): 
supernatant, and (P): pellet. The MW of the full-length GST-hTDP2 is 66kDa. An arrow 
indicates the expected migration position of the recombinant protein.  
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Figure 3.4. Full length TDP2 expressed in E. coli co-purifies with GroEL. A. His6-
tagged hTDP2-FL co-elutes with a ~60 kDa band. B. GST-hTDP2-FL also coelutes with 
a ~60 kDa band (both proteins run very close together on SDS-PAGE gels). C. A Western 
Blot, with an anti-GroEL primary antibody confirming the identity of the ~60 kDa band. 
KEY: (F/T): flow-through, (W): wash, and (El): elution. 
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Expression construct Expressed protein 
pTWO-E/hTDP2-CAT101-362  His6-hTDP2-CAT101-362 
pTWO-E/hTDP2-CAT111-362 His6-hTDP2-CAT111-362 
pTHREE-E/hTDP2-CAT101-362 GST-hTDP2-CAT101-362 
pTHREE-E/hTDP2-CAT111-362 GST-hTDP2-CAT111-362 
 
Table 3.1. Nomenclature of expression constructs and proteins. The pTWO-E constructs 
express an N-terminally His-tagged protein. The pTHREE-E constructs express an N-
terminally GST-tagged protein. Both affinity tags can be removed by incubation with 
human rhinovirus-3C protease (HRV-3C). 
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that, of those conditions tested, overnight induction at 20°C in Turbo-broth (Turbo) media 
was best, in terms of the level of recombinant protein expression observed by SDS-PAGE. 
However, the solubility of the recombinant protein was still very poor, with most of the 
hTDP2 present as insoluble material in inclusion bodies. Similarly, pTHREE-E/hTDP2-
CAT101-362 and pTHREE-E/hTDP2-CAT111-362 were transformed into BL21(DE3) E. coli 
strains and the expression tested in small scale experiments (Figure 3.5C). hTDP2 
expression was the highest in Turbo-broth, for overnight induction at 20°C (Table 3.2), 
however the recombinant protein was again insoluble and accumulated in inclusion bodies. 
3.2.2 Purification and crystallisation of hTDP2-CATC161S 
During this period of troubleshooting, an expression construct encoding a mutated version 
of the catalytic domain (residues Met113 to Ile362) was kindly provided by Prof. Aidan 
Doherty (University of Sussex). The C161S mutation in this plasmid, denoted pET-
28a/hTDP2-CATC161S, corresponds to C273S in the full-length human protein and had 
previously been shown by Prof. Doherty’s group to improve the level of protein solubility, 
by removing a potentially reactive cysteine from the protein surface. This expression 
construct encodes an N-terminal His6-tag and a thrombin cleavage site (Figure 3.6). 
3.2.2.1 Expression and purification of hTDP2-CATC161S 
For initial small-scale expression trials (50ml), expression was tested at different 
temperatures (37°C and 20°C) and in different media (L-broth and Turbo broth). The 
supernatant was loaded onto batch gravity flow column for IMAC capture with TALON 
resin, and the eluted protein samples were analysed by SDS-PAGE (Figure 3.7). Based on 
this experiment, an optimal expression condition, comprising 3.5 hours induction at 30°C, 
with cells grown in Turbo broth was determined. The detailed purification protocol is 
described in Materials and Methods (2.2.6.3). In brief, hTDP2 protein was purified in three 
steps, first recovering TDP2 from the clarified supernatant by IMAC (TALON resin) 
followed by salt fractionation on a Heparin Sepharose 6 Fast Flow column (GE Healthcare) 
(Figure 3.8 A), followed by size exclusion chromatography (Figure 3.8 B). Peak fractions 
containing hTDP2 were pooled, concentrated to 7.3mg/ml, and stored at -80°C. 
3.2.2.2 Crystallisation of hTDP2-CATC161S 
Initial screens, in 96-well, sitting-drop vapour-diffusion format (MRC2 plates, Hampton 
Research, Aliso Viejo, CA USA) were set up using commercial crystallisation screens 
purchased from Hampton Research; these included JCSG+, Index, PEG/Ion and Salt-RX  
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Figure 3.5. Small scale expression trials for pTWO-E and pTHREE-E / hTDP2-CAT
101-
362 
and hTDP2-CAT
111-362
. Cell cultures were grown in L-broth, and grown at 20˚C 
overnight, after induction of protein expression. A. & B. Expression trials for pTWO-E 
constructs in E. coli strains BL21, and Rosetta2(DE3) pLysS, respectively. C. Expression 
trials for pTHREE-E constructs in E. coli strain BL21. The different experimental 
temperatures tested are as indicated at the top of each SDS-PAGE gel. An arrow in each 
case indicates the expected migration position of the recombinant protein. KEY: (Ø): 
pre-induction sample, (w): whole cell lysate, (s): supernatant, and (p): pellet. 
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Figure 3.6. Schematic representation of pET-28a/hTDP2-CAT
C161S
. The catalytic domain of 
hTDP2 (residues spanning from Met113 to Ile362) was cloned into the pET-28a expression 
vector containing an N-terminal His6-tag and a thrombin cleavage site. The lone cysteine at 
position 161 was mutated to serine in order to prevent putative intermolecular disulphide 
bond formation. 
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Figure 3.7. Small scale expression trials and IMAC pull-downs of hTDP2-CAT
C161S
 
expressed in E. coli strain B834(DE3). A. Initial experiments were carried with 
overnight growth, after induction of protein expression, at different temperatures and in 
different growth media. B. Optimised expression condition, with IMAC pull-down: 3.5-
hour induction at 30°C in Turbo broth. KEY: (L): lysate, (F/T): flow-through, (W): wash, 
and (El): elution. The MW of poly-Histidine tagged hTDP2-CAT161-406 is 28kDa. An 
arrow indicates the expected migration position of the recombinant protein.  
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Figure 3.8. Purification of hTDP2-CAT
C161S
. A. Following initial capture by IMAC 
(TALON resin), the recombinant protein was loaded on to a Heparin Sepharose 6FF 
column.  Bound material was eluted with the application of a linear salt gradient, from 
low to high NaCl concentration.  A representative SDS-PAGE gel for fractions collected 
during the elution gradient is shown. B. Fractions containing hTDP2-CATC161S (blue 
box) were identified, pooled and concentrated, then loaded onto a HiLoad 16/600 
Superdex 75pg size exclusion column. A representative SDS-PAGE gel for fractions 
collected during purification is shown. The expected migration position of the 
recombinant protein is marked by an arrow in each case. C. A representative 
chromatograph for the size exclusion chromatography purification step. 
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screens. Screens were checked regularly for the presence of crystal growth, and after a 
period of five days, small needle-shaped crystals were seen to emerge in several different 
conditions (G5, G6, A10 and A11 from Salt RX and condition B4 from Index screens) 
(Figure 3.9 and Table 3.3).  
Crystals obtained in the A10 SaltRx (Hampton Research), looked to be promising, so were 
mounted in a cryoloop, swiped through the mother liquor (2.2M NaCl, 0.1M bis-tris 
propane pH7.0) containing various cryoprotectants (20% ethylene glycol, or 30% glucose, 
or 40% sucrose) to protect the crystals, and then shot in-house on a MicroMax-007HF 
rotating anode source (Rigaku, Sevenoaks, UK). Diffraction was observed, but only to low 
(8-9Å) resolution. It was therefore necessary to try to optimise these initial crystallisation 
conditions. 
A grid-optimisation method, in a hanging-drop vapour-diffusion format using 24-well 
plates [VDX Plate with sealant (Hampton Research)] was used. Crystallisation buffers 
were kept at a constant concentration of 0.1M, but pH was varied by 0.5 unit increments 
between pH7.0 and pH8.5. As TDP2 is known to require magnesium for its catalytic 
activity, it was therefore thought that having this ion in the crystallisation buffer (as 
observed in G5 and G6 conditions of SaltRx and B4 of Index screens) might help to 
stabilise the protein and to promote crystallisation. Different concentrations of both NaCl 
and MgSO4 were screened in 200mM increments (1.8-2.8M for NaCl and 1-2M for 
MgSO4). 
From the grid-optimisations, it became apparent that using 0.1M bis-tris propane as a 
buffer at a pH of 7.0 generated larger crystals in the presence of high concentrations of 
NaCl (1.8M), albeit that these crystals were elongated in only one dimension.  
In a further attempt to improve crystal quality, several different magnesium salts (sulphate, 
acetate, chloride and formate) were screened in the presence of 0.1M bis-tris propane 
pH7.0 across different NaCl concentrations. The presence of 5mM magnesium acetate 
promoted crystal growth when the concentration of NaCl decreased to 0.45M.  
The condition 0.1M bis-tris propane pH7.0, 0.45M NaCl, 5mM Mg acetate provided 
reasonably large needle-shaped crystals. Again, these crystals were cryo-protected, and 
then shot in-house. The resulting diffraction was highly anisotropic, ranging from 2.5Å to  
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Conditions from SaltRx screen 
A10 2.2M NaCl, 0.1M bis-tris propane pH7.0 
A11 2.2M NaCl, 0.1M Tris pH8.5 
G5 1.8M MgSO4 , 0.1M bis-tris propane pH7.0 
G6 1.8M MgSO4, 0.1M Tris pH8.5 
Condition from Index screen 
 B4 0.3M Mg formate, 0.1M Tris pH8.5 
 
Table 3.3. Initial crystallisation ‘hits’ with commercial screens from Hampton Research. 
Sitting-drop vapour-diffusion format (MRC2 plates, Hampton Research). Screens were 
set up using the Phoenix liquid handling system. 
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Figure 3.9. Images of ‘hits’ from initial crystallisation screens with hTDP2-CAT
C161S
.
 
A. SaltRx condition A10: 2.2M NaCl, 0.1M bis-tris propane pH7.0. B. SaltRx 
condition G5: 1.8M MgSO4, 0.1M bis-tris propane pH7.0
.
 C. Index condition B4: 0.1M 
Tris pH8.5, 0.3M Mg formate. 
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3.8Å, depending on crystal orientation. The likely source of anisotropy in this case, was 
due to the morphology of the TDP2 crystals, which were long and thin.  
In order to improve the observed anisotropy, an additive screen from Hampton research 
was employed (Cat no: HR2-138). The additive screen is a library of small molecules and 
can alter sample-sample and sample-solvent interactions and can improve crystal 
formation. From this screen, it was found that the additive trimethylamine N-oxide 
(TMAO) appeared to improve crystal morphology. Therefore, an extended optimisation 
screen, which varied the concentration of TMAO in 0.5% v/v increments (ranging from 0 
to 2.5%) was undertaken.  
Crystals grown in 0.1M bis-tris propane pH7.0, 0.45M NaCl, 5mM Mg acetate + 1.5 % 
v/v TMAO were shorter in length and appeared much thicker (Figure 3.10) (Materials and 
Methods 2.4.1.1). These crystals were harvested, then plunge-frozen in liquid N2 in the 
presence of 20% v/v ethylene glycol, 40% w/v sucrose or 30% v/v glycerol to test the 
effectiveness of different cryoprotectants. An isotropic diffraction dataset to 3.1Å 
resolution was collected on beamline I04 at the Diamond Light Source (DLS, Didcot, UK) 
(Table 3.4). 
3.2.2.3 Expression, purification and crystallisation of Selenomethionine labelled 
hTDP2-CATC161S 
To obtain phase information, we decided to use the single-wavelength anomalous 
dispersion method (SAD) with Selenomethionine-derivatised (SeMet) recombinant 
protein. As the expression construct contained 10 methionine residues, we surmised that 
sufficient phasing power would be generated with this methodology. At this time point, 
there were no available structures for TDP2 deposited in the Protein Data Bank (PDB), 
therefore molecular replacement could not be used to solve the phase problem. 
The pET-28a/hTDP2-CATC161S expression construct was transformed into an auxotrophic 
strain of E.coli, B834(DE3) – which is dependant on an external source of methionine for 
growth. Transformed E.coli cells were first selected on minimal media-agar plates 
containing methionine, supplemented with 50µg/ml kanamycin. Small-scale ‘starter 
cultures’ were grown in LB media. Large-scale expression cultures were then grown in 
Selenomethionine containing media using SelenoMet media from Molecular Dimensions 
(Materials and Methods 2.2.6.4.1). Expression and purification protocols for the  
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Figure 3.10. Image of optimised hTDP2-CAT
C161S 
crystals. Hanging drop vapour-
diffusion format. Crystallisation condition: 100mM bis-tris propane pH7, 0.45M NaCl, 
0.05M MgAc2, 1.5% v/v trimethylamine N-oxide. Crystals appeared after 5 days of 
incubation at 20ºC. Crystals were frozen in the presence of various cryoprotectants (20% 
ethylene glycol, or 30% glucose, or 40% sucrose) of which hTDP2 crystal with 40% 
sucrose diffracted to 3.1Å. 
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Space group P3 
Unit cell dimensions 91.5Å; 91.5Å; 118.0Å   
Internal angles 90°; 90°; 120° 
 
Table 3.4. Space group and cell dimensions of hTDP2-CAT
C161S
 crystals. Crystallisation 
condition: 100mM bis-tris propane pH7, 0.45M NaCl, 0.05M MgAc2, 1.5% v/v 
trimethylamine N-oxide. Crystals appeared after 5 days of incubation at 20ºC. Crystals 
were snap-frozen in liquid N2, after being cryo-protected in in the presence of 
crystallisation buffer supplemented with 40% v/v sucrose. Diffraction data were 
collected on beamline I04, at DLS. 
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Selenomethionine derivatised hTDP2-CATC161S protein are identical to those for the 
unlabelled protein and can be found in Materials and Methods (Section 2.2.6.4)  
Crystallisation conditions for the derivatised protein were also similar: crystals were grown 
in a hanging drop vapour-diffusion format, at a temperature of 20°C. 1 Pl of SeMet-labelled 
protein was combined with 1 Pl of crystallisation buffer (100mM Bis-Tris propane pH7.0, 
0.5M NaCl, 0.05M MgAc2, 1.5% v/v trimethylamine N-oxide) (Materials and Methods 
2.4.1.3). Small rod-shaped crystals appeared after about 5 days (Figure 3.11) and were 
snap-frozen in liquid N2, after being cryo-protected in crystallisation buffer supplemented 
with 30% v/v glycerol. 
Diffraction data were collected on beamline I04, at DLS. However, only a poor, low 
resolution dataset was collected which precluded phasing by the SAD method. 
However, at this time point the structure of the catalytic domain of murine TDP2 (mTDP2-
CAT) was published (Schellenberg et al. 2012). By using the atomic coordinates of the 
murine protein in molecular replacement, it became possible to solve the structure of the 
catalytic domain of human TDP2 (Figure 3.12). 
3.3 Discussion 
The aim of this set of experiments was to express and purify hTDP2 in large enough 
quantities to facilitate crystallography, and ultimately enable structure-based drug design 
efforts, in order to produce inhibitors of TDP2 enzymatic function.  
Full length TDP2 is composed of two domains, connected by an approximately forty amino 
acid long linker region. Because this connecting loop was likely to have a high degree of 
flexibility, which might cause problems during crystallization, constructs expressing just 
the catalytic domain of hTDP2 were also created. 
In expression trials with full-length hTDP2, IMAC pull-downs showed that some soluble 
protein was produced, but that this protein always co-purified with the bacterial chaperone 
GroEL, suggesting misfolding and aggregation. Similarly, in expression trials with the 
catalytic domain, all the expression conditions tested resulted in accumulation of TDP2 in 
the insoluble fraction. It is possible to purify proteins from the insoluble fraction / inclusion 
bodies in denaturing conditions. However, obtaining active and correctly folded protein 
from inclusion bodies can be an arduous task, although it does have some distinct  
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Figure 3.11. Image of Selenomethionine-labelled hTDP2-CAT
C161S 
crystals. 
Crystallisation condition: 100mM bis-tris propane pH7.0, 0.45M NaCl, 0.05M MgAc2, 
1.5% v/v trimethylamine N-oxide. Crystals were snap-frozen in liquid N2, after being 
cryo-protected in the presence of crystallisation buffer supplemented with 30% v/v 
glycerol. 
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Figure 3.12. Carton representation of the catalytic domain of hTDP2. The structure 
was solved by molecular replacement using the catalytic domain of the murine TDP2 
as a search model (PDB accession code: 4GYZ, Schellenberg et al. 2012). 
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advantages, as the protein is already in a semi-pure state, highly concentrated and generally 
protected from the action of bacterial proteases (Palmer and Wingfield 2004). 
However, at this time point, an expression construct was kindly provided by Prof. Aiden 
Doherty. They had determined that a single point mutation of Cysteine 161 to Serine 
(C161S), found on the surface of the hTDP2 catalytic domain, enabled correct folding of 
the protein, which could now be readily purified from the soluble fraction. After initial 
expression trials in E. coli, it was possible to express a substantial amount of soluble protein 
which could be purified to high degree. As an alternative strategy, in overcoming the 
problems of reactive surface cysteines, one can express recombinant protein in a more 
reductive environment, i.e. employing strains deficient in thioredoxin reductase (Rosano 
and Ceccarelli 2014), or as in this case, single point mutations can be introduced in order 
to change the problematic surface residues.  
Preliminary crystallisation trials resulted in crystals that only diffracted to low resolution. 
Therefore secondary optimisation screens were used to try and improve the crystals. 
Protein crystallisation depends on many factors (e.g. buffer and salt conditions, 
temperature), in the case of hTDP2, changing the pH of the buffer to 7.0 and including the 
magnesium co-factor Mg2+ resulted in a considerable improvement in the resolution of 
diffraction; however, this was highly anisotropic.  
Several factors can contribute to anisotropy (Sawaya 2014). The crystal itself is a field of 
anisotropicity, movement of whole molecules as rigid bodies, and vibration along torsion 
angles can also be the source of anisotropy. For hTDP2, the major factor was simply the 
physical dimensions of crystals (elongated and thin crystals, 150µm x 15µm).  
Additive screens were used to try to improve crystal quality. One additive, trimethylamine 
N-oxide, resulted in improved, isotropic diffraction of hTDP2 crystals to 3.1Å resolution. 
However, several crystals still had to been screened in order to obtain this dataset. 
Once diffraction data was obtained, a method for solving the phase problem was required. 
We initially decided to use the single-wavelength anomalous dispersion method (SAD), 
using Selenomethionine derivatised protein. Whilst crystals of this protein were obtained, 
they did not diffract to a sufficient resolution to allow the structure to be solved. However, 
molecular replacement became a viable option when the structure of the catalytic domain 
of the murine TDP2 was published and made available (Schellenberg et al. 2012).  
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CHAPTER FOUR 
 
Small molecule inhibitors  
of TDP2  
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4.1 Introduction 
Selective inhibitors of hTDP2 were identified and described, as part of a collaboration 
between the Caldecott group and the Paterson Institute for Cancer Research (Raoof et al. 
2013). These compounds were identified in a high-throughput screen using a chromogenic 
enzymatic assay (Thomson et al. 2013). 
The report described a series of toxoflavin inhibitors, plus a single deazaflavin, which had 
a sub-micromolar inhibitory effect on the enzymatic action of hTDP2. However, further 
investigations by this team lead to the discovery of redox liability and in vitro drug 
metabolism for the toxoflavin series, making them unsuitable for progression. However, 
despite being a singleton hit, the deazaflavin class did not have the same undesirable 
properties as the toxoflavins. It was therefore selected for progression, and generated a 
series of inhibitors, which provided some limited structure-activity relationship (SAR) 
data. 
Several TDP2 inhibitors were provided by the Cancer Research UK Drug Discovery Unit 
at the Paterson Institute for Cancer Research (University of Manchester, UK). These 
compounds were first tested in a range of additional assays before co-crystallisation 
attempts were made with recombinant hTDP2. 
4.2 Results 
4.2.1 Thermal denaturation assays to investigate compound-
binding 
A thermal denaturation assay, or ThermoFluor assay, is a useful tool to investigate both 
protein folding and stability. The protein in question is denatured by increasing 
temperature in the presence of an environmentally sensitive fluorescent molecule (in our 
case: SYPRO Orange, Sigma-Aldrich). During denaturation, hydrophobic amino acid 
residues normally found in the core of the protein are exposed to solvent. SYPRO Orange 
is able to bind to these exposed hydrophobic residues, leading to an increase of 
fluorescence, which can be measured. The temperature midpoint (Tm) of the folded-to-
unfolded transition for the protein can also be monitored in the absence/presence of a 
compound that may bind to the protein in question. Binding of a compound (to the active 
site of the protein, if an enzyme) can affect the measured Tm point, typically resulting in a 
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positive shift to a higher temperature (although negative shifts, i.e. destabilisation of the 
protein are often seen). Thermal denaturation assays can therefore be used as a high 
throughput method to test if a particular compound interacts / binds to a protein (Lo et al. 
2004, Senisterra et al. 2012). 
Firstly, the suitability of hTDP2-CATC161S for this particular type of assay had to be 
determined; that is, confirming if it unfolded with a preferred sigmoidal shaped 
denaturation profile. Secondly, as compounds often have limited aqueous solubility and 
require organic solvent to remain in solution [3% v/v dimethyl sulfoxide (DMSO) is 
typically sufficient], the tolerance of the protein to increasing concentrations of DMSO 
was also tested. Thirdly, and finally, ten putative TDP2 inhibitor compounds were tested 
as a dilution series with the optimised assay. The assay is described in detail in Materials 
and Methods (section 2.6.1).  
The suitability of the recombinant hTDP2-CATC161S protein was tested in two experimental 
buffers: HEPES pH7.0 and bis-tris propane pH7.5. Bis-tris propane was selected as it 
appeared in several crystallisation conditions that produced TDP2 crystals. From these 
initial experiments, a Tm of 47.6 qC was calculated for the protein in HEPES buffer. The 
Tm in bis-tris propane buffer was slightly higher, at 49.7°C (Figure 4.1). The HEPES 
buffer was selected for ongoing experiments, as it was felt that the lower Tm would be 
beneficial for screening, as compounds producing only moderate shifts in Tm might be 
overlooked in experiments with bis-tris propane; i.e. maximising the potential 'Tm. 
To address the impact of DMSO on the assay, the stability of hTDP2 in a dilution series of 
DMSO was also examined. hTDP2 was found to be tolerant to concentrations of up to 3% 
v/v DMSO, as judged by this assay, as the observed Tm (47.6qC) did not change in the 
presence of DMSO (Figure 4.2). 
Finally, deazaflavin inhibitors of hTDP2 were also tested in this assay format. Depending 
on the solubility of each compound, a dilution series ranging from ~ 50µM to ~ 300µM 
was used. From the 10 compounds supplied by the Paterson Group, two candidates 
produced a significant positive shift in Tm (Table 4.1). Compound C13984 had a 'Tm of 
+2.8°C at a concentration of 333µM, whereas C14005 had a 'Tm of +3.5°C at 300µM 
(Figure 4.3). Interestingly, one compound (C14313) clearly destabilised the protein, 
producing a 'Tm of -6.5°C. 
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Figure 4.1. Thermal denaturation assay of hTDP2-CAT
C161S
 in different buffer systems. 
First order derivatives of the observed melting curves are shown (rate of change of 
fluorescence intensity). Temperature midpoints for the transition from folded to unfolded 
states are determined by the indicated peak minima (vertical line) in each case. Protein 
concentration: 1.7µM. Reaction conditions: HEPES pH7.0 (or bis-tris propane pH7.5), 
300mM NaCl, 0.5mM TCEP. 
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Figure 4.2. Thermal denaturation assay of hTDP2-CAT
C161S
 in various concentrations 
of DMSO. First order derivatives of the observed melting curves are shown (rate of 
change of fluorescence intensity). Temperature midpoints for the transition from folded 
to unfolded states are determined by the indicated peak minima (vertical line) in each 
case. Protein concentration: 1.7µM. Reaction conditions: HEPES pH7.0, 300mM NaCl, 
0.5mM TCEP and 0 or 3% v/v DMSO. 
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Table 4.1. Summary of results for thermal denaturation assays (hTDP2- CAT
C161S
 in the 
presence of different deazaflavin compounds). Compounds were provided by the Cancer 
Research UK Drug Discovery Unit, Patterson Institute for Cancer Research (University 
of Manchester). Stock solutions for each compound were prepared in 100% v/v DMSO 
due to their limited aqueous solubility. Thermal denaturation assays were performed at 
the indicated concentration of compound in the presence of 1.7µM hTDP2-CAT
C161S
. 
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Figure 4.3. Thermal denaturation assay of hTDP2-CAT
C161S
 in the presence of 
compound C14005. First order derivatives of the observed melting curves are shown 
(rate of change of fluorescence intensity). Temperature midpoints for the transition from 
folded to unfolded states are determined by the indicated peak minima (vertical line) in 
each case. Protein concentration: 1.7µM. Final compound concentration: 300µM. 
Reaction conditions: HEPES pH7.0, 300mM NaCl, 0.5mM TCEP and 3% v/v DMSO. 
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As C14005 – a phenylmethanesulfonamide derivative – produced the largest positive shift 
in Tm, it was selected for further biochemical experiments. 
4.2.2 TDP2 enzymatic assay in the presence of compound C14005 
The catalytic activity of recombinant hTDP2-CATC161S enzyme was measured in the 
absence and presence of C14005. The DNA substrates employed in this gel-based assay 
were [α-32P]-labelled oligonucleotide duplexes containing a 5' overhang (4 nt) harbouring 
a 5'-phosphotyrosine moiety (Figure 4.4A). The experimental approach was to (a) test the 
enzyme activity of the recombinant enzyme, (b) test the impact of 3% v/v DMSO on 
activity, and (c) test activity in the presence of C14005. As mentioned in the previous 
section, the compounds require the presence of an organic solvent (in our case DMSO) in 
order to stay in solution. The essay is described in detail in Materials and Methods (section 
2.3.2). 
hTDP2-CATC161S at two different concentrations (6ng and 12ng/reaction) was tested with 
the labelled substrate withdrawing aliquots from the enzymatic reaction at 15, 30 and 60 
minute time points. Under these experimental conditions, the reaction was completed 
within 15 min. The protein concentration was therefore reduced to 10nM and the time 
course was reduced to 15 min in order to observe comparable changes in activity (data not 
shown). 
The impact of DMSO on the assay (Figure 4.4B) was also investigated. Experiments 
revealed that addition of 3% v/v DMSO had no observable effect on the activity of the 
enzyme; therefore, the effect of C14005 on the enzymatic activity of hTDP2-CATC161S was 
studied.  
Preliminary experiments failed to reveal any inhibitory effect of C14005 on hTDP2 activity 
(data not shown). It was thought that some components of the reaction buffer might be 
interfering with compound binding, so additional experiments were designed to test this 
hypothesis. Previous activity assays, undertaken in the laboratory, using cell extracts 
included a competitor oligo in the reaction mix, to order to prevent degradation of [α-32P]-
labelled substrate molecules by cellular nuclease. Bovine serum albumin (BSA) was also 
included in the assay buffer, to help stabilise TDP2. The presence of BSA and the 
competitor oligo abrogated the inhibitory effect of C14005 (Figure 4.5). After removing  
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Figure 4.4. Gel-based enzyme activity assay for hTDP2-CAT
C161S 
in the presence 3% 
v/v DMSO. A. Schematic representation of [α-
32
P]-labelled oligonucleotide duplexes 
with a 5' overhang (4 nt) harbouring a 5'-phosphotyrosine moiety. B. Gel-based assay to 
test the impact of 3% v/v DMSO on enzyme activity. Bands corresponding to the 
substrate 5’-Y-oligo and the product 5’-P-oligo were resolved by denaturing sequencing 
gel. 
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Figure 4.5. Quantification of gel-based activity assays for hTDP2-CAT
C161S 
in the 
presence of compound C14005, testing different experimental conditions. The essay was 
conducted in the presence of 1nM hTDP2-CAT
161-406
 and 50nM inhibitory compound 
(C14005) and at 3% v/v DMSO. KEY: BSA: bovine serum albumin, Comp: competitor 
DNA oligo. Conditions where BSA and competitor oligo were excluded from the 
reaction, thus allowing an inhibitory effect of compound C14005 to be seen, are marked 
with dashed lines to aid visualisation. 
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these two reagents from the experiment, a significant inhibitory effect of C14005 on 
hTDP2 could be observed (Figure 4.6). 
4.2.3 Co-crystallization trials of hTDP2-CATC161S and C14005 
As both the thermal denaturation and activity assays indicated that C14005 bound to and 
inhibited hTDP2, co-crystallisation trials were undertaken (Materials and Methods 
2.4.1.2). Crystals of hTDP2C161S in complex with C14005, were obtained in the following 
condition: 100mM bis-tris propane pH7, 0.45M NaCl, 0.05MgAc2, 1.5% v/v 
trimethylamine N-oxide (TMAO), supplemented with 3% v/v DMSO to improve 
compound solubility. However, the low solubility of C14005 did not allow a molar ratio 
of protein: compound greater than 1:1. Greater ratios would have required a DMSO 
concentration of >3%. Although DMSO is often used to aid protein crystallisation, at 
higher concentrations it can promote protein precipitation and denaturation (Arakawa et 
al. 2007). 
Crystals typically grew after five days at 20ºC (Figure 4.7). They were harvested, cryo-
protected by successive swipes through buffer containing increasing concentrations of 
sucrose (final 40% v/v), and then plunge-frozen in liquid N2 before being stored. 
Diffraction data was collected on beamline I04, DLS. Unfortunately, these crystals only 
diffracted to low resolution (8-9Å). 
In order to obtain a higher resolution dataset, a compound with greater solubility was 
required, in order to improve the protein: compound molar ratio to greater than 1:2, and to 
keep the DMSO concentration relatively low (≤ 3% v/v). Consequently, through 
discussions with the Paterson Institute, a more soluble tetrazole compound (C14297) 
(Figure 4.8) with a similar sub-micromolar disassociation constant was provided. 
4.2.4 Crystallization of hTDP2 in complex with compound C14297 
Thermal denaturation assay of hTDP2-CATC161S in the presence of C14297 showed a 
robust positive shift in Tm (ΔTm=3°C) (Figure 4.9). Consequently, co-crystallisation trials 
with hTDP2 in complex with C14297 were set up, at an increased protein:compound molar 
ratio of 1 to 2.7 (due to the improved solubility of the tetrazole compound) (Materials and 
Methods 2.4.1.2). Crystals were obtained with the SaltRx HT screen (Hampton Research) 
in MRC2 sitting-drop plates in condition C9 (1.2M DL Malic acid pH 7.0, 0.1M bis-tris 
propane pH7.0) after 5 days of incubation at 20ºC. These crystals diffracted fairly poorly  
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Figure 4.6. Gel-based enzyme activity assay in the presence of compound C14005. A. 
Reactions were conducted in the presence of 1nM hTDP2-CAT
161-406
, and 10 and 50nM 
inhibitory compound (C14005), and then resolved on denaturing sequencing gel. B. 
Quantification of the inhibitory effect of C14005 on hTDP2 enzyme activity. Data are 
the mean of three independent experiments, with error bars representing one standard 
deviation.  
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Figure 4.7. Representative image of hTDP2-CAT
C161S
 / C14005 co-crystals.  
Crystallisation condition: 100mM bis-tris propane pH7.0, 0.45M NaCl, 0.05MgAc2, 
1.5% v/v trimethylamine N-oxide (TMAO), 3% v/v DMSO.  
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Figure 4.8. Chemical drawing of C14297. The compound is a tetrazole derivative (R1 
substituent) of the deazaflavin series with an EC50 value in the submicromolar range 
(50nM). Numbers for the three rings of the deazaflavin core are also shown. 
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Figure 4.9. Thermal denaturation assay of hTDP2-CAT
C161S
 in the presence of 
compound C14297. First order derivatives of the observed melting curves are shown 
(rate of change of fluorescence intensity). Temperature midpoints for the transition from 
folded to unfolded states are determined by the indicated peak minima (vertical line) in 
each case. Protein concentration: 1.7µM. Final compound concentration: 300µM. 
Reaction conditions: HEPES pH7.0, 300mM NaCl, 0.5mM TCEP and 3% v/v DMSO. 
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and anisotropically, but by screening several crystals it was possible to collect an isotropic 
dataset on beamline I04, DLS to a resolution of 3.1Å. No further optimisation of 
crystallisation conditions was undertaken.  
4.2.5 Molecular Replacement 
At this time, the structure of the catalytic domain from murine TDP2 (mTDP2-CAT) was 
published (PDB: 4GYZ, (Schellenberg et al. 2012)) at a resolution of 2.4Å. It was therefore 
possible to solve by molecular replacement the structure of both the apo- and liganded 
forms of hTDP2C161S, using the atomic coordinates of the murine protein. Molecular 
replacement used PHASER (CCP4 software suite, (Winn et al. 2011)). The initial 
molecular replacement model was then improved by iterative rounds of rebuilding and 
refinement, with COOT (Emsley et al. 2010) and REFMAC5 (Vagin et al. 2004) to obtain 
the final refined model. 
The catalytic domain of human TDP2 has the same fold as other phosphodiesterases of the 
Mg-dependent phosphodiesterase class (e.g. AP endonuclease). It is comprised of two 
central β-sheets surrounded by eight alpha helices (Figure 4.10A).  
Electron density maps clearly indicated the position of the bound compound. Surprisingly, 
it did not bind directly to the enzyme’s active site (Figure 4.11); rather it made contact with 
the large hydrophobic platform formed by the ‘M7-loop’ of the enzyme (Figure 4.12A). 
The M7- loop was originally described by Schellenberg et al. (2012). It consists of two 
highly conserved short amino acid motifs ‘TWDT’ and ‘RFDR’ that are separated by a 
poorly conserved 14 amino acid linker (Figure 4.12B), and serves to generate a platform 
for interaction with an incoming DNA substrate (Schellenberg et al. 2012) (Figure 4.11B). 
As the resolution of the diffraction data was relatively low, only a few conclusions could 
be drawn from the modelled structure. In particular, the Nε of the Arg266 side chain 
appeared to be poised to form a hydrogen bond to the carbonyl group located on ring 1 of 
the deazaflavin ring system. Several amino acid residues from the divergent region of the 
M7-loop make stacking interactions with the core of the compound. (Figure 4.13). Arg231, 
which as part of the M5 ‘cap’ motif, helps bind an incoming DNA substrate by interacting 
with the sugar-phosphate backbone, also appears to play a role in compound binding and 
orientation (Schellenberg et al. 2012). 
At low resolution, the placing of water molecules becomes difficult and problematic; as 
only electron density for highly coordinated water molecules is generally seen. The  
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Figure 4.10. Cartoon representation for the structure of hTDP2-CAT
161-406
 in complex 
with compound C14297. A. Schematic representation of the structure of the catalytic 
domain of hTDP2 in complex with the compound highlighting the M7-loop. The 
positions of the conserved ‘TWDT’ and ‘RFDR’ amino acid sequence motifs, which 
flank the M7-loop, are respectively indicated by the cyan and orange-coloured regions. 
Residues of the divergent M7-loop, are additionally highlighted in yellow, and by the 
dotted line red coloured box. B. Multiple amino acid sequence alignment for the M7-
loop across several different species indicates the divergent region. 
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Figure 4.11. Molecular surface representation of hTDP2-CATC161S highlighting the 
position of C14297 relative to the enzyme’s active site. The active site and 
hydrophobic platform are coloured red and yellow, respectively.  For orientation, the 
sidechain of Arg231 is additionally highlighted in blue. 
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Figure 4.12. C14297 binds to the ‘hydrophobic platform’ of hTDP2. A. Molecular 
surface representation for hTDP2-CAT
C161S
 in complex with C14297. The hydrophobic 
platform, formed by residues of the M7-loop, making several van der Waals interactions 
with the inhibitory compound. Regions of the M7-loop highlighted similar to Figure 
4.10. Arg231 -part of the DNA binding motif ‘cap’- is highlighted in blue. B. Figure 
depicts the positioning of the substrate DNA by the DNA binding motifs.  
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Figure 4.13. Schematic figure, indicating key amino acids that are involved in C14297 
binding. Compound binding is facilitated via hydrogen bond formation and stacking 
interactions. The DNA binding platform formed by the M7-loop is highlighted by orange 
(TWDT motif), yellow (divergent region), and cyan (RFDR motif). 
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position of water molecules can often provide valuable information for rational drug 
design, by ‘mapping’ potential hydrogen bond donors/acceptors, and indicating a potential 
‘path’ for expansion of a compound. Ordered water molecules can often be replaced by 
water mimicking substituents, through chemical expansion of the inhibitory compound, to 
increase both its binding affinity and specificity (Lounnas et al. 2013). 
As crystals of hTDP2-CATC161S typically diffracted poorly and anisotropically, we sought 
a better system for our drug discovery efforts. As the structure of the catalytic domain from 
mouse TDP2 was solved at high resolution, it was a logical step to employ this protein in 
structural studies. 
4.2.6 Thermal denaturation and activity assays with mTDP2-CAT 
4.2.6.1 Thermal denaturation assay with C14297 
Expression and purification of mTDP2-CAT is described in section 2.2.6.5. The mTDP2-
CAT expression construct contains an N-terminal polyhistidine-tagged SUMO moiety that 
is cleavable by Sentrin-specific protease 1 (SENP1) (Figure 4.14). Following purification 
(Figure 4.15 and 4.16), mTDP2-CAT was used in thermal denaturation assays in order to 
verify binding of C14297 to the enzyme (Figure 4.17) (Material and Methods 2.6.1). 
However, there was no observable shift in melting temperature in these experiments, 
suggesting that the compound did not bind the murine form of the enzyme. 
4.2.6.2 Enzyme activity assays with C14297 
To verify that C14297 did not bind or inhibit the murine form of TDP2, it was taken 
forward into the gel-based assay (Materials and Methods 2.3.2). There was a significant 
difference in the inhibition profiles of the two enzymes; the compound being far more 
active on the human protein that on the mouse (Figure 4.18). It is important to note that the 
enzyme activity of the recombinant mTDP2-CAT was approximately 3-fold less than that 
of the hTDP2-CATC161S. In order to obtain comparable data of the inhibition of both 
enzymes by the compound, the experiments were conducted in the presence of 1nM 
hTDP2-CATC161S and 3nM mTDP2-CAT. Together these experiments confirmed that 
C14297 poorly bound and inhibited the murine protein. 
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Figure 4.14. Schematic representation of the murine TDP2-CAT expression construct. 
The construct encodes the catalytic domain of the catalytic domain (amino acid 
boundaries Leu118 and Leu372) and an N-terminal His-SUMO solubility tag, in order 
to improve yields of soluble recombinant protein. The tag can be removed by overnight 
digestion by SENP1 protease. 
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Figure 4.15. Representative images of SDS-PAGE gels for key steps in the purification 
of murine TDP2 (mTDP2-CAT). A. Clarified supernatant (S/N) was loaded onto 
TALON resin. The eluent was subjected to buffer exchange (b. change) before it was 
digested with SENP1 overnight. B. The overnight digest was loaded onto Heparin 
column and eluted with increasing NaCl. C. Eluent from Heparin column was further 
purified by gel filtration column. Samples were run on Novex 4-12% Tris-Glycine 
Protein Gels and then stained with InstantBlue Protein Stain. KEY: (S/N): supernatant, 
(F/T): flow-through, (W1/W2): wash, (b. change): buffer change, (o/n digest): overnight 
digest. An arrow indicates the expected size of the recombinant protein and the 
removed His-SUMO-tag. MW of mTDP2-CAT is 28.8 kDa. 
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Figure 4.17. Thermal denaturation assay of the catalytic domain of murine TDP2 in the 
presence of compound C14297. First order derivatives of the observed melting curves 
are shown (rate of change of fluorescence intensity). Temperature midpoints for the 
transition from folded to unfolded states are determined by the indicated peak minima 
(vertical line) in each case. Protein concentration: 1.7µM. Final compound 
concentration: 300µM. Reaction conditions: HEPES pH7.0, 300mM NaCl, 0.5mM 
TCEP and 3% v/v DMSO. 
  
150 
 
 
 
Figure 4.18. Activity assays comparing the inhibitory effect of compound C14297 on 
hTDP2-CAT and mTDP2-CAT. A. Reactions were conducted in the presence of 1nM 
hTDP2-CAT
161-406
 and 3nM mTDP2-CAT at 3% v/v DMSO (mTDP2-CAT was 
approximately 3 fold less active than hTDP2-CATC161S). To compare the inhibitory effect 
of C14297 on enzyme activity, human and murine TDP2 were incubated in the presence 
of 50nM and 150nM inhibitory compound, respectively, and then resolved on denaturing 
sequencing gel. B. Quantification of the inhibitory effect of C14297 on hTDP2 and 
mTDP2. Data are the mean of three independent experiments, with error bars 
representing one standard deviation. 
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4.2.7 Structure comparisons of the catalytic domains of human and 
mouse TDP2  
To try to explain the observed differences in inhibition profiles, we compared the structure 
of the catalytic domain of mTDP2 (Schellenberg et al. 2012) to hTDP2 (Figure 4.19). 
hTDP2-Cys311 is replaced by a tyrosine residue in the mouse protein (mTDP2-Tyr321); 
through model comparisons it is evident that Tyr321 is likely to occlude compound binding 
to mTDP2. Moreover, this residue is located within the divergent region of the M7-loop 
(Figure 4.10B) and its identity is not conserved across species. Furthermore, other non-
conserved residues (including those of the M7-loop) are critical for a number of protein-
compound interactions (Figure 4.13, Figure 4.19). Three other amino acid substitutions 
were thought to play significant roles in abrogating compound binding. 1) Leu313 forms 
an integral part of the ‘hydrophobic platform’ and its alteration to histidine in mouse is 
likely to disrupt compound binding. 2) Gly232, which is changed to a glutamate in the 
mouse, may produce steric clashes with the tetrazole ring of the compound. 3) Gln278, 
which is altered to arginine in the mouse, will affect the hydrogen-bonding potential for 
any bound compound. For more a detailed understanding of the interaction between 
hTDP2 and compound C14297, crystals that diffracted isotropically to higher resolution 
were required. As the murine protein seemed to provide such a system, it was hypothesised 
that by mutation of each of the amino acids described above, back to their human 
counterparts, compound binding might be restored. This work is described in the following 
Chapter.  
4.3 Discussion 
Our primary goal was to obtain structural information about the catalytic domain of human 
TDP2 in order to assist a structure-based drug design approach, for the development of 
small-molecule inhibitors of TDP2. A series of deazaflavin compounds were provided by 
the Cancer Research UK Drug Discovery Unit at the Patterson Institute for Cancer 
Research (University of Manchester). In order to find suitable candidates for structural 
studies, the compounds first were subjected to binding assays. 
 
The thermal denaturation assay has become a commonly employed technique, not only for 
optimising buffer conditions to promote protein stability, but also for screening compounds 
for binding (Lo et al. 2004, Senisterra et al. 2012). By use of this assay format, it was  
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Figure 4.19. Molecular cartoon representation for hTDP2-CAT
C161S
 aligned with 
mTDP2. Carbon atoms of hTDP2-CAT
C161S
 and mTDP2 are coloured in green and blue, 
respectively.  The four amino acids mutated to create m2hTDP2-CAT are shown in stick 
representation. C14297 is also show in stick representation (carbon atoms coloured in 
coral), to highlight the position of bound compound, and its relation to the mutated amino 
acids. 
  
153 
 
possible to show that several deazaflavin compounds bound to the catalytic domain of 
hTDP2, producing a positive shift in temperature midpoint (Tm). In particular, compound 
C14005, a phenylmethanesulfonamide derivative of the deazaflavin series, produced the 
largest increment in melting temperature (3.5 °C). 
 
As C14005 clearly bound and stabilised hTDP2, it was taken forward into enzyme activity 
assays, to examine any inhibitory affect. The assay used is a modified form of that reported 
by Ledesma et al., who determined that TDP2 is a 5'-tyrosyl DNA phosphodiesterase 
(Cortes Ledesma et al. 2009). Whilst that assay was performed using cell extracts, in the 
modified format, the activity of recombinant protein is tested. Initially, there was no 
observable inhibition of C14005 on the enzyme activity of human TDP2. However, by 
removing competitor oligo and bovine serum albumin (BSA) from the reaction mix, it was 
possible to restore and monitor the inhibitory effect of the compound. Competitor oligo 
was originally included in order to prevent degradation of [α-32P]-labelled substrate 
molecules by contaminating nucleases, whereas BSA stabilized TDP2 activity in cell 
lysates. 
These results suggest that C14005 is likely to be a weakly binding inhibitor of TDP2; the 
presence of competitor oligonucleotide at high concentration (400µM) prevented 
compound binding to hTDP2, presumably by preventing access to its binding site by direct 
competition. The presence of BSA has a similar effect, again preventing compound from 
binding to TDP2, presumably by sequestering the compound due to non-specific binding 
and/or aggregation effects. However, as dissociation constants have not been determined 
for each compound/protein interaction, this hypothesis requires confirmation. Future 
experimental work should therefore ideally include determination of binding constants for 
each compound, using a suitable technique such as iso-thermal titration calorimetry (ITC). 
 
Nevertheless, in the modified assay, C14005 clearly inhibited the enzymatic activity of 
recombinant hTDP2. So, in order to determine the molecular parameters for how (and 
where) the compound binds the protein, the complex was taken into crystallisation trials. 
However, the poor aqueous solubility of C14005 hindered this approach. However, a new 
opportunity presented itself when an additional compound (C14297) was provided that had 
improved solubility characteristics. Crystals were obtained for this compound in complex 
with hTDP2-CATC161S and diffraction data collected. It was possible to obtain phases by 
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molecular replacement, using the atomic coordinates of the catalytic domain of murine 
TDP2 as a search model. The resultant electron density maps clearly indicated the position 
and binding mode of C14297. Perhaps surprisingly, the compound did not bind directly to 
the active site, rather it made a series of van der Waals contacts with the so-called 
‘hydrophobic platform’, formed by the M7-loop first described by Schellenberg et al., 
(Schellenberg et al. 2012) and providing an interaction surface for the incoming DNA 
substrate. However, as crystals of hTDP2-CATC161S typically diffracted anisotropically 
and to low resolution, and alternative strategy was sought. It was initially thought that the 
murine version of the enzyme (mTDP2-CAT) might provide a viable alternative. However, 
thermal denaturation and gel-based activity assays demonstrated that the compound did 
not demonstrably bind, or inhibit mTDP2 to the same or similar extent as it did with 
hTDP2. 
Structural comparisons of the catalytic domains of mTDP2 and hTDP2 show that there are 
certain amino acid changes, in close proximity to the compound binding site that may 
explain the lack of an inhibitory effect. In order to substantiate the hypothesis that these 
particular amino acid changes (or at least some of them) inhibited compound binding, a 
‘humanised’ version of the murine catalytic domain was created, in which the residues 
were mutated ‘back’ to their human counterparts; i.e. E242G, Q278R, Y321C and H323L. 
It was anticipated that this ‘humanised’ construct (called m2hTDP2-CAT, ‘mouse-to-
human’) would provide co-crystal structures at higher resolution, and without anisotropic 
diffraction. This experimental work is described in the following chapter.  
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CHAPTER FIVE 
 
Structures of ‘humanised’ murine 
TDP2 in complex with small 
molecule inhibitors 
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5.1 Introduction 
In the previous chapter, the structure of the catalytic domain of human TDP2 in complex 
with a small molecular inhibitor, provided preliminary information about the binding mode 
of the deazaflavin series. However, the resolution of diffraction data resulting from 
hTDP2-CATC161S crystals was limited and was typically highly anisotropic. Therefore, in 
order to obtain higher resolution structures, a protein ‘surrogate’ of human TDP2 was 
developed: m2hTDP2-CAT. In this expression construct, four amino acids of the murine 
protein, lining the compound-binding pocket, were mutated to their human counterpart in 
order to restore binding and enzyme inhibition by the deazaflavin compounds. 
5.2 Results 
5.2.1 Expression and purification of m2hTDP2-CAT 
The expression and purification protocol for the humanised catalytic domain of mouse 
TDP2 (m2hTDP2-CAT), is described in Materials and Methods (2.2.6.6). This expression 
construct encodes an N-terminal polyhistidine-tagged SUMO moiety that is cleavable by 
Sentrin-specific protease 1 (SENP1) (Figure 5.1). During cell lysis and Talon capture steps 
(i.e. the first purification steps) a HEPES buffer at a pH of 7.5 was used. However, after 
overnight digestion with SENP1 protease –to remove the His-SUMO solubility tag – the 
theoretical isoelectric point (pI) of the m2hTDP2-CAT protein drops from pH6.2 to pH7.5. 
As a ThermoFluor assay clearly indicated that lowering the pH greatly increased the 
thermal stability of the protein (Figure 5.2), a MES buffer at a pH of 6.0 was used during 
subsequent chromatographic steps, which served to keep the recombinant protein in 
solution (Figure 5.3).  
5.2.2 Enzyme activity assays  
Gel-based enzyme activity assays were performed with purified m2hTDP2-CAT, in 
parallel with hTDP2-CATC161S and mTDP2-CAT as controls (Material and Methods 
2.3.2). As predicted, the activity of m2hTDP2-CAT was similar to both the murine and the 
human proteins. More importantly, C14297 now demonstrably inhibited m2hTDP2-CAT 
to a similar extent as hTDP2-CAT, thereby validating our hypothesis and approach (Figure 
5.4). 
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Figure 5.1. Schematic representation of the ‘humanised’ catalytic domain of mouse 
TDP2 (m2hTDP2-CAT). The amino acids mutated to their human counterpart are 
indicated. The expression construct encodes an N-terminal His-SUMO 
affinity/solubility tag to improve yields of soluble recombinant protein. The tag can be 
removed by digestion with SENP1 protease. 
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Figure 5.2. Thermal denaturation assay: m2hTDP2-CAT in different buffer systems. 
First order derivatives of the measured melting curves are shown (rate of change of 
fluorescence intensity). Temperature midpoints for the transition from folded to unfolded 
states are determined by the indicated peak minima (vertical line) in each case. Protein 
concentration: 1.7µM. Reaction conditions: HEPES pH7.5 (or MES pH6.0), 300mM 
NaCl, 0.5mM TCEP. 
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Figure 5.3. Purification of recombinant m2hTDP2. A. A representative SDS-PAGE 
gel, for fractions eluted from a HiLoad 16/600 Superdex 75pg size exclusion 
chromatography column across the indicated peak (asterisk). The expected migration 
position of the recombinant protein is indicated by an arrow. B. A representative 
chromatograph for the size exclusion chromatography purification step.   
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Figure 5.4. Gel-based enzyme activity assay, comparing the inhibitory effect of 
compound C14297 on all three recombinant TDP2 proteins. A. Reactions were 
conducted with 1nM hTDP2-CAT
C161S
, 3nM mTDP2-CAT and 1nM m2hTDP2-CAT, in 
the presence of 50, 150 and 50nM C14297, respectively (for an explanation of the 
different enzyme concentrations please see Materials and Methods 2.3.2) and then 
resolved on a denaturing sequencing gel. B. Quantification of the inhibitory effect of 
C14297 on enzyme activity. Plotted data are the mean of three independent experiments. 
Error bars represent 1 standard deviation. The star, triangle and square symbols 
correspond to hTDP2, mTDP2 and m2hTDP2 activity, respectively, for easier 
comparison. 
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5.2.3 Crystallization of m2hTDP2-CAT in complex with C14297 
Crystallisation trials, in MRC2 sitting drop plates, were set up as before (Materials and 
Methods 2.4.1.4) using several commercially available screens. After 5 days of incubation 
at 20°C, crystals from condition G11 of the PACT premier HT-96 screen (0.2M Sodium 
citrate, 0.1M bis-Tris propane pH7.5, 20% w/v PEG 3350, Molecular Dimensions) were 
harvested (Figure 5.5) and cryo-protected by successive swipes through buffer containing 
increasing concentrations of cryo-protectant (8% v/v glycerol and 5% w/v glucose) and 
then plunge-frozen in liquid N2 before being stored. Diffraction data to a resolution of 1.7Å 
were collected from a single crystal, on beamline I04, DLS. As crystals readily diffracted 
to high resolution, no further optimisation was required (Table 5.1). The dataset was auto-
processed at Diamond through the xia2 system using the 3dii mode (Winter, 2010), and 
then indexed and integrated by Mosfilm (Leslie, 2006) and scaled by XSCALE (Kabsch, 
2010). 
5.2.4 Molecular replacement 
Molecular replacement, with the published structure of mTDP2-CAT as a search model 
(PDB: 4GYZ) in PHASER (CCP4 software suite (Winn et al. 2011)) was sufficient to 
phase the diffraction data. The molecular replacement model was then improved by 
iterative rounds of rebuilding and refinement, using COOT (Emsley et al. 2010) and 
REFMAC5 (Vagin et al. 2004) to obtain the final refined model. Water molecules were 
placed in position where the sigma level was 2.0 or above and positioned in relation to 
hydrogen bonding to the protein or other ligands. Models were validated with the 
MolProbity server (Chen et al. 2010) at several stages throughout building, to inspect and 
correct side-chain rotamers, and to highlight problematic region, i.e. Ramachandran 
outliers. The final model had an R-factor of 0.1954 (Rfree 0.2256) and agreed well with 
electron density (Table 5.1). 
Two molecules of m2hTDP2-CAT comprise the asymmetric unit (Figure 5.6). 
Interestingly, they are covalently coupled by a disulphide bond formed between the two 
protomers via the side chain of cysteine 137. It is likely that this disulphide bond is created 
opportunistically during the exposure of crystals to X-rays, as m2hTDP-CAT behaves as a 
monomer in solution, under most experimental conditions (unpublished observations). 
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Figure 5.5. Image of a m2hTDP2-CAT / C14297 co-crystal. Crystals emerged from 
condition G11 (0.2M Sodium citrate, 0.1M bis-tris propane pH7.5, 20% w/v PEG 3350) 
from PACT premier HT-96 screen (Molecular Dimensions) after 5 days of incubation at 
20°C. 
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Data collection statistics  
Wavelength (Å) 0.97949 
Unit cell parameters 
  a (Å) 61.130 
  b (Å) 42.450 
  c (Å) 108.680 
  α (°) 90.000 
  β (°) 93.950 
  γ (°) 90.000 
Space group P 1 21 1 
Resolution range  54.79-1.46 (1.50-1.46)* 
Completeness 99.3 (98.1) 
Multiplicity 3.0 (2.8) 
Mean(I)/σ(I) 19.9 (2.1) 
Unique reflections 96352 (1159) 
Rmerge 0.028 (0.432) 
Rpim 0.025 (0.350) 
  
Refinement statistics  
Protein molecules per in the asymmetric unit 2 
Rwork / Rfree 0.1954 / 0.2256 
Number of atoms 4549 
  Protein 3927 
  Ligands 76 
  Water 546 
  Protein residues 494 
Ramachandran plot (%)  
  Favoured 98 
  Additionally allowed 2 
RMSDs  
  Bond lengths (Å) 0.01 
  Bond angles (°) 1.46 
B-factor (Å2)  
  Average B-factor  25.90 
  macromolecules                       23.11 
  ligands                        33.90 
  solvent                        45.10 
 
Table 5.1. Data collection and refinement statistics for the m2hTDP2-CAT / C14297 
complex. *Values in parentheses are for highest-resolution shell. 
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Figure 5.6. Molecular cartoon representation of the asymmetric unit of m2hTDP2-CAT 
crystals. A. C14297 bound to each molecule of the asymmetric unit is shown in stick 
representation (carbon atoms coloured brown).  Inset: Representative 2Fo-Fc electron 
density map (grey mesh, contoured at 1.5σ) surrounding both C14297 molecules B. 
Disulphide bond formed (Cys137 to Cys137) between the two protomers of the 
asymmetric unit. Inset: Representative 2Fo-Fc electron density map for the disulphide 
bond; note: two alternative conformational states are modelled, each at half occupancy. 
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5.2.5 Structure of m2hTDP2-CAT in complex with C14297 
As described for human TDP2 (Chapter 4.2.5), the deazaflavin ring system of bound 
C14297 – through a series of van der Waals contacts – interacts with residues from the 
divergent region of the M7-loop, which include Trp307, Ile317, Ala319, Cys321 and 
Leu323. However, due to the improved resolution, the positions of many ordered water 
molecules could now be observed. As before, the guanidinium head group (atoms Nε and 
Nη) of Arg266 (Arg276 in hTDP2-CATC161S) is poised to form hydrogen bonds to the 
carbonyl and nitrogen atoms of ring 1 of the deazaflavin core (Figure 5.7); Arg266 also 
interacts with the side chain of Asn274 via a water molecule. The ‘back-mutated’ Arg268 
(Arg278 in hTDP2-CATC161S) also makes contact with the same ring system via a water-
mediated interaction. The side chain of Arg241 (Arg251 in hTDP2-CATC161S) also helps to 
stabilise compound binding by stacking with both the pyrimidodione moiety (ring 1) and 
the tetrazole substituent. It is worth noting here, that due to its close proximity, Pro318 
from the other protomer of the asymmetric unit is involved in an intermolecular stacking 
interaction with the benzene moiety and tetrazole ring of C14297. However, as this 
interaction most likely emerges from the fact that the two m2hTDP2-CAT proteins are 
covalently connected via a disulphide bond, it is likely to be a crystallisation artefact. A 
ligand interaction diagram for m2hTDP2-CAT in complex with C14297 is presented in 
Figure 5.8. 
5.2.6 Crystallization of m2hTDP2-CAT in complex with LEP-0259 
As part of an ongoing collaboration with the Sussex Drug Discovery Centre, a new series 
of inhibitory compounds, based on the deazaflavin series, were synthesised. These 
compounds had higher aqueous solubility, with similar EC50 values (in the nM range) to 
the earlier deazaflavin compounds. In order to assess their binding capability, as before, 
each of the compounds was first tested in the thermal denaturation assay. Of the 4 
compounds tested, 3 did not show any measureable shift in temperature midpoint (ΔTm); 
however, one compound, a 3-hydroxyphenol derivative (LEP-0259, Figure 5.9), produced 
a small, but reproducible shift (ΔTm=1.3ºC) (Figure 5.10). This compound was therefore 
taken forward into crystallisation trials.  
In this instance, during purification of the m2hTDP2-CAT protein, the gel filtration buffer 
was supplemented with manganese chloride (iso-structural with magnesium, but readily 
discernible in electron density maps) in order to more fully define the catalytic environment  
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Figure 5.7. Molecular cartoon representation of m2hTDP2-CAT in complex with 
C14297, highlighting the residues surrounding the compound-binding site. The 
‘hydrophobic platform’ formed by residues of the M7-loop is shown, and is represented 
by amino acids coloured in orange (TWDT motif), yellow (divergent region) and cyan 
(RFDR motif). Pro318, which contacts C14297, from the other protomer of the 
asymmetric unit, is coloured in salmon. C14297 is shown in stick representation, and is 
coloured in green (carbon atoms). Dotted lines represent potential hydrogen bonds. 
Water molecules involved in compound interactions are shown as red spheres, and 
labelled with the letter ‘w’. 
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Figure 5.8. C14297 ligand interaction diagram. Key: W: water; blue arrows represent 
hydrogen bonds, dashed line: coordination bond. Blue circles represent residues 
involved in hydrogen bond formation and water mediated interaction, the orange circle 
represents Trp308 from the TWDT motif, the cyan circle depicts Phe325 from the RFDR 
motif, yellow circles represent residues from the divergent region. Pro318 represented 
as a red circle from the other protomer in the asymmetric unit is also involved in stacking 
interaction.  
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Figure 5.9. Chemical drawing of LEP-0259. The compound is a 3-hydroxyphenol 
derivative (R1 substituent) of the deazaflavin series with an EC50 value in the 
submicromolar range (50nM). Numbers for the three rings of the deazaflavin core are 
also shown. 
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Figure 5.10. Thermal denaturation assay of m2hTDP2-CAT in the presence of LEP-
0259. First order derivatives of the measured melting curves are shown (rate of change 
of fluorescence intensity). Temperature midpoints for the transition from folded to 
unfolded states are determined by the indicated peak minima (vertical line) in each case. 
Protein concentration: 1.7µM. Final compound concentration: 300µM. Reaction 
conditions: 20mM MES pH6.0, 300mM NaCl, 0.5mM TCEP and 3% v/v DMSO. 
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of the enzyme. As TDP2 is a magnesium-dependent phosphodiesterase, Mn2+ was 
expected to form a coordination complex at the active site of the enzyme. 
Crystallisation trials, in MRC2 sitting drop plates, were set up as before (Materials and 
Methods 2.4.1.5) using several commercially available screens. After 5 days of incubation 
at 20°C, crystals from condition F9 of the PACT premier HT-96 screen (0.2M Potassium 
sodium tartrate tetrahydrate, 0.1M bis-Tris propane pH6.5, 20% w/v PEG 3350; Molecular 
Dimensions) were harvested (Figure 5.11), and cryo-protected by successive swipes 
through buffer containing increasing concentrations of cryo-protectant (8% v/v glycerol 
and 5% w/v glucose) and then plunge-frozen in liquid N2 before being stored. Diffraction 
data to a resolution of 1.6Å were collected from a single crystal on beamline I04, DLS, 
As the space-group was identical, and the cell-dimensions were similar to m2hTDP2-CAT 
/ C14297 crystals, a simple rigid-body refinement was sufficient to phase the diffraction 
data (Table 5.2). 
Again the starting model was then improved by iterative rounds of rebuilding and 
refinement, using COOT and REFMAC5 as before. Again, models were validated with the 
MolProbity server at several stages throughout building (Chen, Arendall et al. 2010). 
5.2.7 Structure of m2hTDP2-CAT in complex with LEP-0259 
As in the previous complex, two TDP2 molecules comprised the asymmetric unit, again 
connected together by the same disulphide bond, formed by the side chain of Cys137 in 
each protomer.  
The binding mode of LEP-0259 is essentially identical to that observed for C14297 (Figure 
5.12). Residue Arg241, part of the ‘cap’ motif described by Schellenberg et al, is packed 
directly against the face of the tricyclic core. As before, the guanidinium group of Arg276 
forms several hydrogen bonds with the carbonyl and nitrogen atoms of ring 1 of the 
deazaflavin core of the compound, and also involved in a water-mediated interaction with 
the carbonyl group of Asn274. Arg278 stabilizes compound binding further through an 
ordered water molecule.  
Interestingly, the hydroxyl group of the R1 substituent in the para position, points directly 
towards the catalytic core of the protein – and makes a series of water-mediated contacts 
to the side chains of Asp272 and Asn274. Electron density maps also clearly showed the  
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Figure 5.11. Image of a m2hTDP2-CAT / LEP-0259 co-crystal. Crystals emerged from 
condition F9 (0.2M Potassium sodium tartrate tetrahydrate, 0.1M bis-tris propane pH6.5, 
20% w/v PEG 3350) from PACT premier HT-96 (Molecular Dimension) screen after 5 
days of incubation at 20°C. 
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Data collection statistics  
Wavelength (Å) 0.97949 
Unit cell dimensions: 
  a (Å) 61.040 
  b (Å) 42.860 
  c (Å) 109.010 
  α (°) 90.000 
  β (°) 94.050 
  γ (°) 90.000 
Space group P 1 21 1 
Resolution range (Å) 54.80-1.65 (1.69-1.65)* 
Completeness (%) 99.5 (98.6) 
Multiplicity 3.1 (2.8) 
Mean(I)/σ(I) 17.7 (2.1) 
Unique reflections 67784 (2371) 
Rmerge 0.04 (0.432) 
Rpim 0.035 (0.367) 
  
Refinement statistics  
Protein molecules per in the asymmetric unit 2 
Rwork / Rfree 0.2054 / 0.2361 
Number of atoms 4526 
  Protein 3894 
  Ligands 68 
  Manganese 2 
  Tartrate 4 
  Water 522 
  Protein residues 490 
Ramachandran plot (%)  
  Favoured 97.5 
  Additionally allowed 2.5 
RMSDs  
  Bond lengths (Å) 0.015 
  Bond angles (°) 1.51 
B-factor (Å2)  
  Average B-factor  24.40 
  macromolecules                       25.11 
  ligands                        34.70 
  solvent                        47.10 
 
Table 5.2. Data collection and refinement statistics for m2hTDP2-CAT / LEP-0259 
complex. *Values in parentheses are for highest-resolution shell. 
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Figure 5.12. Molecular cartoon representation of m2hTDP2-CAT in complex with 
LEP-259, highlighting the residues surrounding the compound-binding site. The 
‘hydrophobic platform’ formed by residues of the M7-loop is shown, and is 
represented by amino acids coloured in orange (TWDT motif), yellow (divergent 
region) and cyan (RFDR motif). LEP-0259 is shown in stick representation, and is 
coloured in green (carbon atoms).  Dotted lines represent potential hydrogen bonds. 
Water molecules involved in compound interactions are shown as red spheres, and 
labelled with the letter ‘w’. KEY: TAR: tartrate, Mn2+: manganese. 
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position of a tartrate molecule (picked up from the crystallisation solution) which is 
hydrogen-bonded to the side chain of Ser239, as well as an extensive series of water-
mediated interactions with several amino acid residues surrounding the catalytic centre. 
The tartrate molecule also completes the octahedral coordination of the Mn2+ ion (marking 
the position of the catalytic Mg2+ co-factor). 
A ligand interaction diagram for m2hTDP2-CAT in complex with compound LEP-0259 is 
presented in Figure 5.13. 
5.3 Discussion 
In this chapter, two high-resolution structures of m2hTDP2-CAT in complex with small 
molecule inhibitors are described.  
Several derivatives of deazaflavin-based compounds have been proven to be effective in 
vitro inhibitors of TDP2, with reported EC50 values in the sub-micromolar range (Raoof et 
al. 2013). Molecular docking studies, predicted that this series of compounds bound to 
TDP2 via ring 1 (pyrimidodione ring) of the tricyclic core, and that bound directly to the 
magnesium co-factor that is required for TDP2 enzyme activity, and made little (if any) 
hydrogen bonds directly to the protein (Raoof et al. 2013). However, the x-ray crystal 
structures of m2hTDP2-CAT in complex with two different inhibitors, presented here, 
show that the docking poses are in fact incorrect, and the binding of deazaflavins is actually 
driven by the tricyclic core making a series of van der Waals contacts to the hydrophobic 
platform of TDP2 (formed by the M7-loop). In particular, the hydroxyl and nitrogen atoms 
of ring 1, of the deazaflavin core, are liganded by the side chain of Arg278. Residues 
Arg241 and Cys321 also provide additional contacts through stacking interaction with the 
top and bottom of the tri-cyclic ring system. 
The tetrazole ring of C14297 was thought to increase compound solubility (Raoof et al. 
2013) but was originally introduced to provide a chemical group that would provide 
additional hydrogen-bonding potential, if presented towards the catalytic core of TDP2. 
However, early docking studies did not indicate any specific interactions, and it was 
hypothesised that the tetrazole ring might form non-specific hydrogen bonds and water 
mediated interactions with polar residues either in the hydrophobic DNA-binding ‘wall’ or 
on the opposite loop, due to the meta substitution of the tetrazole moiety (Raoof et al. 
2013). However, in the hTDP2-CAT / C14297 complex, the tetrazole ring is actually  
175 
 
 
 
Figure 5.13. LEP-0259 ligand interaction diagram. Key: TAR: tartrate, W: water 
molecule; blue arrows represent hydrogen bonds; dashed line: coordination bond. 
Residues involved in hydrogen bond formation and water mediated interaction are 
circled in blue.  Trp308 from the TWDT motif, is circled in orange. Phe325 from the 
RFDR motif is circled in cyan.  Residues circled in yellow indicate residues from the 
divergent region of the M7-loop.  Pro318 (circled in red) is involved in stacking 
interactions with the compound, but arises from the second protomer in the asymmetric 
unit. 
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pointed out to solvent, and does not interact with any residues of the catalytic site. 
Furthermore, the tetrazole moiety is involved in crystal contacts with a symmetry-related 
molecule. Moreover, in the m2hTDP2-CAT/C14297 complex, the tetrazole moiety is still 
pointed out to solvent, but is now no longer involved in any direct crystal contacts. As the 
two C14297 complexes are found in different crystal forms, we can surmise that the 
observed position of the tetrazole moiety is not driven by crystallisation contacts, and does 
not represent a crystallisation artefact; it therefore correctly represents the binding mode 
of this particular compound. 
In contrast, the 3-hydroxyphenol moiety of LEP-0259 points into the active site of TDP2, 
and makes several hydrogen bonds with key amino acid residues, and also (via a water 
mediated interaction) interacts with a tartrate molecule trapped at the active site. 
In order to improve binding and specificity of the next iteration of compounds, it is likely 
to be advantageous to extend or ‘grow’ the molecule towards the active site of TDP2. By 
adding substituents with functional groups capable of fitting into, or maintaining the 
extensive hydrogen bond network around the active site, the inhibitory activity of 
compounds may be increased. A good starting point has been fortuitously provided by the 
tartrate molecule found bound in the m2hTDP2-CAT/LEP-0259 complex. The position of 
the tartrate, and the series of water-mediated interactions made with it, provide several 
‘molecular paths’ to explore in future drug design. 
In a drug discovery project, small molecule inhibitors are not only tested by biochemical 
and biophysical assays, but are also examined in vivo, to determine whether a compound 
has the same inhibitory profile in the context of the cell. Cell based assays can provide 
valuable information about the absorption, bioavailability, metabolism and excretion 
(ADME) profile, and pharmacodynamics and pharmacokinetic characteristics (PK/PD) of 
a compound (Meibohm and Derendorf 1997, Doogue and Polasek 2013). These type of 
assays can aid selection of compounds, from a list of ‘hits’, which have the desired 
properties of a ‘hit-to-lead’ compound. 
The next chapter describes some initial experiments looking at whether the deazaflavin 
series of TDP2 inhibitors function in the context of human cells. 
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CHAPTER SIX 
 
Cell-based assays with TDP2 
inhibitors  
  
178 
 
6.1 Introduction 
In this chapter, preliminary results from two-cell based assays are described: a clonogenic 
survival assay and a double-strand break repair assay (monitoring γH2AX formation). Both 
assay formats have already been used in our own laboratory, in order to test the effect of 
deleting TDP2 in vertebrate cells (Zeng et al. 2011, Zeng et al. 2012). Here, the assays 
were used to test the effects of both the tetrazole compound C14297 and the hydroxyphenyl 
derivative LEP-0259 in cells. 
6.2 Results 
6.2.1 Clonogenic survival of U2OS cells in the presence of 
C14297 
TDP2 is the major, if not only, enzyme capable of resolving TOP2 covalent complexes and 
protects genome integrity in vertebrate cells (Zeng et al. 2011, Gomez-Herreros et al. 
2013). Cells in which TDP2 has been deleted (e.g. avian DT40 and mouse MEFs) have 
extreme sensitivity to TOP2 poisons, such as etoposide. Consequently, cells treated with 
etoposide ought to be hypersensitive to inhibitors of TDP2 activity.  
The human osteosarcoma cell-line U2OS is commonly employed in cell-based assays, as 
these cells are large and flat, grow in monolayers, and generate easily countable colonies 
after 10-14 days in culture. (For the full description Materials and Methods 2.8.3). Cells 
were pre-treated with C14297 for 4 hr at a final concentration of 1µM, which was far in 
excess (approximately 20 fold) of the EC50 determined from in vitro experiments, chosen 
as the maximum dose that would prevent toxicity induced by the DMSO vehicle, and then 
treated with 0-800nM etoposide for 4 days in continued presence of the inhibitor (Figure 
6.1). Control experiments suggested that C14297 is not toxic to cells at 1µM, over the 
period of the experiment (typically 10-12 days). However, C14297 also had no 
demonstrable impact on the sensitivity of U2OS cells to etoposide. Similar results were 
also obtained when experiments were carried out with an increased concentration of 
C14297 (5µM) (Figure 6.2). 
6.2.2 γH2Ax assay in the presence of C14297 
To measure the impact of C14297 on DNA double strand break repair (DSBR), we 
measured the induction and loss of γH2AX immunofoci; an indirect marker of DNA  
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Figure 6.1. Clonogenic survival assays in U2OS cells. Cells were treated with the 
indicated concentrations of etoposide (VP16) in the presence of DMSO vehicle or 1µM 
C14297. Data are the mean of three independent experiments, with error bars 
representing 1 standard deviation. Data points were normalised to the control (100%). 
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Figure 6.2. Clonogenic survival assays in U2OS cells. Cells were treated with the 
indicated concentrations of etoposide (VP16) in the presence of DMSO vehicle or 5µM 
C14297. Data are the mean of three independent experiments, with error bars 
representing 1 standard deviation. Data points were normalised to the control (100%). 
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double-strand breaks (DSBs) (Materials and Methods 2.8.4). Human primary fibroblast 
cells (1BR) were employed for these experiments, because γH2AX foci are readily 
detected and countable in these cells. 1BR cells were first serum starved to arrest cells in 
a G1-phase of the cell cycle, thereby omitting S/G2 phase cells from the assay and so 
enabling the assay to detect specifically NHEJ-mediated DSB repair. Arrested cells were 
pre-treated with C14297 (5µM) for 1 hour, before the addition of etoposide (20µM) for a 
further hour. Cells were subsequently then incubated for a further period in etoposide free 
medium and cells fixed for immune-labelling at the indicated time points (Figure 6.3). 
However, C14297 did not affect the kinetics of DSBR, under the experimental conditions 
employed in these experiments. 
6.2.3 Assays in the presence of LEP-0259 
Similar results were obtained in both assays with LEP-0259. Due to the higher aqueous 
solubility of LEP-0259, it was possible to carry out the clonogenic survival assay at a 
higher concentration of compound (10µM). Controls indicated that at this concentration 
the compound was not toxic to cells. Although the concentration of LEP-0259 tested was 
much higher, again there was no reduction in colony numbers compared to controls (Figure 
6.4). There was no difference between controls and cells treated with LEP-0259 in the 
γH2Ax focus formation assay (Figure 6.5) at this compound concentration. 
6.3 Discussion 
Cell based assays are important, especially during the early stages of the drug development 
process, in order to provide valuable information about the absorption, bioavailability, 
metabolism, excretion and toxicity (ADME/Tox) profile, and physicochemical and 
pharmacokinetic (PK) characteristics of a compound (Li 2001). These type of assays can 
aid selection of compounds, from a list of ‘hits’, which have the desired properties of a 
‘hit-to-lead’ compound. The tetrazole (C14297) and the hydroxyphenyl derivatives (LEP-
0259) of the deazaflavin series of TDP2 inhibitors were tested in clonogenic cell survival 
and DNA double-strand break repair assays. 
In the clonogenic cell survival assays, cells were subjected to continuous treatment with 
both etoposide and deazaflavin compound. As this assay was previously used to 
demonstrate that TDP2-depleted and/or deleted cells were extremely sensitive to etoposide 
treatment (Cortes Ledesma et al. 2009, Zeng et al. 2011), it was reasonable to think that an  
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Figure 6.3. γH2AX assays in 1BR cells. Cells were treated with 20μM etoposide (VP16) 
in the presence of DMSO vehicle or 5µM C14297. Data are the mean of three 
independent experiments, with error bars representing 1 standard deviation. 
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Figure 6.4. Clonogenic survival assays in U2OS cells. Cells were treated with the 
indicated concentrations of etoposide (VP16) and DMSO vehicle or 10µM LEP-0259. 
Data are the mean of three independent experiments, with error bars representing 1 
standard deviation. Data points were normalised to the control (100%). 
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Figure 6.5. γH2AX assays in 1BR cells. Cells were treated with 20μM etoposide (VP16) 
and DMSO vehicle or 10µM LEP-0259. Data are the mean of three independent 
experiments, with error bars representing 1 standard deviation. 
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inhibitor of TDP2 enzymatic activity would produce similar levels of sensitivity. However, 
neither of the compounds tested resulted in a reduction in cell viability. Similarly, neither 
compound had any observable effect on the kinetics of DSBR, as measured by the γH2AX 
focus formation assay. 
As the EC50 of each compound is in the micromolar range (C14297: 40nM, LEP-259: 
50nM) one would have expected to observe some cellular effects. However, the poor 
aqueous solubility of the deazaflavin compounds, along with low cell penetrability, may 
have prevented the compounds from entering the cell. This problem should be addressed 
directly in future, to find a suitable hit molecule in the future. Several methodologies can 
be applied to evaluate a drug candidate ability to cross the intestinal barrier and to study 
their transport mechanism through biological membranes. The Caco-2 cell system has been 
proven to be an important tool to test drug permeability in drug discovery projects (Angelis 
and Turco 2011). 
  
186 
 
 
 
 
 
 
 
 
CHAPTER SEVEN 
 
The Phosphate-binding pocket of 
the BRCT1 domain of XRCC1 
binds poly(ADP-ribose) 
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7.1 Introduction 
The synthesis of poly(ADP-ribose) (PAR) by PARP1 promotes XRCC1 accumulation at 
DNA damage sites (Caldecott et al. 1996). It was also hypothesised that the first BRCT 
domain of XRCC1 (BRCT1) is responsible for this interaction, and binding to PARP1 
might be mediated though the poly(ADP-ribose) polymer (PAR). Initial studies attributed 
the PAR-binding activity to the C-terminal basic region of BRCT1 (Pleschke et al. 2000). 
This motif consists of two conserved regions: the first rich in basic amino acids and located 
N-terminally from the second motif comprised of mainly basic and hydrophobic amino 
acid residues (Figure 1.2.6 A). Similar PAR-binding motifs have been identified in other 
proteins also involved in DNA repair, such as Ku70, DNA-PKcs and XPA (Pleschke et al. 
2000). However, mutations of this motif failed to cause any delay or inhibition of XRCC1 
recruitment to DNA strand breaks in cells (unpublished observations, Caldecott lab), 
suggesting that another motif must be responsible for the interaction.  
BRCT domains have a well-established role in phosphorylation-dependent interactions via 
a highly conserved phosphate-binding pocket (Sheng et al. 2011). Based on examination 
and comparison of the publically available NMR structure of the BRCT1 domain of 
XRCC1 and other phosphate binding BRCT domains , it was possible to identify the 
phosphate-binding pocket, comprised of the conserved amino acid side chains of Ser328, 
Arg335 and Lys369 (Figure 7.1). Mutation of the latter two amino acids to alanine result 
in a severe delay in repair and XRCC1 recruitment at DNA damage sites, in cellular assays 
(Breslin et al. 2015). The aim of the experimental work described in this chapter was to 
examine whether the interaction between XRCC1 and PARP1 is mediated by the 
phosphate-binding pocket of the BRCT1 domain.  
7.2 Results 
7.2.1 XRCC1 co-purifies with PARP1 in a BRCT1 phosphate-
binding pocket dependent manner  
XRCC1-mutant EM9 cells (which are null for XRCC1) were complemented with 
expression constructs encoding either full-length C-terminal histidine-tagged wild-type 
XRCC1 (XRCC1-His), full-length C-terminal histidine-tagged mutant XRCC1 harbouring 
the phosphate-binding mutations R335A and K369A (XRCC1-HisRK), or N-terminal His 
and Myc tagged truncated XRCC1161-406 (His-XRCC1161-406) encompassing the BRCT1  
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Figure 7.1. Molecular cartoon representation of XRCC1 BRCT1 superimposed on the 
first BRCT domain of MDC1 (PDB accession code: 2AZM) (Stucki et al. 2005), 
coloured light blue and pale cyan, respectively. Conserved amino acids involved in 
phospho-binding interactions are labelled and also shown in stick representation. 
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domain (Figure 7.2). His-tagged XRCC1 proteins were then recovered from EM9 cell 
extracts using Ni-agarose resin in affinity ‘pull-down’ experiments, and probed by western 
blot for the presence of PARP1 (Materials and Methods 2.7.2) (Figure 7.3). 
Both XRCC1-His and His-XRCC1161-406 co-precipitated PARP1, suggesting that the 
extended-BRCT1 domain of XRCC1 is sufficient to bind PARP1 (Figure 7.3). Conversely, 
the phosphate-binding mutant protein XRCC1-HisRK did not pull-down PARP1, 
supporting the idea that binding is directly mediated by the phosphate-binding motif of 
BRCT1. Following PARP1 detection, the blot was stripped and re-probed for XRCC1, 
using either an anti-XRCC1 polyclonal (Bethyl Laboratories) or anti-Myc-tag antibody 
(Cell Signalling Technology), to detect full-length and truncated XRCC1, respectively 
(Figure.7.3).  
7.2.2 Expression and purification of recombinant His-XRCC1161-
406, His-XRCC1161-406 RK and PARP1 from E. coli 
In the previous section, the interaction between PARP1 and XRCC1 was demonstrated 
using pull down experiments from human cell lysates. These experiments also highlighted 
the role of BRCT1 residues R335 and K369 in the interaction, supporting the idea that the 
interaction is mediated via the phosphate-binding pocket. To examine this interaction in 
more detail I expressed and purified the recombinant proteins for biochemical assays, in 
vitro.  
DNA encoding amino acid residues 161-406 of XRCC1 was amplified from mammalian 
expression constructs pCD2E-XH and pCD2E-XHR335A/K369A (Caldecott et al. 1995) and 
sub-cloned into the bacterial expression vector pTWO-E, using flanking NdeI and EcoRI 
restriction sites encoded by the PCR primers (Materials and Methods 2.2.10.1). Successful 
cloning was confirmed by restriction digest (see Appendix A.3) and E. coli strain 
Rosetta2(DE3) pLysS was employed for subsequent expression of both proteins. The 
purified proteins are depicted in Figure 7.4A, and a full description of the purification 
protocol is included in Materials and Methods, (Section 2.2.10.1). To verify that His-
XRCC1161-406 RK was correctly folded, the wild type and mutant recombinant proteins were 
analysed by fluorescence-based thermal denaturation assays and by circular dichroism 
spectroscopy (Sections 2.6.1 and 2.6.2). First order derivatives of the thermal denaturation 
melting curves, or direct fitting of the curves using a modified Boltzmann equation,  
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Figure 7.2. Schematic representation of the XRCC1 fragment (spanning residues 161 
and 406) used in pull down assays. The constructs harboured an N-terminal Myc- and 
his-tag for detection and purification purposes. The phosphate-binding mutant harboured 
the R335A/K369A mutations to abolish phosphate interaction. 
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Figure 7.3. The phosphate-binding pocket of the first BRCT domain of XRCC1 binds 
PARP1. A. IMAC pull-down experiments employing cell extracts prepared from 
XRCC1-mutant EM9 cells stably transfected with expression constructs encoding either 
full-length wild type human XRCC1-His, XRCC1-HisR335A/K369A, (EM9-XHRK) or His-
XRCC1161-406 (EM9-HX161-406). Note that the XRCC1 ORFs encode either an N-terminal 
(truncated XRCC1) or C-terminal (full length XRCC1) His6-tag. Aliquots of the 
supernatant (S), flow-through (F/T), final wash (W), the eluent (E), and boiled beads 
(Ni), were fractionated by SDS-PAGE, transferred to nitrocellulose, and immunoblotted 
for PARP1 (mouse monoclonal anti-PARP1). B. The above membrane was stripped and 
re-probed for XRCC1, using either the anti-phospho (pS485/pT488) XRCC1 polyclonal 
antibody or the XRCC1161-406 fragment and was detected by mouse c-Myc monoclonal 
antibody (the Myc tag is N-terminally located on the XRCC1161-406 construct). 
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Figure 7.4. Purification of recombinant human His-XRCC1
161-406
, His-XRCC1
161-406
 
RK
, 
and PARP1. A. PARP1 was expressed in Sf9 cells and purified on Sepharose 4B 3-
aminobenzamide resin followed by gel filtration as described in materials and methods. 
The three peak fractions from the gel filtration step were run on Novex 4-12% Tris-
Glycine Protein Gels and then stained with InsantBlue Protein Stain. XRCC1
161-406
 
fragments were expressed in Rosetta
TM
2 (DE3)pLysS. The initial talon capture was 
followed by a Heparin column elution. B. PARP1 was auto-ribosylated to test enzyme 
activity. Autoribosylated PARP1 is retarded during electrophoresis resulting in a smear. 
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indicated that there was no significant difference between the unfolding temperature 
midpoints of the two proteins, suggesting that the RK-mutant had no significant effect on 
tertiary structure (Figure 7.5). Similarly, CD spectra of both proteins indicated that the wild 
type and mutant proteins adopted a similar fold in solution (Figure 7.6). 
In addition to recombinant XRCC1, full-length human PARP1 was expressed in, and 
purified from, Sf9 insect cells as described in Materials and Methods, Section 2.2.5 (Figure 
7.4.A). PARP1 activity was verified by incubating the enzyme in the presence of NAD+ 
and a single-stranded DNA substrate for 30 min at room temperature, followed by analysis 
of reaction products on poly-acrylamide gels (Figure 7.4B). 
7.2.3 XRCC1 interaction with non-ribosylated and ribosylated 
PARP1, in vitro. 
7.2.3.1 Binding of His-XRCC1161-406 and His-XRCC1161-406 RK to PARP1 on slot blots. 
To examine if XRCC1 interacted with PARP1 in vitro, I first employed slot blot 
methodology. Recombinant His-XRCC1161-406 WT and His-XRCC1161-406 RK were adsorbed 
onto nitrocellulose membrane and then incubated with either mock-ribosylated or auto-
ribosylated PARP1 (Materials and Methods 2.5.1.1) (Figure 7.7). This experiment strongly 
suggested that both the wild type and mutant XRCC1 proteins bound auto-ribosylated 
PARP1 with higher affinity than non-ribosylated PARP. However, these experiments did 
not support the idea that PAR binding required the phosphate-binding pocket, because wild 
type and mutant XRCC1 appeared to bind PARP1 with similar efficiency. 
7.2.3.2 Binding of His-XRCC1161-406 and His-XRCC1161-406 RK to PAR on slot blots 
In the next set of experiments, binding of His-XRCC1161-406 to naked PAR was investigated 
(Materials and Methods 2.5.1.2). A dilution series of PAR polymer (Trevigen, Abingdon, 
UK) was prepared in PBS and blotted onto a nylon membrane (GE Healthcare). After UV-
crosslinking and blocking in non-fat dried milk, the membrane was incubated with His-
XRCC1161-406 WT or His-XRCC1161-406 RK (Figure 7.8). In contrast to the previous result, 
this experiment supported the idea that PAR binding is mediated by the phosphate-binding 
pocket. To resolve this discrepancy, I established a more and quantitative and reproducible 
assay, using micotitre plate-binding assays that lend themselves to ELISA analysis. 
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Figure 7.6. CD spectra for XRCC1161-406 WT and XRCC1
161-406 RK
. Protein samples in 
10mM HEPES, pH7.5, 300mM NaCl and 0.5mM TCEP were concentrated to 
1.55mg/ml. Spectra were measured between the wavelengths 198nm and 280nm.  
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Figure 7.7. XRCC1 BRCT1 domain binds PARylated PARP1. 15µg of either wild type 
His-XRCC1
161-406 
or His-XRCC1
161-406 RK
 were absorbed onto nitrocellulose membrane. 
The membrane was incubated in the presence of either 100nM ribosylated, or non-
ribosylated PARP1. Non-ribosylated PARP1 was detected by mouse anti-PARP1 
antibody (a-PARP1) (Bio-Rad), and ribosylated PARP1 (“PAR-PARP1”) was detected 
by mouse anti-PAR antibody (a-PAR) (Enzo Life Sciences). Amido black staining 
shows equal loading of XRCC1161-406 proteins. 
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Figure 7.8. XRCC1 binding experiment to naked PAR polymer. Dilution series of naked 
PAR polymer (10, 2, and 0.4ng) were absorbed onto Hybond-XL nylon membrane (GE 
Healthcare) and were incubated with either WT or the R335A/K369A mutant XRCC1
161-
406
 fragment (100nM). Proteins were detected by anti-polyhistidine antibody. In the last 
lane, poly(ADP-ribose) was detected by anti-poly(ADP-ribose). 
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7.2.3.3 Binding of His-XRCC1161-406 WT and His-XRCC1161-406 RK to ribosylated 
proteins in a plate-binding assay 
A colorimetric-based assay was established previously in the laboratory to measure protein 
binding to ribosylated proteins (Rulten at al., 2008), which I adapted here for my 
experiments (Figure 7.9). A full description of the protocol is included in the Materials and 
Methods (section 2.5.2.1). However, in brief, a 96 well plate is coated with calf thymus 
histone type II (Sigma-Aldrich), PARP1, or other proteins of interest (e.g. BSA), and the 
histones or control proteins then either mock-ribosylated or trans-ribosylated by 
recombinant PARP1. After extensive washing to remove unbound proteins, the ability of 
His-XRCC1161-406 to bind the mock-ribosylated or ribosylated histones or control proteins 
was measured by incubating the recombinant His-XRCC1161-406 with the coated well for 
30 min. The wells were then extensively washed and bound His-XRCC1161-406 detected 
using a mouse monoclonal anti-polyhistidine antibody (Sigma Aldrich), anti-mouse 
alkaline-phosphatase conjugated secondary (DAKO), and TACS Sapphire detection 
reagent (Trevigen).  
In this assay, His-XRCC1161-406 RK was less able to bind auto-ribosylated PARP-1, trans-
ribosylated calf thymus histone H1, or trans-ribosylated Bovine Serum Albumin (BSA) 
than was His-XRCC1161-406. This was most evident when low concentrations of NAD+ 
were employed to limit the total level of PAR synthesis (Figure 7.10). These data strongly 
support the notion that the phosphate-binding pocket of the BRCT1 domain is required for 
PAR binding by XRCC1, at low levels of PAR synthesis at least. This in turn supports a 
model in which the phosphate-binding pocket of the BRCT1 domain binds the phosphate 
moieties present in the PAR polymer directly (Figure 7.1B). One potential caveat is that 
the recombinant PARP1 and histone employed here derived from insect cells and calf 
thymus respectively, raising the possibility that these proteins were phosphorylated and 
that the phosphate-binding pocket found in XRCC1 bound this phosphate, albeit in a 
ribosylation dependent manner. To rule out this possibility, the experiment was repeated 
using recombinant histone H1 expressed in E. coli, with similar results (Figure 7.11). 
7.2.3.4 XRCC1161-406 binds poly(ADP-ribose) but not mono(ADP-ribose) 
The plate-binding assays suggested that the BRCT1 phosphate-binding pocket interacts 
directly with PAR. A major question that arose in light of this result was what is the 
minimal chain length required for efficient BRCT1 binding? The basic unit of poly (ADP-
ribose) is adenosine diphosphate ribose (ADP-ribose; ADPr). It was hypothesised that if  
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Figure 7.9. Schematic representation of the plate-binding assay. First, histones, PARP1, 
or BSA (as a control) were absorbed onto the wells of a 96 well plate. After extensive 
washing, the proteins were either mock-ribosylated or ribosylated in the presence of 
various concentration of NAD
+
, rinsed extensively and incubated with wild type or 
mutant His-XRCC1
161-406
 for 30 min. After washing, His-XRCC1 detected by 
polyhistidine antibody as described in materials and methods (2.5.2.1). 
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Figure 7.10. The XRCC1 BRCT1 phosphate-binding pocket binds PAR, in vitro. 
Binding of His-XRCC1161–406 and His-XRCC1161–406 RK to the indicated mock-
ribosylated (-NAD+) or ribosylated (1–50µM NAD+) proteins was measured as indicated 
in Figure 7.9. Data are the mean (±1 SD) of at least three experiments. KEY: CTHist: 
calf thymus histone, BSA: bovine serum albumin. 
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Figure 7.11. The XRCC1 BRCT1 phosphate-binding pocket binds PAR, in vitro. 
Binding of His-XRCC1161–406 and His-XRCC1161–406 RK to the indicated mock-
ribosylated (-NAD+) or ribosylated (1–50µM NAD+) proteins was measured as indicated 
in Figure 7.9. Data are the mean (±1 SD) of at least three experiments. KEY: recH1: 
recombinant histone H1, BSA: bovine serum albumin. 
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the phosphate-binding pocket binds a single ADPr unit (mono ADPr) then it should be 
outcompeted by an increasing concentration of free unbound ADPr. To test this, different 
concentrations of mono ADP-ribose competitor (50nM, 0.5µM, 50µM, 500µM) were pre-
incubated with 25nM His-XRCC1161-406 before incubation with the adsorbed ribosylated 
histones (Materials and Methods 2.5.2.3). After extensive washing, the bound His-
XRCC1161-406 was detected as previously described (section 2.5.2.1). Notably, mono(ADP-
ribose) (MAR) failed to prevent His-XRCC1161-406 binding, even when present at 1000-
fold molar excess (Figure 7.12). I conclude from these experiments that phosphate-binding 
pocket binds PAR, but not mono(ADP-ribose). To further test this hypothesis, I employed 
naked poly(ADP-ribose) (PAR; Trevigen), comprised of heterogeneous polymers of 2 to 
300 units in length, as a competitor, along with auto-ribosylated PARP1 (Materials and 
Methods 2.5.2.3). His-XRCC1161-406 was pre-incubated with different competitor 
concentrations prior to adding to the adsorbed ribosylated histones, as above. Unlike MAR, 
both PAR and auto-ribosylated PARP1 competed effectively with His-XRCC1161-406 for 
binding to ribosylated histone protein (Figure 7.13). 
7.2.3.5 The use of biotinylated NAD+ to measure PAR synthesis 
To further examine the necessity for PAR, versus MAR, for XRCC1 binding, I developed 
an assays using biotin-NAD+ to label the ADP-ribose products of PARP activity, directly 
(Materials and Methods 2.5.2.4). This was necessary to measure the polymer product of 
PARP enzymes, since available antibodies fail to detect MAR, or short chains of PAR. To 
test His-XRCC1161-406 binding to biotinylated-PAR, calf thymus histone type II (Sigma-
Aldrich) was either mock-ribosylated or ribosylated in the presence of biotinylated-NAD+ 
(1, 10, or 50µM) with PARP1. The experiment was conducted in a duplicate to detect both 
biotin-NAD+ (using streptavidin) and His-XRCC1161-406 binding (using anti-polyhistidine 
antibody). His-XRCC1161-406 also bound the biotinylated substrate, and the level of biotin 
incorporation was dependent on the NAD+ concentration, as expected (Figure 7.14). 
Importantly, the binding by XRCC1 was again dependent on the phosphate-binding pocket 
(Figure 7.15). The overall level of XRCC1 binding was less than observed in experiments 
employing radiolabelled NAD+ however, as suggested by the total absorbance values. This 
most likely reflects that biotinylated-NAD+ might be not as efficient substrate for PAR 
synthesis. Alternatively, the biotin moiety might interfere with the XRCC1 interaction due 
to steric hindrance. It is important to point out that the signal emerging from the biotin  
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Figure 7.12. The XRCC1 BRCT1 phosphate-binding pocket does not bind mono(ADPr-ribose) 
(MAR). A. Binding of His-XRCC1161–406 to calf thymus histone mock-ribosylated in the absence 
of NAD+ (‘0’) or ribosylated in the presence of 0.5 µM NAD+. Where indicated, XRCC1 binding 
was measured in the presence of 43 nM PARP1 competitor that was first autoribosylated in the 
presence of 0 or 2µM NAD+, as indicated. Alternatively, His-XRCC1161–406 WT binding was 
measured the presence of the indicated concentration of mono (ADP-ribose) (‘MAR’) 
competitor. MAR competitor concentrations are total ADP-ribose units (µM) present as MAR. 
Data are the mean (±1SD) of at least three experiments. B. Schematic representation of the 
experiment. 
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Figure 7.13. The XRCC1 BRCT1 phosphate-binding pocket bind PAR A. Binding of either His-
XRCC1161–406 WT or His-XRCC1161–406 RK to calf thymus histone mock-ribosylated in the absence 
of NAD+ (‘0’) or ribosylated in the presence of 0.5 µM NAD+. Where indicated, XRCC1 binding 
was measured in the presence of 43nM PARP1 competitor that was first auto-ribosylated in the 
presence of 0, 0.2, 0.4 and 0.8µM NAD+, as indicated. Alternatively, His-XRCC1161–406 WT 
binding was measured in the presence of the indicated concentration of PAR competitor. PAR 
competitor concentrations are total ADP-ribose units (µM) present as PAR (2-300 subunit 
lengths). Data are the mean (±1SD) of at least three experiments. B. Schematic representation 
of the experiment. 
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Figure 7.14. The phosphate-binding pocket of the first BRCT domain of XRCC1 binds 
biotinylated PAR polymer. Calf thymus histone was either mock ribosylated or 
ribosylated with biotinylated NAD
+
 in the presence of PARP1. 25nM wild type 
XRCC1
161-406
 was added to the wells and incubated for 30 min. The binding of XRCC1 
fragment was detected as described in Materials and methods. Additionally, in a parallel 
experiment the synthetized biotinylated PAR polymer was detected using HRP 
conjugated Streptavidin. B. Schematic representation of the experiment, showing 
parallel detection of the signals emerging from the biotinylated ADPr moieties 
incorporated into the forming PAR polymer and the bound XRCC1161-406.  
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Figure 7.15. Biotinylated PAR binds XRCC1
161-406 WT 
and XRCC1
161-406 RK
. Calf 
Thymus histone was ribosylated in the presence of biotinylated NAD
+
 with PARP1. 
25nM XRCC1 fragment was added and incubated for 30 min on ice, then detected as 
described in Materials and Methods (2.5.2.1). 
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moiety detected by HRP-conjugated streptavidin antibody saturates the assay already at 
10µM substrate concentration. 
7.2.3.5.1 Binding of His-XRCC1161-406 to products of PARP3 activity  
In the previous section I demonstrated that His-XRCC1161-406 can bind to biotinylated PAR 
synthesised by PARP1. Next, I employed PARP3, which primarily mono-ribosylates 
proteins, to ribosylate calf thymus histone type II (Sigma-Aldrich), in the presence of 10-
100PM biotinylated NAD+ (Materials and Methods 2.5.2.4). As expected for an enzyme 
that primarily mono-ribosylates proteins, His-XRCC1161-406 was unable to bind the product 
of PARP3 activity, despite clear biotin-NAD+ dependent ribosylation of calf thymus 
histone proteins (Figure 7.16).  
7.2.3.5.1 Ribosylated histones do not recruit XRCC1 after PARG treatment 
To prove that XRCC1 requires more than one ADPr unit for binding, the biotinylated 
products of histone ribosylation by PARP1 were pre-treated with enzymes that degraded 
either PAR (e.g. PARG) or MAR (e.g. MACROD1; MacD1) prior to incubation with His-
XRCC1161-406 (Materials and Methods 2.5.2.4). Notably, binding of His-XRCC1161-406 was 
prevented by PARG treatment at all NAD+ concentrations tested (Figure 7.17). In contrast, 
MACROD1 treatment did not affect His-XRCC1161-406 binding to PARylated histones 
(Figures 7.18). Biotin detection confirmed that PARG greatly reduced biotin label, but did 
not ablate it completely, as expected given the residual protein-proximal MAR left behind 
by PARG (Figure 7.19). Together, these experiments confirm that the phosphate-binding 
pocket of XRCC1 binds PAR, but not MAR. 
7.2.3.4 Impact of PAR length on His-XRCC1161-406 binding  
In order to pursue a structural biology approach to examine the molecular nature of the 
interaction between the His-XRCC1161-406 and the PAR polymer, distinct unit lengths of 
PAR were synthetized and purified (Material and Methods 2.5.3.2). 
Because the chemical synthesis of homogenous PAR polymer with distinct unit length is 
still challenging, the only viable approach was to obtain PAR from enzymatic reactions 
employing a poly(ADP-ribose) polymerase. Tan et al presented a protocol to scale up the 
preparation of homogenous PAR polymer (Tan et al. 2012), which I followed with minor 
modifications (See Material and Methods 2.5.3). This approach resulted in recovery of 
numerous distinct UV absorbance peaks during chromatography (Figure 7.20). Peak 1-9,  
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Figure 7.16. The phosphate-binding pocket does not bind mono(ADP-ribose). Calf 
thymus histone was either mock ribosylated or ribosylated with biotinylated NAD+ in 
the presence of PARP3. 25nM wild type XRCC1161-406 was added to the wells and 
incubated for 30 min. The binding of XRCC1 fragment was detected as described in 
Materials and methods (2.5.2.1). Additionally, in a parallel experiment the synthetized 
biotinylated mono(ADP-ribose) moiety was detected using HRP conjugated 
Streptavidin. 
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Figure 7.17. The phosphate-binding pocket of the first BRCT domain of XRCC1 binds 
PAR polymer and not MAR. A. For substrate, a mix of NAD+ and biotinylated NAD+ in 
a molar ratio of four to one was employed. The ribosylated proteins were either mock-
treated or treated with PARG, then incubated with XRCC1
161-406 WT
. The binding of 
XRCC1
161-406 WT
 was detected as described in Materials and Methods (2.5.2.1). In a 
parallel experiment the level of ribosylation before and after PARG treatment was also 
detected using HRP-conjugated streptavidin. Data are the mean (±1SD) of three 
independent experiments. B. Schematic representation of the experiment. 
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Figure 7.18. The phosphate-binding pocket of the first BRCT domain of XRCC1 binds 
PAR polymer and not MAR. A. Calf thymus histone was ribosylated in the presence of 
NAD
+
 -biotinylated NAD
+
 mixture (4 to 1 ratio) with PARP1. The ribosylated proteins 
were either mock-treated or treated with PARG/MACROD1 then, incubated with 
XRCC1
161-406 WT
. The binding of XRCC1
161-406 WT
 was detected as described in Materials 
and Methods (2.5.2.1). Data are the mean (±1SD) of three independent experiments. 
(MACROD1 is denoted as MacD1 on the figure) B. Schematic representation of the 
experiment. 
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Figure 7.19. The phospho-binding pocket of the first BRCT domain of XRCC1 binds 
PAR polymer and not MAR. A. Calf thymus histone was ribosylated in the presence of 
NAD
+
 -biotinylated NAD
+
 mixture (4 to 1 ratio) with PARP1. The ribosylated proteins 
were either mock-treated or treated with PARG or/and MACROD1 (MacD1 on the 
figure). The level of ribosylation before and after PARG treatment was detected using 
HRP-conjugated streptavidin. Data are the mean (±1SD) of three independent 
experiments. B. Schematic representation of the experiment. 
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Figure 7.20. Preparation of PAR polymer with distinct unit length. A. Fractions of PAR 
polymers were eluted from MonoQ ION-exchange column by applying increasing salt 
concentration. Fractions noted from Peak1 (P1) to Peak9 (P9) were collected individually and 
desalted. Peak 10-20, Peak 20-30 and Long PAR were also collected and desalted as described 
in Materials and methods. B. Mono(ADP-ribose) was also loaded and eluted from MonoQ 
column and eluted at 12.4% Buffer B. 
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peak 10-20, and longer PAR lengths were fractionated by denaturing PAGE on sequencing 
gels and detected by silver staining as described previously (Malanga et al. 1995) above, 
revealing that each peak fraction represented a high purity polymer with distinct unit length 
(Figure 7.21) (Materials and Methods 2.5.3.3). It is worth pointing out that during the 
preparation of PAR, the polymers are detached from the target proteins by KOH treatment, 
thus resulting in species of different molecular masses for polymers of the same unit length. 
These differences might arise from decomposition of the proximal ribose moiety 
(Kiehlbauch et al. 1993). Whilst confirmation requires mass spectrometry, these data 
suggest that peak 1 is most likely 2 units Peak 2&3 are 3 units, Peak 4&5 are 4 units, etc. 
Next, we employed these polymers in competition assays, to further define the unit lengths 
that best bind XRCC1 (2.5.2.3). The competition assay was carried out using 15nM-15µM 
(total ADP-ribose units) of each peak fraction (Figure 7.22). Interestingly, between Peak 6 
& 7 (both ~5 units) there is a significant increase in ability to bind XRCC1 in these 
competition assays. Strangely, Peak 8 did not compete at these concentrations, whereas 
peaks 10-20 and longer polymers were also effective competitors. 
7.3 Discussion 
In this chapter I demonstrated that the phosphate binding pocket of the XRCC1 BRCT1 
domain a PAR binding module. Pull down assays confirmed that the phosphate-binding 
pocket is required for interaction between ribosylated PARP1 and XRCC1. To further 
investigate the interaction on molecular level, I progress to experiments employing 
recombinant proteins. Slot blot experiments in which wild type or mutant XRCC1161-406 
was absorbed onto nitrocellulose membrane suggested that binding to auto-ribosylated 
PARP1 was not greatly impacted by mutation of the phosphate binding pocket. However, 
I obtained contradictory results if PAR polymer was absorbed onto nylon membrane and 
was incubated with either wild type or His-XRCC1161-406 RK. One possible explanation was 
that there are two modes of XRCC1 binding, one that is dependent on the phosphate-
binding pocket and one that is not, with the former evident only at low levels of 
PARylation.  
To test this, I developed and employed a more quantitative ELISA plate-binding assay. 
This proved successful. The first set of experiments revealed a significant difference in 
XRCC1 binding between wild type and mutant XRCC1 harbouring a mutated phosphate- 
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Figure 7.21. Acrylamide gel electrophoresis of purified PAR polymer fractions. PAR 
fractions were prepared in a final concentration of 0.3µM and diluted in loading buffer 
(40% urea, 4mM EDTA, 0.02% bromophenol blue, and 0.02% xylene cyanol). The 
samples were run at a constant power of 15W, then the gel was fixed in 50% ethanol and 
5% acetic acid solution for 2 hours. The gel was stained with Pierce® Color Silver Stain 
Kit (Thermo Scientific). 
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binding pocket, at lower concentrations of NAD+. However, at higher NAD+ 
concentrations, the mutant XRCC1161-406 also bound PAR. Formerly, the PAR binding 
ability was assigned to a degenerate basic patch at the C-terminal part of the first BRCT 
domain (Pleschke et al. 2000). It is thus possible that this domain bind PAR by itself at 
high concentrations of polymer, but that this region normally functions cooperatively with 
the phosphate-binding pocket at lower PAR concentrations. For example, perhaps PAR 
polymer of an appropriate size can occupy both the phosphate-binding pocket and the 
degenerate basic patch. However, it is worth noting that in cell based assays loss of the 
phosphate binding pocket is sufficient to ablate XRCC1 recruitment to damage sites and 
also XRCC1 functionality, suggesting that at physiological levels of PARylation the 
phosphate-binding pocket is essential (Breslin et al. 2015). 
Consistent with the idea that there may be two cooperative PAR binding sites in the 
XRCC1 BRCT1 domain, by purifying PAR polymers of distinct unit length it was possible 
to demonstrate that longer polymers bind to XRCC1 more efficiently, in competition 
assays. Competition assays also revealed that the phosphate-binding pocket requires at 
least two ADPr units for binding, since mono(ADP-ribose) (MAR) was not sufficient to 
compete with ribosylated PARP1 even at >1000x molar excess. This hypothesis was 
supported by experiments employing PARG or MacD1 to degrade MAR or PAR, in 
conjunction with biotinylated NAD+ to measure levels of ADP-ribosylation. These 
experiments revealed that XRCC1 binding to ribosylated histone protein is sensitive to pre-
treatment with PARG, which degrades PAR, but not MacD1, which degrades MAR. Pre-
treatment with both enzymes ablated XRCC1 binding.  
In future, another way to test the idea that there are two cooperative PAR-binding sites in 
the BRCT1 domain might be to express and purify a mutant XRCC1 lacking both putative 
PAR-binding domains. To date, however, this has not proved possible. In addition, X-ray 
crystallography or NMR may prove useful, especially in conjunction with the PAR 
molecules of distinct size that I have purified. 
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CHAPTER EIGHT 
 
Summary and Discussion 
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8.1 Overall Perspective 
During my PhD, I was fortunate enough to be involved in two exciting projects. The first 
project was focusing on determining X-ray crystal structures of TDP2 in complex with 
small molecule inhibitors, in order to aid an ongoing structure-based drug design approach. 
My second project focused on biochemical characterisation of the interaction between the 
single-strand break repair protein XRCC1 and poly(ADP-ribose). 
8.2 Project I: Small molecule inhibitors of TDP2 
8.2.1 TDP2 as a potential drug target 
TDP2, also known as TTRAP, was identified in a screen for new tyrosyl-DNA 
phosphodiesterase activities (Cortes Ledesma et al. 2009). Enzyme assays with a substrate 
harbouring a 5’-tyrosyl moiety, covalently attached to DNA, clearly demonstrated that the 
protein TDP2 possessed a phosphodiesterase activity capable of removing this type of 
adduct. Further experiments proved that TDP2 can also liberate trapped covalent 
complexes of Topoisomerase 2 (TOP2) from damaged DNA termini; thereby indicating 
that TDP2 is an important factor for DNA double-strand break repair in vertebrate cells 
(Zeng et al. 2011) and functions as part of the Non-Homologous End-Joining pathway 
(NHEJ) (Gomez-Herreros et al. 2013). Cells in which TDP2 is either depleted (siRNA) or 
deleted are highly sensitive to the TOP2-poison etoposide; suggesting that inhibitors of 
TDP2 may produce elevated levels of cell death in cancer cells, treated with both agents 
(Cortes Ledesma et al. 2009). 
Recent findings have raised the possibility that inhibitors of TDP2 may also have utility as 
a monotherapy. For example, it was demonstrated that TDP2 protects transcriptional 
programmes, which require activation by TOP2 (Gomez-Herreros et al. 2013) and that in 
hormone-driven cancer cell models, depletion of TDP2 inhibited the transcription of 
certain genes, even at endogenous levels of abortive TOP2 activity. Therefore, 
hypothetically, a monotherapy using TDP2 inhibitors to treat hormone-driven cancer cells 
would also lead to elevated levels of cell death. Interestingly, the enzyme activity of TDP2 
is also required for host-pathogen interactions in some members of the picornavirus family 
(human papilloma virus, rhinovirus; (Virgen-Slane et al. 2012). Rhinoviruses are the most 
common viral infectious agents, and are the cause of the common cold, as well as 
meningitis, encephalitis and hepatitis. Targeting TDP2 could therefore offer an excellent 
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target, for combating viral infections and would open new avenues in anti-picornavirus 
drug development. 
8.2.2 High-throughput Screening (HTS): assay development and 
compound screening  
In order to find promising small molecule inhibitors of TDP2, a high-throughput screening 
(HTS) method was needed. Thomson and co-workers at the Paterson Institute of Cancer 
Research, University of Manchester developed a chromogenic assay that allowed the 
screening of a compound library in a HTS fashion (Thomson et al. 2013). The substrate 
molecule employed was 4-nitrophenyl phenylphosphonate (NPPP). Approximately 100 
000 compounds were screened in the HTS screen, with several toxoflavins and a singleton 
deazaflavin identified as ‘hits’ (Raoof et al. 2013). Although the toxoflavins showed clear 
structure activity relationships (SAR) for inhibition of TDP2, their redox liability hindered 
any further exploration of this chemical scaffold. However, the deazaflavin singleton was 
expanded into a promising series of compound, which also showed clear SAR through a 
secondary screen. The deazaflavin series had no observable redox liability, had good EC50 
values and showed clear dose dependent inhibition of TDP2 enzyme activity. 
8.2.3 Structural studies 
In order to have a better understanding of how these compounds inhibit TDP2 enzyme 
activity, and to aid a structure-based drug design approach, structural studies were 
undertaken. My involvement with the project started by optimising the expression and 
purification of recombinant TDP2, in order to obtain multi-milligrams of purified protein 
to facilitate crystallographic screens (Chapter 4). The expression of recombinant proteins 
can be challenging, and to maximise the yields of soluble protein, it is often more effective 
to generate expression constructs that encode compact structural units (domains) of a 
protein, rather than the full length protein. Protein domains are also generally more 
amenable to crystallisation. Crystallising the catalytic domain of human TDP2 in complex 
with a small molecule inhibitor would provide the molecular information necessary for a 
structure-guided drug discovery approach.  
Despite the early difficulties of expressing hTDP2, I managed to obtain a sufficient amount 
of soluble material, which could then be used in crystallisation trials (as described in 
chapter 5). These experiments produced crystals diffracting to a resolution of 3.2Å. 
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However, despite purifying and crystallising Selenomethionine-derivatised protein it was 
not possible to phase the native diffraction data, due to the poor quality of the data collected 
for the derivative.  
At this point of my PhD, two reports describing X-ray crystal structures of the catalytic 
domains of TDP2 (from different species) were published (Schellenberg et al. 2012, Shi et 
al. 2012). We reasoned that we could then simply use the structures as search models in 
molecular replacement, in order to solve the structure of TDP2 in complex with an 
inhibitory compound. It was therefore not necessary to continue with an experimental-
phasing approach (MIR, MAD, SAD etc). 
In collaboration with the Cancer Research UK Manchester Institute (formerly the Paterson 
Institute) at the University of Manchester, our laboratory was provided with several 
compounds with IC50 values in the low micromolar range. These inhibitors were first tested 
in a ThermoFluor assay, in order to verify binding to TDP2. From this early series of 
deazaflavin compounds, C14005, a phenylmethanesulfonamide derivative showed strong 
binding characteristics, producing a large shift in melting temperature midpoint. This 
compound then was taken forward into a gel-based assay in order to confirm its inhibitory 
effect, as compound binding does not necessarily correlate with inhibition. However, the 
solubility of this compound was particularly low, in both organic and aqueous buffers, 
limiting the amount of compound that could be combined with TDP2, to take forward into 
crystallisation trials. Whilst putative co-crystals were obtained, they only diffracted to low 
resolution. 
I was provided with a second compound C14297 that had improved solubility: a tetrazole 
derivative supplied by the Sussex Drug Discovery Centre at the University of Sussex. As 
before the compound was tested in both binding and activity assays. Once confirmed in 
both assay formats, it was taken forward into crystallisation trials in complex with the 
catalytic domain of hTDP2. The resultant crystals provided a usable diffraction dataset and 
the structure of the protein/compound complex was solved at a resolution of 3.1Å by 
molecular replacement using the structure of the catalytic domain of murine TDP2 
(mTDP2-CAT) as a search model (Schellenberg et al. 2012). Importantly, this structure 
provided the first information about the binding mode of the deazaflavin class of TDP2 
inhibitor, and revealed it to be radically different to that predicted by molecular docking 
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studies. However, due to the low resolution of diffraction data, and the generally poor 
behaviour of hTDP2-CATC161S crystals, we sought an improved experimental system. 
It was reasoned that the murine protein might provide such a system. However, through a 
series of experiments testing compound binding and effects on enzyme activity, it was 
shown that the deazaflavins did not inhibit the mouse enzyme. Through the experiments 
and analyses presented in Chapter 4, it became clear that deazaflavin binding is highly 
dependent on the amino acids found within the divergent region of the M7-loop of the 
catalytic domain (Schellenberg et al. 2012). It is worth noting here, that any future in vitro 
/ in vivo experiments using non-human cells, and / or other model organisms will need to 
take this particular fact into consideration. 
Based on comparison of the structure of hTDP2-CAT bound to C14297, with the murine 
protein, it was possible to design a novel ‘surrogate’ protein, m2hTDP2-CAT; generated 
by mutating key amino acid residues of the mouse protein back to their human equivalents, 
with the view of obtaining co-crystals that diffracted to high resolution.  
This approach was highly successful, and I collected two high resolution datasets, one with 
a tetrazole derivative (C14297), and a second with a hydroxyphenyl-substituted 
deazaflavin (LEP-0259), validating this experimental approach, and providing the 
foundation for an ongoing structure-based drug design programme, at the University of 
Sussex, aiming to develop small molecule inhibitors of TDP2 as therapeutic agents. 
By analysis of the structures obtained, we are able to suggest viable alterations to the 
structure of these compounds, in order to make a more effective, selective inhibitor e.g. 
substitutions at the R1 position of the deazaflavin ring system which extend towards the 
active site, to pick up additional hydrogen bonds; the tartrate molecule trapped at the active 
site in the LEP-0259 structure provides a useful path in order to directly connect the 
compound to the active site. 
8.2.4 Cell based assays for analysis of TDP2 inhibitors 
It is necessary to conduct assays at the cell and organismal level, as part of a drug 
development programme, in order to obtain important and relevant information about the 
solubility, absorption, and activity profiles of these compounds in living matter. In chapter 
6, I described the initial results from two different phenotypic assay formats: a clonogenic 
survival assay, and a DNA double-strand break repair assay (γH2AX assay). Both C14297 
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and LEP-0259 compounds were tested in both assay formats, but neither produced results 
that indicated an in vivo inhibitory effect. As part of future work, these assays could be 
repeated at higher compound concentrations or with similar compounds with improved 
solubility profiles. However, any inhibitory effect that is observed in cells, also needs 
rigorous testing in control experiments as the observed phenotypes could be produced by 
off-target effects of the inhibitors. Experiments to examine off-target effects could be 
carried out in cells where TDP2 has been knocked down or deleted. Interestingly, 
derivatives of deazaflavins have already been described as effective inhibitors of HDM2 – 
an ubiquitin E3 ligase – that targets p53 for proteolytic degradation (Kitagaki et al. 2008). 
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8.3 Project II: The phosphate-binding pocket of the BRCT 
domain of XRCC1 binds poly(ADP-ribose). 
It has been long hypothesised that poly(ADP-ribose) synthesis promotes the acceleration 
of single stranded DNA break repair (SSBR) by recruiting the scaffold protein XRCC1 
(El‐Khamisy et al. 2003), however, reports in the literature (Parsons et al. 2005, Abdou 
et al. 2015) challenged this idea in the last few years. 
My project was a part of a collaborative work regarding XRCC1 recruitment by PAR and 
its effect on SSBR at the biochemical and cellular level. It is known that PAR binding is 
mediated by the BRCT1 domain of XRCC1 (El‐Khamisy et al. 2003, Okano et al. 2003) 
and initially it was assigned to a degenerate motif located at the C-terminal part of BRCT1 
(Pleschke et al. 2000). However, unpublished results in our lab suggest that this motif is 
not required for XRCC1 function (unpublished observation). Recently, PAR binding was 
designated to the phosphate-binding pocket of BRCT1 (Li et al. 2013) formed by residues 
Arg335 and Lys369. Mutation analysis conducted in the Caldecott lab has shown that 
mutating both of these residues resulted in a severe delay in repair of SSBs and reduced 
resistance to genotoxic agents. 
In agreement with Li et al, I found that the phospho-binding motif is responsible for PAR 
binding, However, in contrast to Li et al, my results suggest that mono(ADP-ribose) is not 
a partner of XRCC1. My experiments employed a truncated XRCC1 construct encoding 
only the BRCT1 domain of XRCC1 and an N-terminal extension containing the nuclear 
localization signal (NLS). This truncated XRCC1 construct (denoted as XRCC1161-406) was 
sufficient to confer resistance in EM9 cells to genotoxins (Breslin et al. 2015). 
My work on the project started with XRCC1 pull down assays from stably infected EM9 
cells with various XRCC1 constructs. These assays demonstrated that the phosphate-
binding pocket located on BRCT1 domain is required for the interaction with PARylated 
PARP1. In order to analyse the interaction between BRCT1 and PAR on a biochemical 
level, initially, I employed the slot blot assay format, which concluded in contradictory 
results. A possible explanation maybe that the non-specific PAR binding motif comes into 
play due to the high level of ribosylation and the long PAR polymer. Subsequently, I started 
using the plate-binding assay, which turned out to be a very versatile assay format. These 
assays showed that PAR binding is phosphate-binding pocket dependent, at least at low 
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substrate NAD+ concentration. It is in good agreement with experimental results obtained 
from cells exposed to UVA laser damage or peroxide (H2O2), where the recruitment of the 
mutant XRCC1 is greatly reduced (Breslin et al. 2015) to sites of DNA damage. In 
biochemical assays, at higher NAD+ concentration PAR binding of XRCC1161-406 RK is still 
observable, almost to similar extent than that of the wild type protein. A possible reason 
may be that in these assays at higher NAD+ concentration the forming polymer is long 
enough to make contact with the hypothetical C-terminal degenerative motif (Pleschke et 
al. 2000). This secondary interaction might not be physiologically relevant, as in cells, 
there is no observable recruitment of the mutant XRCC1. 
As PAR is a homopolymer of ADP-ribose units, our initial assumption was that including 
ADP-ribose in the assay as competitor would ablate BRCT1 binding to ribosylated 
histones. To our surprise ADP-ribose did not compete in these assays suggesting, that the 
phosphate-binding pocket requires PAR and not mono(ADP-ribose) (MAR) for efficient 
binding, which contradicts with the data published by Li et al (Li et al. 2013). Competition 
assay with PAR and experiments conducted with PAR processing enzymes completely 
verified this hypothesis. Further experiments with purified PAR with distinct unit length 
also showed that the interaction between PAR and XRCC1 is dependent on polymer length. 
It is in great accordance with a report in which the authors were able to quantitatively 
monitor the binding affinity of XRCC1 for PAR with a kinetic assay using time-resolved 
fluorescence resonance energy transfer (TR-FRET) (Kim et al. 2015). The authors stated 
that the BRCT1 domain has a strong preference for PAR chain with length greater than 7 
ADPr units. However, in my hands, competition assays suggested that His-XRCC1161-406 
can bind PAR with shorter chain lengths (5 ADPr unit). However, a deeper understanding 
of this molecular mechanism of XRCC1 binding to PAR will require structural analyses. 
The BRCT1 domain of XRCC1 homologues is well conserved in from plants to mammals 
(Taylor et al. 2002). In Arabidopsis the XRCC1 homologue only harbours the central 
BRCT1 highlighting the importance its central role in DNA repair (Martinez-Macias et al. 
2013). We, and others demonstrated that the phospho-binding pocket of BRCT1 is 
indispensable in recruitment of XRCC1 to damage sites (Breslin et al. 2015, Li et al. 2013). 
The question arises: why is this particular PAR-binding module the central organizer and 
operator in SSBr? I.e. the PBZ domain is also capable of recognising ADPr units on the 
polymer and the biding affinity is dependent on the number of adenine binding sites within 
single or tandem PBZ motif (Eustermann et al. 2010, Oberoi et al. 2010). Hypothetically, 
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PBZ domains in tandem would also accelerate the recruitment of XRCC1. A possible 
explanation maybe that the phospho-binding pocket has a high selectivity towards 
poly(ADP-ribose), however, it does not bind to mono-ribosylated target proteins. 
Aprataxin and PNKP like factor (APLF) harbours the PBZ motif, which is responsible for 
recognising target proteins mainly ribosylated by PARP3 (Rulten et al. 2008, Rulten et al. 
2011). PARP3 mainly mono-ribosylates its target proteins, and with APLF, it act together 
to accelerate nonhomologous end joining. Perhaps, BRCT1 functions as a selector towards 
single stranded break repair. It would be interesting to see how XRCC1 recruitment to 
damage sites would be effected in cells if the BRCT1 domain was replaced by single or 
tandem PBZ motifs. On a biochemical level, my plate binding assays would clearly prove 
PBZ domain affinity to mono(ADP-ribose), either in competition assays (as in section 
7.2.3.4) or binding assays employing PARP3 or PARP1 and PARG (section 7.2.3.5).  
8.4 Conclusions 
In this chapter, I have provided an overview of the initial steps in the development of a 
small molecule inhibitor of TDP2 enzymatic activity; which is hoped to find utility in the 
treatment of cancer, as well as a possible novel anti-viral agent. The structural studies 
described in this thesis, have provided the molecular details underpinning the binding 
mode of the deazaflavin series of compounds. Careful examination of the high resolution 
structures obtained, has already suggested new routes for improving the binding affinity 
and selectively of future iterations of inhibitors targeted against TDP2. Although, in my 
hands, the phenotypic cell-based assays indicated no in vivo inhibitory activity, we can 
certainly look positively into the future. In collaboration with the Sussex Drug Discovery 
Centre (SDDC), a new series of compounds with better solubility characteristics have 
already been developed, and are currently in co-crystallisation trials. The work described 
in this thesis, has provided the framework for the identification of a hit-to-lead candidate 
molecule in the near future. 
My project regarding the recruitment of XRCC1 to sites of DNA damage by poly(ADP-
ribose) was part of an ongoing work and was published recently (Breslin et al. 2015). Plate 
binding assays provided good interpretation how PAR binding is mediated on a 
biochemical level; however, in order to have a deeper understanding of this interaction, we 
must pursue structural studies. It is reassuring that there are structures of proteins in 
complex with PAR reported in the literature (Barkauskaite et al. 2013), however, X-ray 
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crystallography can be difficult and usually requires substantial amount of protein. Other 
methods such as small angle X-ray scattering (SAXS) and NMR can provide an easier 
approach on the expense of far less material. As we managed to obtain purified PAR with 
distinct unit length and preliminary expression trials with BRCT1 of XRCC1 optimised 
for structural work concluded in success, it is more than possible to obtain structural data 
of the interaction.  
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Appendix 
 
 
Figure A.1. Cloning of the full-length hTDP2 (hTDP2-FL). The coding DNA was 
extracted from the original pUC57 vector by NdeI / EcoRI double restriction digest, then 
cloned into pTHREE-E and pTWO-E expression vectors. A. Several pTHREE-
E/hTDP2-FL and B. pTWO-E/hTDP2-FL clones were subjected to diagnostic digest, 
then clones #1 and #2 from each construct sent for sequencing. Samples were run in 1% 
agarose gels, in 1x TAE buffer, and visualised by Ethidium Bromide staining. Ladder: 
1Kb Plus DNA ladder. The expected fragment size of hTDP2-FL is 1086bp. Arrows 
indicate the migrating bands of digested DNA. 
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Figure A.2. Cloning of the catalytic domain of hTDP2. Following PCR, the two hTDP2 
fragments (hTDP2-CAT111-362 and hTDP2-CAT101-362) were cloned into pTWO-E and 
pTHREE-E expression vectors (Table 3.1). Several clones were subjected to diagnostic 
digest then clones #1 and #2 from each construct sent for sequencing. Samples were run 
in 1.2% agarose gels, in 1x TAE buffer, and visualised by Ethidium Bromide staining. 
Ladder: 1Kb Plus DNA ladder. The expected fragment size of hTDP2-CAT111-362 is 
774bp; hTDP2-CAT101-362 is 804bp. Arrows indicate the migrating bands of digested 
DNA. 
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Figure A.3. Cloning of XRCC1161-406. Following PCR, the coding DNA was cloned into 
NdeI / EcoRI double restriction digested pTWO-E. Several clones were subjected to 
diagnostic digest then clones #1 and #2 from each construct sent for sequencing. Samples 
were run in 1.2% agarose gels, in 1x TAE buffer, and visualised by Ethidium Bromide 
staining. Ladder: 1Kb Plus DNA ladder. Expected size of XRCC1161-406 is 735bp. 
Arrows indicate the migrating bands of digested DNA. 
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ABSTRACT
Poly (ADP-ribose) is synthesized at DNA single-
strand breaks and can promote the recruitment of the
scaffold protein, XRCC1. However, the mechanism
and importance of this process has been challenged.
To address this issue, we have characterized the
mechanism of poly (ADP-ribose) binding by XRCC1
and examined its importance for XRCC1 function. We
show that the phosphate-binding pocket in the cen-
tral BRCT1 domain of XRCC1 is required for selective
binding to poly (ADP-ribose) at low levels of ADP-
ribosylation, and promotes interaction with cellular
PARP1. We also show that the phosphate-binding
pocket is required for EGFP-XRCC1 accumulation
at DNA damage induced by UVA laser, H2O2, and at
sites of sub-nuclear PCNA foci, suggesting that poly
(ADP-ribose) promotes XRCC1 recruitment both at
single-strand breaks globally across the genome and
at sites of DNA replication stress. Finally, we show
that the phosphate-binding pocket is required follow-
ing DNA damage for XRCC1-dependent acceleration
of DNA single-strand break repair, DNA base excision
repair, and cell survival. These data support the hy-
pothesis that poly (ADP-ribose) synthesis promotes
XRCC1 recruitment at DNA damage sites and is im-
portant for XRCC1 function.
Single-strand breaks (SSBs) are the commonest lesions
arising in cells, resulting both directly from disintegration
of deoxyribose and indirectly during the excision repair of
DNA base damage [reviewed in (1)]. SSBs usually lack con-
ventional 3′-hydroxyl and 5′-phosphate termini, often pos-
sessing modifications such as 3′-phosphate or 5′-hydroxyl
termini, or fragments of deoxyribose or topoisomerase. If
not repaired rapidly, such termini can block progression
of RNA or DNA polymerases, disrupting transcription or
replication, respectively. The threat posed by SSBs is indi-
cated by the existence of human genetic diseases associated
with neurological dysfunction in which single-strand break
repair (SSBR) is attenuated (1).
To date, all known SSBR-defective diseases are associ-
ated with defects in end processing, the step of repair dur-
ing which conventional 3′-hydroxyl and 5′-phosphate ter-
mini are restored. One critical component of end process-
ing is XRCC1, a molecular scaffold protein that interacts
with and recruits, stabilizes, and/or stimulates end process-
ing enzymes and accelerates SSBR ∼5-fold (2,3). The im-
portance of XRCC1 is illustrated by the hypersensitivity of
XRCC1-mutant cells to a broad range of genotoxins and
to their elevated frequency of chromosome aberrations, ge-
netic deletions and sister chromatid exchanges (4–6). More-
over, mice with conditional deletion of Xrcc1 in brain re-
capitulate many of the pathologies associated with loss of
SSBR in humans, including cerebellar defects, ataxia and
seizures (7).
A number of observations suggest that XRCC1 re-
cruitment at chromosomal SSBs is promoted by poly
(ADP-ribose) (PAR) synthesis. First, XRCC1 interacts
directly with both PAR and with the poly (ADP-
ribose) polymerases PARP1 and PARP2 (8–10). Second,
small molecule-mediated inhibition of PAR synthesis, or
depletion/deletion of PARP1, greatly reduces the accumu-
lation of XRCC1 at sites of H2O2 or UV laser-induced
DNA damage (11–15). Third, mutations that disrupt fold-
ing of the PAR-binding BRCT1 domain in XRCC1 re-
duce or ablate XRCC1 accumulation at DNA damage
(9,11,15,16). Finally, depletion of PARG, the enzyme re-
sponsible for PAR degradation following SSBR, increases
both steady state cellular levels of PAR and the accumula-
tion and/or persistence of XRCC1 in sub-nuclear foci be-
fore and after DNA damage (17).
Despite these observations, however, several recent re-
ports have challenged the importance of PAR binding for
XRCC1 function, instead ascribing XRCC1 recruitment to
DNA binding protein partners such as DNA polymerase
! (Pol!), polynucleotide kinase/phosphatase (PNKP), and
DNA ligase III" (Lig3") (18–22). One reason this uncer-
tainty remains is a lack of clarity concerning themechanism
of PAR binding by XRCC1. PAR binding was first ascribed
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to a degenerate motif present at the C-terminus of the cen-
tral BRCT1 domain in XRCC1, comprised of an alternat-
ing series of basic/hydrophobic residues and present in nu-
merous other PAR binding proteins (9). However, a recent
study instead assigned PAR binding to the phosphate bind-
ing pocket present in the BRCT1 domain (16). Not know-
ing the site of PAR interaction has prevented the generation
of point mutations that specifically reduce or ablate PAR
binding, and consequently an analysis for their impact on
XRCC1 function. Here, we have confirmed the site of PAR
binding in XRCC1, enabling us to mutate this site and ad-
dress directly, for the first time, its importance for XRCC1
cellular function.
MATERIALS AND METHODS
Cell lines
The osteosarcoma cell line U2OS (obtained from the
Genome Damage and Stability Centre cell repository)
and derivatives of the Chinese hamster ovary (CHO) cell
line EM9 (4) were maintained as monolayers in modi-
fied Eagle’s medium (MEM) or Dulbecco’s modified Ea-
gle’s medium (DMEM), respectively, supplemented with
10% (vol/vol) foetal calf serum, 100 U/ml penicillin, 2 mM
glutamine and 100 #g/ml streptomycin. Expression con-
structs were introduced into the XRCC1-mutant CHO cell
line EM9 by Genejuice transfection (Novagen) and sta-
ble cell lines prepared by selection in media containing 1.5
mg/ml G418 (Gibco-Invitrogen) for 10–14 days. The cell
line U2OSGFP-XRCC1 was generated by transfection of 1 ×
106 U2OS cells with 0.5 #g pEGFP-XRCC1 by nucleofec-
tion (Lonza kit V) according to the manufacturer’s instruc-
tions. Twenty four hours after nucleofection, cells were se-
lected in media containing 1 mg/ml G418 for 3 weeks and
single clones selected based on their level of GFP expres-
sion. One clone, denoted U2OSGFP-XRCC1, was selected for
further use.
XRCC1, PARP1 and PCNA expression constructs
To create pCD2EXHR335A,K369A (denoted pcD2EXHRK),
encoding human XRCC1-His R335A,K369A, the
XRCC1 ORF in pCD2EXH (23) was mutated
using a QuikChange Mutagenesis Kit (Agi-
lent Technologies) using the oligonucleotides 5′-
CCAGAACCCCTTCGCCTCCGAGCTGCGAG-3′ and
5′-TGCCAACACCCCCGCGTACAGCCAGGTCC-
3′. All mutated ORFs were confirmed by se-
quencing. To create pmRFP-XRCC1161–406 and
pmRFP-XRCC1161–406 RK, encoding human mRFP-
XRCC1161–406 and mRFP-XRCC1161–406 RK, respec-
tively, cDNA encoding XRCC1 residues 161–406
was amplified by PCR using the oligonucleotides 5′-
AAGAATTCCATGCACCATCACCATCACCATCC
GTCCCAGAAGGTGACAGTG-3′ (forward) and 5′-
CCCGAATTCTGCAGTCATGGCCCTGCCATGAG
GTA-3′ (reverse) and either pCD2EXH or pCD2E-XHRK
as template, as appropriate. Note that these constructs
also possess an N-terminal histidine tag (underlined).
PCR products were verified by sequencing and cloned
into the EcoR1 site of pmRFP (24). PARP1-pmCherry
and PARP1E988K-pmCherry were kind gifts from Gyula
Timinszky (Ludwig-Maximilians University, Munich).
pCCC-TagRFP is a chromobody-Tag plasmid encoding
PCNA-VHH fused to RFP (Chromotek), which enables
detection of endogenous PCNA.
Western blotting
Proteins were fractionated on 8% or gradient SDS-PAGE
gels and transferred onto nitrocellulose membrane (GE
Healthcare). Membranes were blocked in 5% non-fat dried
milk/TBST for 30 min at room temperature or overnight
at 4◦C. After washing, blocked membranes were incubated
with rabbit anti-GFP polyclonal antibody (#2555, Cell Sig-
nalling Technology), rabbit anti-phospho (pS485/pT488)
XRCC1 polyclonal antibody (1:5000; A300-231A; Bethyl
Laboratories, Inc.), mouse anti-PAR (10H) Mab (1:1000),
mouse anti-PARP1 Mab (1:1000, MCA1522G, Bio-Rad),
mouse anti-ActinMab (1:2000, A4700, Sigma), mouse anti-
XRCC1 (33-2-5) Mab (23), or mouse anti-polyhistidine
(His-tag) Mab (Sigma). Anti-mouse and anti-rabbit HRP-
conjugated secondary antibodies (Dako Cytomation) were
employed at 1:5000, in 5% non-fat milk for 1 h at room tem-
perature. Detection was by ECL (GE Healthcare) and au-
toradiography.
Transfection and fluorescence imaging
U2OS cells or U2OSGFP-XRCC1 cells were seeded onto cov-
erslips and transfected 1 day later with appropriate con-
structs using FuGENE 6 transfection reagent according
to the manufacturer (Promega). Twenty four hours later,
the cells were mock-treated or treated with 10 mM H2O2
for 10 min, incubated at 37◦C in drug free media for 15
min, washed with phosphate buffered saline (PBS) and
then fixed for 10 min in 4% paraformaldehyde in PBS at
room temperature. After fixation the cells were washed 2×
with PBS, treated with ice-cold methanol/acetone solu-
tion for 10 min, washed 2× with PBS and mounted us-
ing VECTASHIELD Mounting Media. Images were cap-
tured on a Leica SP8 confocal microscope. For EdU la-
beling of sites of DNA replication, the Click-iT R⃝ EdU
Alexa Fluor R⃝ 647 Imaging Kit fromMolecular Probes was
used according tomanufacturer’s instructions. For laser mi-
croirradiation, 2 × 105 EM9 cells were seeded onto glass-
bottom dishes (Mattek) and transfected with 1 #g of the
indicated pmRFP-XRCC1 construct usingGenejuice (Mili-
pore). Twenty four hours later, cells were pre-incubatedwith
10 #g/ml Hoechst 33258 (for micro-irradiation with a 351
nm laser) or Hoechst 34580 (for a 405 nm laser) for 30
min prior to localised micro-irradiation with a 351 nm or
405 nm UV-laser at a dose of 0.22 J/m2 as previously de-
scribed (25). Time-lapse images were recorded at the inter-
vals shown after micro-irradiation. For experiments with
PARP inhibitor, cells were pre-incubated with either 100
nM Olaparib (Selleckchem) as indicated or with 500 nM
Ku58948 (AstraZeneca) 30 min before micro-irradiation.
Clonogenic survival assays
The indicated cells (500) were plated in duplicate in 10 cm
dishes and incubated for 4 h at 37◦C. Cells were rinsed with
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PBS and either mock treated or treated with H2O2 (diluted
in PBS at the indicated concentration immediately prior to
use) or methyl methanosulfonate (MMS) (diluted in com-
plete medium at the indicated concentration immediately
prior to use) for 15min at room temperature (H2O2) or 37◦C
(MMS). After treatment, cells were washed twice with PBS
and incubated for 10–14 days in drug-free medium at 37◦C
to allow formation of macroscopic colonies. Colonies were
fixed in ethanol (95%), stained with 1% methylene blue in
70% ethanol and colonies of >50 cells counted. Percentage
survival was calculated for each drug concentration using
the equation 100 × [average mean colony number (treated
plate)/average mean colony number (untreated plate)].
Alkaline single cell agarose gel electrophoresis (alkaline
comet assay)
Sub-confluent cell monolayers were trypsinised, diluted to
2 × 105 cells/ml in ice-cold PBS (for H2O2 treatment) or
complete media (for MMS treatment) immediately prior to
treatment, and either mock-treated or treated with 150 #M
H2O2 (diluted in ice-cold PBS immediately prior to use) for
20 min on ice or with the indicated concentration of MMS
(diluted in complete medium) for 15 min at 37◦C. Cells were
then rinsed in ice-cold PBS and incubated, where appropri-
ate, in fresh drug-free media for the desired repair period at
37◦C. Cells (100 per data point) were then analysed by alka-
line comet assay as previously described (26) using Comet
Assay IV software (Perceptive Instruments).
Expression and purification of His-XRCC1161–406 and His-
XRCC1161–406 RK
For expression of recombinant XRCC1 proteins, we
employed RosettaTM2 (DE3)pLysS (Merck Millipore) Es-
cherichia coli harbouring the expression plasmids pTWO-
E-His-XRCC1161–406 or pTWO-E-His-XRCC1161–406 RK.
pTWO-E is modified from pET-17b, encoding an N-
terminal Rhinovirus 3C-cleavable, His6 affinity tag. For
XRCC1 expression, 100ml LB ampicillin/chloramphenicol
media was inoculated with a single bacterial colony and
incubated with shaking (220 rpm) at 37◦C for 8 h and
then stored at 4◦C overnight. The next day, 6× 1 l of
LB-ampicillin/chloramphenicol media supplemented
with antibiotics as above was inoculated with the starter
culture (10 ml/l) and again incubated, with shaking, at
37◦C until and OD600 of 0.8–1.0 was reached, after which
protein expression was induced by the addition of 0.2 ml
1 M IPTG/litre for a period of 3 h at 30◦C. Cells were
harvested by centrifugation and the resulting pellet stored
at −20◦C. For purification, cell pellets were thawed on ice,
resuspended in 50 mM HEPES pH 7.5, 250 mM NaCl, 10
mM imidazole and 1 mM Tris(2-carboxyethyl)phosphine
(TCEP), and lysed by sonication on ice for 10 min (10 s
on/10 s off) using a large parallel probe at 25% amplitude
(Sonics Vibra-Cell, VWR). The lysate was clarified by
centrifugation for 50 min at 40 000 × g at 4◦C and the
resulting supernatant added to a 5 ml bed volume of Talon
resin (Clontech) in a gravity flow column. After 30 min
incubation with the resin, with mixing at 4◦C, unbound
material was removed by sequential washes (3 × 10 ml)
with resuspension buffer. Bound protein was eluted by
addition of (2 × 5 ml) elution buffer (50 mM HEPES
pH7.5, 250 mM NaCl, 300 mM imidazole and 1 mM
TCEP). The eluate was loaded onto a pre-equilibrated (20
mMHEPES pH 7.5, 150 mMNaCl and 1 mMTCEP) 5 ml
FF Heparin column (GE Healthcare) and bound material
eluted with a linear salt gradient (20 mMHEPES pH 7.5, 1
M NaCl and 1 mM TCEP). Fractions containing XRCC1
were identified by SDS-PAGE, then pooled and concen-
trated, using Vivaspin 20 (10 000 MWCO) centrifugal
concentrators (Sartorius Stedim), to a final concentration
of 0.3 mg/ml, and then stored at −80◦C until required.
Thermal denaturation and circular dichroism
For thermal denaturation, samples containing 2.0 #M
protein and 5× SYPRO Orange (diluted from a 5000 ×
stock supplied in DMSO; catalogue number S5692, Sigma–
Aldrich) were prepared in sample buffer [50 mM HEPES
pH 7.5, 300 mM NaCl, 0.5 mM TCEP and 5× Sypro Or-
ange (from Sigma–Aldrich R⃝)]. Denaturation curves were
monitored in 96-well PCR plates in a Roche LightCycler
480 II, using 465 and 580 nm filters for excitation and
emission wavelengths, respectively. Temperature midpoints
(Tm) for each folded to unfolded transition were determined
by non-linear regression fitting of a modified Boltzmann
model (27) to normalized data in Prism5 (GraphPad Soft-
ware).
Y = (anX+ bn)+ (ad X+ bd )− (anX+ bn)
1+ e Tm−Xm
where: an and ad are the slopes, bn and bd the y-intercepts,
of the native and denatured baselines, respectively. Tm is the
melting temperature and m a slope factor.
For circular dichroism, spectra were measured at 20◦C
between the wavelengths 198 and 280 nm in a JASCO J-
715 spectropolarimeter attached to a JASCO PTC-384W
temperature control system. CD spectra were measured us-
ing a 0.1 mm path length cell (Starna Scientific), with pro-
tein at a concentration of 54 #M, that had been buffer-
exchanged into 10 mMHEPES pH 7.5, 300 mMNaCl, 0.5
mM TCEP. Spectra were measured using a 0.1 mm path
length cell (Starna Scientific) and represent the average of
10 consecutive scans, where the signal from buffer alone has
been subtracted.
Poly (ADP-ribose) binding assays
The wells of flat bottomed 96 well PS-microplates (Greiner)
were incubated with either 50 #l recombinant histone
H1, PARP1 or BSA at 0.1 mg/ml in PBS overnight at
4◦C and the wells rinsed (4×) with 0.2 ml 0.1% Triton
X100 in PBS. The adsorbed proteins were mock ribosy-
lated in the absence of NAD+ or ribosylated in the pres-
ence of the indicated concentration of NAD+ (Sigma)
in PARP1 reaction buffer (50 mM Tris–HCl pH8, 0.8
mM MgCl2, 1% glycerol and 1.5 mM DTT) containing
40 nM single-stranded oligodeoxyribonucleotide (Eurogen-
tec: 5′-CATATGCCGGAGATCCGCCTCC-3′) and 5 nM
PARP1 (recombinant, human, full length) in a final volume
of 50 #l at room temp for 30 min. After rinsing (4×) with
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50 #l of 0.1% Tween 20 in PBS, 50 #l of His-XRCC1161–406
or His-XRCC1161–406 RK (diluted to 25 nM in 20 mM Tris
pH7.5, 130 nM NaCl) was added to the adsorbed pro-
teins and incubated on ice for 30 min. Where indicated,
His-XRCC1 proteins were pre-incubated withmono (ADP-
ribose) or poly (ADP-ribose)(Trevigen) competitor at the
concentrations indicated for 30 min at 4◦C, before their
addition to the adsorbed proteins. The wells were then
rinsed (4×) as above and incubated with 50 #l mouse anti-
polyhistidine (His-tag) Mab (Sigma, diluted 1: 3000 in 20
mM Tris pH7.5, 130 nM NaCl) followed by 50 #l HRP-
conjugated rabbit anti-mouse IgG (Dako, 1: 5000 in dilu-
tion buffer) for 30 min each on ice. After a final wash with
0.1% Tween 20 in PBS, 50 #l of TACS Sapphire (Trevigen)
was added to the wells, incubated in the dark for 15 min,
stopped by adding 0.2MHCl, and the absorbance was read
at 450 nm.
GFP pull down experiments
U2OSGFP-XRCC1-His cells (see above), or U2OS cells 48 h af-
ter nucleofection (Amaxa; Lonza, Slough, UK) with 4 #g
each of pEGFP-XRCC1161–406 or pEGFP-XRCC1161–406 RK
and either pmCherry-PARP1 or pmCherry-PARP1E988K
were snap frozen until needed. Cells were then thawed on
ice and lysed on ice for 20 min in 0.4 ml/5 × 106 cells
in 25 mM HEPES (pH 7.8), 150 mM NaCl, 10% glyc-
erol, 0.5% Triton X-100, and including Protease Inhibitor
Cocktail and Phosphatase Inhibitor Cocktail 3 (Sigma-
Aldrich R⃝, Dorset, UK). Where indicated, the PARP1 in-
hibitor KU58948 (500 nM) was added to the cell culture
medium 1 h prior to cell harvest and/or was included in the
cell lysis buffer. Lysed cells were sonicated in a Bioruptor
and clarified by centrifugation at 4◦C. Unless stated other-
wise, all subsequent steps were performed on ice. Forty mi-
croliters of the clarified extract was retained on ice as ‘input’
and 360 #l was mixed with 15 #l (bed volume) of GFP-
Trap A beads (ChromoTek GmbH, Germany) prewashed
in 0.5 ml wash buffer (lysis buffer containing 1 mM DDT
and 25 mM imidazole). After 1 h on a carousel at 4◦C,
the GFP-Trap R⃝ A beads were gently pelleted by centrifu-
gation at 2000 × g for 2 min. Sixty microliters of the su-
pernatant was retained as ‘unbound’ material and the pellet
was washed three times in wash buffer, with 50 #l of the fi-
nal wash retained as ‘final wash’. Proteins were eluted from
the beads by re-suspension in 50 #l 2× Laemmli buffer (250
mMTris (pH 8.0), 10% SDS, 500 mMDTT, 50% glycerol)),
heating for 5 min at 95◦C, and centrifugation at 2700 × g
for 2 min to recover the supernatant.
RESULTS
To further examine the importance of PAR binding for
XRCC1 functionwe first addressed the location of the PAR-
binding site. The most evolutionary conserved and func-
tionally important region of XRCC1 is the central BRCT1
domain that mediates binding to PAR (see Figure 1A) (28).
PAR-binding by the BRCT1 domain was initially ascribed
to a degenerate motif of hydrophobic/basic amino acids
that is present in many PAR binding proteins (Figure 1B,
dotted red box) (9). However, a different putative PAR-
binding motif in BRCT1 was recently reported, comprised
of the phosphate-binding pocket common to several other
BRCT domains (Figure 1B, solid red boxes and Figure
1C) (16). Within this pocket, Ser328, Arg335 and Lys369
are all predicted to contribute to phosphate binding, based
on the structure of other phosphate-binding BRCT do-
mains of this type. Consequently, for subsequent analysis in
vitro, we expressed and purified both a wild-type histidine-
tagged fragment of human XRCC1 spanning the conserved
BRCT1 domain (denoted His-XRCC1161–406) and a mutant
derivative in which both Arg335 and Lys369 were mutated
toAla (denotedHis-XRCC1161–406 RK) (Figure 1D, left).We
employed both mutations because mutation of R335 alone
failed to have any measurable impact on XRCC1 function
(data not shown).
Next, to confirm PAR binding by the BRCT1 phosphate-
binding pocket we adsorbed PARP1, histone H1, or
BSA to microwell plates, mock-ribosylated or ribosylated
these proteins with PARP1 in the absence or presence of
NAD+, respectively, and compared their binding to His-
XRCC1161–406 and His-XRCC1161–406 RK, in vitro (Figure
1D, right). Wild-type His-XRCC1161–406 bound both to ad-
sorbed PARP1 and histone H1, if these proteins were first
ribosylated in the presence of 1–50 #M NAD+, and was
fully bound even at the lowest concentration of NAD+ em-
ployed (1#M) (Figure 2A, blue bars). In contrast, relatively
little binding was observed to BSA, irrespective of whether
or not it was first incubated with PARP1 and NAD+, con-
sistent with this protein being a poor substrate for PARP1.
More importantly, His-XRCC1161–406 RK bound ribosylated
PARP1 and histone H1 to a much lesser extent, and not at
all at the lowest concentration (1 #M) of NAD+ employed
(Figure 2A, red bars). This did not reflect a non-specific im-
pact of the mutations on folding of the BRCT1 domain,
because His-XRCC1161–406 and His-XRCC1161–406 RK ex-
hibited similar thermal stabilities and circular dichroism
spectra (Figure 2B). Importantly, His-XRCC1161–406 bound
specifically to PAR in these experiments, because it was sup-
pressed by a 8-fold molar excess of ADP-ribose competi-
tor if present as polymer (PAR), but was not suppressed
even at 500-fold molar excess if present as ADP-ribose
monomer (MAR) (Figure 2C). These data confirm that the
phosphate-binding pocket of the XRCC1 BRCT1 domain
promotes binding to PAR in vitro, particularly at low levels
of poly (ADP-ribosylation).
Next, we examined whether PAR binding by the
phosphate-binding pocket is physiologically relevant, by
comparing wild type and mutant XRCC1 for interac-
tion with cellular PARP1. As expected, full length EGFP-
XRCC1 co-precipitated endogenous PARP1 from stably
transfected U2OS cells (U2OSGFP-XRCC1 cells; see ’Materi-
als and Methods’ section) in a manner that was inhibited
by PARP inhibitor (Figure 3A). Similarly, truncated EGFP-
XRCC1161–406 spanning the BRCT1 domain co-precipitated
mCherry-PARP1 in transient co-transfection experiments,
but co-precipitated mutant mCherry-PARP1E988K lacking
polymerase activity (29,30) to a much lesser extent (Figure
3B). More importantly, EGFP-XRCC1161–406 RK was also
less able to pull-down wild type mCherry-PARP1, confirm-
ing that the phosphate-binding pocket promotes interac-
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Figure 1. Conservation of the XRCC1 BRCT1 domain and its phosphate-binding pocket. (A) Schematic depicting conservation of XRCC1 domains in
human (Hs), frog (Xl), fly (Dm), and plant (At) XRCC1. Binding sites for the indicated protein partners are shown. Asterisks denote CK2 phosphorylation
sites that mediate FHA-dependent interactions with PNKP, APTX and APLF. Black boxes denoted the nuclear localization signal. (B) Alignment of the
BRCT1 domain from human, frog, fly and plant. Solid red boxes denote the residues predicted to form the phosphate-binding pocket and the dotted red
box denotes the degenerate putative PAR-binding motif identified by Pleschke et al. (9). Conserved identical residues are in red. Asterisks denote residues
mutated in this study. (C) Model of the BRCT1 domain based on the NMR structure (PDN accession code: 2D8M), highlighting the residues predicted to
form phosphate-binding pocket. (D) Left, purified recombinant His-XRCC1161–406 and His-XRCC1161–406 RK proteins, fractionated by SDS-PAGE and
stained with coomassie brilliant blue. Right, cartoon of the in vitro PAR-binding assay. Proteins were adsorbed to microwell dishes and mock-ribosylated
(‘-NAD+’) or ribosylated (‘+NAD+’) by PARP1 in absence or presence of NAD+ as indicated. Bound proteins were then incubated with recombinant
wild type His-XRCC1161–406 or mutant His-XRCC1161–406 RK, and bound XRCC1 detected with anti-His tag antibodies colourmetrically (A450) using
HRP-conjugated secondary antibody.
tion with PARP1 (Figure 3B). Consistent with these data,
mRFP-XRCC1161–406 rapidly accumulated at sites of UVA
laser damage at a rate similar to full-length mRFP-XRCC1
and in a manner that was greatly inhibited by PARP in-
hibitor (500 nMKu58948), suggesting that the region span-
ning the BRCT1 domain is sufficient for XRCC1 accumu-
lation at sites of cellular PAR synthesis (Figure 3C and
D). Note that we confirmed previously that this concen-
tration of Ku58948 greatly reduces or ablates PAR syn-
thesis in UVA laser tracks (31). In contrast, neither full-
length mRFP-XRCC1RK nor mRFP-XRCC1161–406 RK ac-
cumulated at sites of UVA laser damage (Figure 3C and D).
Similarly, full-length EGFP-XRCC1RK failed to accumu-
late in sub-nuclear foci at sites of H2O2-induced oxidative
stress, confirming that the phosphate-binding pocket is also
required for accumulation of EGFP-XRCC1 at this more
physiologically relevant source of SSBs (Figure 4A).
XRCC1 has also been reported to colocalise with PCNA
in replication foci in human cells, consistent with its pro-
posed role during SSBR at sites of stalled or collapsed repli-
cation forks (1,32–35). However, whether XRCC1 accumu-
lation at such sites is also regulated by PAR synthesis is
not known. Indeed, the accumulation of EGFP-XRCC1 in
sub-nuclear foci with endogenous PCNA, detected by ex-
pression of anti-PCNA antibody, was greatly reduced by
PARP inhibitor in both early and late S phase cells (Fig-
ure 4B, left panels). We confirmed in these experiments that
the sites of PCNA and EGFP-XRCC1 colocalisation were
sites of DNA replication, by pulse labeling with EdU (Fig-
ure 4B, right panels). Importantly, EGFP-XRCC1 accu-
mulation at sites of PCNA accumulation was greatly re-
duced or ablated by mutation of the phosphate-binding
pocket, suggesting that PAR binding is also critical for
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Figure 2. TheXRCC1BRCT1 phosphate-binding pocket binds PAR, in vitro. (A) Binding of His-XRCC1161–406 andHis-XRCC1161–406 RK to the indicated
mock-ribosylated (-NAD+) or ribosylated (1–50 #M NAD+) proteins was measured as indicated in Figure 1D. Data are the mean (±1 SD) of at least
three experiments. (B) Top, thermal stability of recombinant His-XRCC1161–406 and His-XRCC1161–406 RK. 2 #M XRCC1 protein was assayed in the
presence of SYPROOrange and unfolding temperatures determined as described in materials andmethods. Data are the mean (±1SD) of four independent
measurements. Bottom, circular dichroism of His-XRCC1161–406 and His-XRCC1161–406 RK. Data are the average of 10 sequential scans, with the spectrum
from sample buffer alone subtracted. (C) Binding of His-XRCC1161–406 and His-XRCC1161–406 RK to calf thymus histone mock-ribosylated in the absence
of NAD+ (‘0’) or ribosylated in the presence of either 0.5 #M NAD+ (left panel) or 1 #M NAD+ (right panel). Where indicated, XRCC1 binding was
measured in the presence of 43 nM PARP1 competitor that was first autoribosylated in the presence of 0, 0.2, 0.4, 0.8 or 2 #M NAD+, as indicated.
Alternatively, His-XRCC1161–406 and His-XRCC1161–406 RK binding was measured the presence of the indicated concentration of either poly (ADP-ribose)
(‘PAR’, left) or mono (ADP-ribose) (‘MAR’, right) competitor. PAR/MAR competitor concentrations are total ADP-ribose units (#M) present as PAR
(2–300 subunit lengths) or MAR. Data are the mean (±1SD) of at least three experiments.
the recruitment/accumulation of EGFP-XRCC1 at sites of
DNA replication (Figure 4C).
Finally, to address the importance of the phosphate-
binding pocket for XRCC1 function, we employed deriva-
tives of XRCC1-mutant EM9 cells stably transfected with
either empty vector (EM9-V) or with expression vector en-
coding either full-length human XRCC1-His (EM9-XH)
or XRCC1-HisRK (EM9-XHRK) (Figure 5A). In contrast
to XRCC1-His, XRCC1-HisRK was unable to promote cell
survival in XRCC1-mutant EM9 cells much more than
empty vector, following H2O2 or MMS treatment (Figure
5B). This was also true in experiments inwhichwemeasured
rates of chromosomal SSBR using alkaline comet assays, in
which XRCC1-HisRK again failed to correct the slow rate
of DNA strand break repair observed in EM9 cells (Figure
5C).
Collectively, these data demonstrate that the XRCC1
phosphate-binding pocket binds PAR in vitro and in cells,
promotes XRCC1 accumulation at sites of DNA damage,
and is required for XRCC1 cellular function.
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Figure 3. The XRCC1 BRCT1 phosphate-binding pocket mediates PAR-dependent interaction with PARP1 and recruitment at sites of UVA laser induced
damage. (A) EGFP-XRCC1 was affinity purified from cell extract from U2OSGFP-XRCC1 cells using GFP-Trap beads. Aliquots of the column input,
unbound, last wash, and eluate samples were fractionated by SDS-PAGE and immunoblotted with pS485/pT488 anti-XRCC1 polyclonal antibody or anti-
PARP1 antibody. Where indicated (‘+PARPi’), PARP inhibitor (500 nM Ku-58948) was included in the cell lysis buffer and was present in the cell culture
medium for 1 h at 37◦C prior to lysis. (B) U2OS cells were transiently co-transfected with expression vector encoding either EGFP, EGFP-XRCC1161–406,
or EGFP-XRCC1161–406 RK and with expression vector encoding either mCherry-PARP1 or mCherry-PARP1E988K. EGFP-XRCC1 was recovered from
whole cell extract and aliquots of column input, unbound, last wash and eluate (bound material) fractionated by SDS-PAGE and immunoblotted with
anti-GFP or anti-PARP1 antibody. The position of mCherry-PARP1 and endogenous PARP1 are indicated by black and red arrows, respectively. (C)
XRCC1-mutant EM9 cells were transiently transfected with pmRFP-XRCC1, pmRFP-XRCC1RK, pmRFP-XRCC1161–406, or pmRFP-XRCC1161–406 RK
and treated with UVA laser. mRFP fluorescence was measured at the indicated times (seco) following microirradiation in the presence or absence of 500nM
PARP inhibitor (Ku-58948). Representative images are shown. (D) Left, quantitation of the mRFP-XRCC1 fluorescence proteins at sites of 405 nm UVA
laser-inducedDNAdamage in the above experiments. Inset, pmRFP-XRCC1 and pmRFP-XRCC1RK expression levels in the transfected cells, asmeasured
by immunoblotting with pS485/pT488 anti-XRCC1 polyclonal antibody. Right quantitation of the mRFP-XRCC1161–406 fluorescence at sites of 351 nm
UVA laser damage. Data is expressed as change in mean fluorescence in ten or more cells per construct ± SEM.
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Figure 4. The XRCC1 BRCT1 phosphate-binding pocket is important for
XRCC1 accumulation at sites of H2O2-induced damage and for colocal-
ization with PCNA. (A) U2OS cells were transfected with pEGFP-XRCC1
or pEGFP-XRCC1RK, mock-treated or treated with 10 mM H2O2 for 10
min, and after 15 min recovery in drug-free medium fixed and analysed
by fluorescence microscopy. (B) Left, U2OSGFP-XRCC1 cells were trans-
fected with pCCC-TagRFP to detect endogenous PCNA in the presence
or absence of the PARP inhibitor olaparib (100 nM) and analysed as
above 24 h later. Right, cells were transfected as above and additionally
pulse labelled with EdU (blue) to identify sites of DNA replication. Dot-
ted square denotes the area expanded on the right. (C) U2OS cells were
co-transfected with either pEGFP-XRCC1WT or pEGFP-XRCC1RK and
pCCC-TagRFP plasmid to detect endogenous PCNA. Representative im-
ages are shown.
DISCUSSION
The synthesis of poly (ADP-ribose) (PAR) by PARP1 can
accelerate SSBR, but the molecular mechanism by which
PAR achieves this is unclear (17). One likely role is promot-
ing recruitment of the SSBR scaffold protein, XRCC1 (11–
15), although this idea has proved controversial (18–22). To
further address this possibility we have clarified the mecha-
nism of PAR binding by XRCC1 and addressed its impor-
tance for SSBR and cell survival. PAR binding was initially
ascribed to a degenerate motif present at the C-terminus of
the central BRCT1 domain in XRCC1, comprised of an al-
ternating series of basic/hydrophobic residues and present
in numerous other PAR binding proteins (9). Interestingly,
this motif in XRCC1 harbours a common polymorphism
at amino acid 399 (arginine/glutamine), which in some epi-
demiological studies has been implicated in altered predis-
position to cancer. However, in cellular assays this poly-
morphism does not impact measurably on XRCC1 func-
tion, suggesting that it does not influence PAR binding (36).
Moreover, replacement of five of the basic residues charac-
teristic of this degenerate motif with alanine also fails to
impact on XRCC1 function, suggesting that the degenerate
motif is not, by itself at least, important for PAR binding
(unpublished observations).
Recently, PAR binding by XRCC1 was assigned to a dif-
ferent region of the BRCT1 domain; the highly conserved
phosphate binding pocket in (16). In agreement with Li
et al., we found that the phosphate-binding pocket inter-
acts directly with PAR. However, in contrast to Li et al.,
we did not detect binding to mono(ADP-ribose) (MAR)
by this motif. Indeed, our competition assays indicate that
binding by this motif is highly selective for PAR. We found
that the phosphate-binding pocket confers on XRCC1 the
ability to bind PAR at low concentrations of polymer, as in-
dicated by its greater impact on PAR binding by XRCC1 at
low concentrations of NAD+, in vitro. This might be an ad-
vantage at low levels of SSBs such as those arising endoge-
nously in cells, in which PAR polymer might be present at
a low concentration and distributed at only a small number
of sites across the genome. However, XRCC1 harbouring a
mutated phosphate-binding pocket still bound PAR at high
concentrations of polymer, albeit to a lesser extent thanwild
type XRCC1. This may reflect incomplete ablation of PAR
binding by the R335A/K369A mutation or, alternatively,
weak PAR binding conferred by the degenerate PAR bind-
ing motif described above. Nevertheless, mutation of the
phosphate-binding pocket greatly reduced mRFP-XRCC1
recruitment at sites of UVA laser-induced damage, and also
EGFP-XRCC1 at sites of DNA damage induced by H2O2,
suggesting that this pocket is critical for accumulation of
EGFP-XRCC1 at cellular sites of DNA strand breakage.
Interestingly, the impact ofmutating the phosphate-binding
pocket on XRCC1 accumulation at sites of UVA laser in-
duced damage was greater than incubation with PARP in-
hibitor. This might reflect incomplete inhibition of PAR
synthesis by inhibitor or, alternatively, a low level of pro-
tein ribosylation generated prior to incubation with PARP
inhibitor.
Mutation of the phosphate-binding pocket also greatly
reduced XRCC1 accumulation at sites of PCNA accumula-
tion, suggesting that PAR synthesis also promotes XRCC1
accumulation at sites of damaged replication forks. The
latter is consistent with our model for replication-coupled
SSBR, in which XRCC1 promotes repair of SSBs either
ahead of an approaching fork or after replication fork col-
lapse (35,37). It is also consistent with a role for PARP1 in
regulating fork progression in the presence of DNA strand
breaks (38–41). However, it is important to note that we
have so far only observed XRCC1 accumulation at sites
of ongoing DNA replication in cells co-expressing RFP-
PCNA or anti-PCNA antibody (data not shown). Con-
sequently, we suggest that both approaches perturb nor-
mal PCNA function to some extent, thereby generating
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Figure 5. XRCC1-mediated acceleration of SSBR and cell survival requires the XRCC1 BRCT1 phosphate-binding pocket. (A) XRCC1 protein expression
in XRCC1-mutant EM9 cells stably transfected with empty expression vector (EM9-V) or expression vector encoding either XRCC1-His (EM9-XH)
or XRCC1-HisRK (EM9-XHRK). Cell extracts were fractionated by SDS-PAGE and immunoblotted with anti-XRCC1 Mab (33–2–5) and anti-Actin
antibodies. (B) Clonogenic survival of XRCC1-mutant EM9 cells stably transfected with empty expression vector (EM9-V) or expression vector encoding
either XRCC1-His (EM9-XH) or XRCC1-HisRK (EM9-XHRK). Cells were treated with the indicated concentrations of H2O2 (left) or MMS (right) for
15 min and then in drug free medium for 10–14 days to allow colony formation. Data are the mean (±SEM) of three independent experiments. Where
not visible, error bars are smaller than the symbols. (C) Chromosomal SSBR rates were measured in the above EM9 cell lines in alkaline comet assays
following treatment with 150 #MH2O2 for 20 min on ice, followed by recovery in drug-free medium for the indicated time at 37◦C, or with the indicated
concentration ofMMS for 15min at 37◦C tomeasure the accumulation of SSB intermediates during BER.Data are themean (±SEM) of three independent
experiments.
SSBs and/or other sources of replication stress that trigger
PARP1 activation.
Finally, XRCC1 harbouring a mutated phosphate-
binding pocket was unable to restore rapid rates of chro-
mosomal SSBR to XRCC1-mutant EM9 cells, following
treatment with either H2O2 or MMS, and only slightly in-
creased cellular resistance to these genotoxins. This work
thus highlights the importance of the PAR-binding motif
for XRCC1 functionality, both at oxidative breaks induced
by H2O2 and following MMS-induced DNA alkylation.
The latter is particularly intriguing, because MMS-induced
SSBs arise as intermediates of DNA base excision repair
(BER), suggesting that PAR is important for XRCC1 func-
tion during BER. Whereas several reports have suggested
that PARP1 is required during BER following DNA alkyla-
tion (42,43), others have reported that it is dispensable (44–
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46). To reconcile this discrepancy, we previously suggested
that PARP1 may be required to detect SSBs arising during
BER only if the SSB intermediate becomes uncoupled from
the canonical pathway, and/or during replication-coupled
SSBR (35,37). However, in the current work, the PAR-
binding pocket appeared to be required to accelerate most if
not all XRCC1-dependent BER events, as measured by al-
kaline comet assays following MMS treatment. The extent
to which PAR synthesis promotes BER events thus war-
rants further investigation.
In summary, we confirm that PAR binding is mediated
by the phosphate-binding pocket of the XRCC1 BRCT1
domain, and show that the PAR-binding pocket promotes
XRCC1 accumulation at DNA damage globally across the
genome and at sites ofDNA replication stress.We also show
that the phosphate-binding pocket is required for accelera-
tion of SSBR by XRCC1, and for XRCC1-dependent cell
survival, supporting the hypothesis that poly (ADP-ribose)
synthesis is important for XRCC1 recruitment and func-
tion.
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